Australian Evidence-based Guideline for unexplained infertility: ADAPTE process from the ESHRE Evidence-Based Guideline on Unexplained Infertility 2023.
DISCLAIMER

The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the original 2023 Unexplained Infertility (UI) clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the field of human reproduction and embryology. The Australian Centre for Research Excellence in Women’s Health in Reproductive Life (CRE-WHIRL) partnered with ESHRE in this endeavour with input into scope, methodology, expert engagement on the guideline group and peer facilitating and providing peer review.

The original ESHRE UI guideline represent the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders including Australian CRE-WHIRL experts was achieved.

As noted by ESHRE, the aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients.

However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional’s clinical judgement in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgement, knowledge, and expertise, and considering the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer.

The Centre for Research Excellence in Women’s Health in Reproductive Life, administered by Monash University, funded by the National Health and Medical Research Council (NHMRC) Australia has participated in the ESHRE guideline throughout development and has here adapts the final version of the ESHRE guideline to the Australian context, applying the ADAPTE and NHMRC processes.

ESHRE and Monash University make no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE and Monash University shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. While every effort to compile accurate information and to keep it up to date, it cannot, however, guarantee the correctness, completeness, and accuracy of the guideline in every respect. In any event, these clinical practice guidelines do not necessarily represent the views of all clinicians that are member of ESHRE, CRE-WHIRL or our partners.

The information provided in this document does not constitute business, medical or other professional advice, and is subject to change.
### Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction, background and abstract</td>
<td>5</td>
</tr>
<tr>
<td>Principles</td>
<td>13</td>
</tr>
<tr>
<td>List of recommendations</td>
<td>14</td>
</tr>
<tr>
<td>Definition</td>
<td>19</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>23</td>
</tr>
<tr>
<td>Treatment</td>
<td>78</td>
</tr>
<tr>
<td>Quality of life</td>
<td>93</td>
</tr>
<tr>
<td>Annexes</td>
<td>96</td>
</tr>
<tr>
<td>Annex 1: Governance and guideline development group ESHRE and Australian ADAPTE team</td>
<td>97</td>
</tr>
<tr>
<td>Annex 2: Abbreviations</td>
<td>102</td>
</tr>
<tr>
<td>Annex 3: Recommendations for research on unexplained infertility</td>
<td>104</td>
</tr>
<tr>
<td>Annex 4: Methodology including for the Australian adaptation (ADAPTE)</td>
<td>106</td>
</tr>
<tr>
<td>Annex 5: Stakeholder consultation for ESHARE guideline and summary of the Australian process</td>
<td>112</td>
</tr>
</tbody>
</table>

**Technical Report – separate document**

- Literature study: flowcharts, PICO, inclusion/exclusion criteria/studies and Evidence tables
- Summary of Evidence tables
- RIGID framework and integrity check with removed studies
- GRADE tables and evidence to decision templates

**Publication approval**

The guideline recommendations will be submitted to the National Health and Medical Research Council (NHMRC) of Australia for review under section 14A of the National Health and Medical Research Council Act 1992. Approval is sought, but not yet provided, to endorse that the guidelines meet the NHMRC standard for clinical practice guidelines, are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for healthcare professionals. This public consultation is part of the guideline review process. Following public consultation and guidelines team responses the guideline recommendations and supporting documents will be submitted to NHMRC.

Publication history - Original version 2023 – ESHRE Unexplained Infertility Guideline
Adapted Australian Version - October 2023
AUTHORSHIP

ESHRE authors: Daniela Romualdi, Baris Ata, Siladitya Bhattacharya, Ernesto Bosch, Michael Costello*, Samula Dos Santos-Ribeiro, Ksenija Gersak, Roy Homburg, Nathalie Le Clef, Mina Mincheva, Robert Norman*, Terhi Piltonen, Sara Somers, Sesh K Sunkara, Harold Verhoeve, Donia Scicluna. * CRE WHiRL Australian representatives

Australian authors; Michael Costello, Helena Teede, Cindy Farquhar, Lisa Bedson, Marlene Kong, Maree Pickens, Natalie Vujovich, Rebecca Kerner, Rhonda Garad, Trudy Loos, Luk Rombauts, Aya Mousa, Robert Norman on behalf of the Centre for Research Excellence in Reproductive Life UI Guideline Network. (See Annex 1)

Copyright information

This work builds on the work of ESHRE and sections where relevant are reproduced here with permission. Copyright of the original UI Guideline belongs to © European Society of Human Reproduction and Embryology - All rights reserved. The content of the original ESHRE guidelines has been published for personal and educational use only and is ADAPTED here with permission. No commercial use is authorised. No part of the ESHRE guidelines may be translated or reproduced in any form without prior written permission of the ESHRE communications manager. Monash University is subject to copyright. Monash holds the copyright for the Australian adapted UI Guideline and recommendations. Apart from any use permitted under the Copyright Act 1968, no part may be reproduced by any process without written permission from ESHRE and Monash University. Electronic documents: This work is subject to copyright as above. You may download, print, and link to this material in unaltered form only (retaining this notice) for your personal use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved.

Copies of the guideline, administrative and technical report and disclosures of interest containing all relevant evidence, will be accessible on the website https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation

Introduction and Background

Preface

This Australian Evidence-based Guideline for unexplained infertility is generated through an ADAPTE process from the ESHRE Evidence-Based Guideline on Unexplained Infertility 2023 and is designed to provide clear information to assist clinical decision making, support optimal patient care and improve health outcomes. It is the culmination of the largely voluntary efforts of multidisciplinary experts, clinicians and patients/consumers across Europe and Australia. We appreciate the contributions of the ESHRE Guideline Development Group and evidence synthesis lead Natalie Le Clef from ESHRE. In Australia we acknowledge the evidence synthesis lead Dr Aya Mousa, the project manager Linda Downes. Dr Michael Costello and Professor Robert Norman contributed to the ESHRE Guideline and Professor Helena Teede led the ADAPTE process.

Dr Michael Costello  Prof Helena Teede  Prof Robert Norman
CRE WHiRL  CRE WHiRL lead  CRE WHiRL
University of NSW  Monash University  University of Adelaide

Abstract Summary

Objective and Background: To develop and translate rigorous, comprehensive evidence-based guidelines for diagnosis, assessment and treatment of unexplained infertility (UI), by adapting the 2023 European Society of Human Reproduction and Embryology (ESHRE) Evidence-Based Guideline on Unexplained Infertility into the Australian Evidence-based Guideline for unexplained infertility using an ADAPTE process. We sought to address the question - What is the recommended management for couples presenting with UI, based on best available evidence in the Australian context? Gaps addressed included the fact that UI is diagnosed in the absence of abnormalities of the female and male reproductive systems after ‘standard’ investigations. However, there was no consistent understanding of what a diagnostic work-up should involve. Treatment of UI has been mostly empirical with limited research and evidence synthesis. Consideration of efficacy, safety, costs, and risks of treatments had not been integrated across evidence, multidisciplinary expertise and consumer perspectives.

Participants: Health professional and consumers engagement from ESHRE and Australia, informed the Guideline priority areas. The Guideline Development Groups included consumers, and experts in reproductive endocrinology, endocrinology, primary care, psychology, public health, project management, evidence synthesis guideline development and translation. Indigenous perspectives were also considered by the GDG.

Evidence: Best practice, evidence-based guideline development involved extensive evidence synthesis completed by the ESHRE evidence team. Papers written in English and published up to 24 October 2022 were captured in evidence synthesis. In the Australian context additional requirements and processes were instituted in generating recommendations including use of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework covering evidence quality, and in the Australian context, feasibility, acceptability, cost, implementation and ultimately recommendation strength. The Australian process also included an Integrity check to ensure evidence could be trusted to guide practice. Process: Australian governance included a Steering Committee, Reference Group, Guideline Development Group and Integrity committee. The Centre for Research Excellence in Women’s Health in Reproductive Life, funded by the Australian National Health and Medical Research Council (NHMRC), and led by Monash University, partnered with ESHRE. Here we generated evidence-based recommendations with accompanying practice points. The ESHRE Guideline underwent peer
review including in Australia. Independently methodological review was sought and the Australian adaptation is submitted to NHMRC for public consultation currently.

**Recommendations:** The ESHRE UI Guideline and this Australian adaptation have generated recommendations to help clinicians provide the best care for couples with UI. The Australian context was considered across geography and regionality, populations including Indigenous, and our health system. Here we refine the definition of UI and address basic diagnostic procedures for infertility assessment. Treatment is also addressed with first-line treatment for couples with UI recommended as intra utero insemination, with ovarian stimulation. Additional and alternative treatments were considered. The GDG formulated evidence-based recommendations, which included strong and conditional recommendations. Practice points were added in the ESHRE Guideline and expanded to consider the Australian setting during Guideline adaptation. Research recommendations were also made. No evidence-based recommendations were underpinned by high-quality evidence, with most having low or very low quality evidence. In this context research recommendations were also generated including those for the Australian context. Following peer review and submission to NHMRC, Guideline translation will include evidence-based resources for health professionals and consumers (ASK app) and policy makers.

**Funding:** The initial 2023 UI Guideline was funded, led and developed by ESHRE, in collaboration with the Monash University led Australian NHMRC Centre of Research Excellence in Women’s Health in Reproductive Life (CREWHIRL). The guideline group members did not receive any financial incentives; all work was provided voluntarily.

**Plain Language Statement**

This guideline is about making new recommendations for doctors, healthcare professionals and those affected by unexplained infertility. To develop these guidelines, experts and patients from Europe and Australia gathered to address important questions, look at the best evidence, consider health professional and patient perspectives and work together to make recommendations for care. The Guidelines were developed initially in Europe with Australian input and then adapted to the Australian context using the same evidence, considering the health system, geography and specific population factors. We used best practice to bring together evidence, expert perspectives and the preferences of consumers. We refined the definition of unexplained infertility, provided recommendations on diagnosis and on effective and ineffective treatments. The guideline process highlighted that the evidence in this area is relatively limited and recommend much more research in the future. The guidelines will be translated into a range of resources and tools for those with UI and their health professionals, and will be freely available to improve the outcomes for the UI.
**INTRODUCTION**

About 30% of infertile couples are considered affected by “unexplained infertility” (UI) (2019, 2020). This controversial diagnosis is made when no abnormalities of the female and male reproductive systems are clearly identified. UI is inevitably a diagnosis by exclusion, after “standard” investigations. However, a real standardisation of the diagnostic work-up is still lacking. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) defined UI as “infertility in couples with apparently normal ovarian function, fallopian tubes, uterus, cervix and pelvis and with adequate coital frequency; and apparently normal testicular function, genito-urinary anatomy and a normal ejaculate. The potential for this diagnosis is dependent upon the methodologies used and/or those methodologies available” (Zegers-Hochschild et al., 2017). In some instances, the terms “unexplained” and “idiopathic” infertility have been used interchangeably. The definition of idiopathic infertility varies according to previously published reports depending on the hypothesised possible aetiological factors and diagnostic work-up performed by the investigators (Ventimiglia et al., 2021). Generally, idiopathic male infertility in the literature refers to those men from couples where female factor is missing and who display abnormal semen parameters and no known aetiologic factor for their infertility (Krausz, 2011, Schubert et al., 2022). Idiopathic male infertility is considered outside the scope of this guideline.

The proportion of couples with UI is related to the extent of diagnostic exams performed to uncover putative causes for unsuccessful attempts at pregnancy (ESHRE Capri Workshop Group, 2004). Furthermore, the criteria for labelling specific features as “normal” are heterogeneous. Finally, apart from the clearly recognised causes of infertility, several undetectable defects in the reproductive process might prevent conception.

The management of UI is likewise traditionally empirical. The efficacy, safety, costs and risks of treatment options have not been subjected to robust evaluation.

Existing guidelines for UI were released from the Canadian Fertility and Andrology Society (Buckett and Sierra, 2019) in 2019 and from the American Society for Reproductive Medicine (ASRM) in 2020 (2020). Both documents exclusively address the treatment of UI.

Based on the lack of comprehensive guidelines, the ESHRE Special Interest Group (SIG) Reproductive Endocrinology initiated the development of an ESHRE guideline focussing on both the diagnosis and the therapeutic management of couples with UI. The guideline was developed according to a well-documented methodology, universal to ESHRE guidelines and described in the Manual for ESHRE guideline development (www.eshre.eu/guidelines). Details on the methodology of the ESHRE guideline are outlined in Annex 4.

The guideline development group (GDG) was composed of members of the SIG Reproductive Endocrinology, SIG Andrology, SIG Safety and Quality in ART, and SIG Nurses and Midwives, and a patient representative from Fertility Europe. This guideline was developed in collaboration with Monash University NHMRC Centre for Research Excellence in Women’s Reproductive including Australian Representatives throughout the process. The members of the ESHRE and Australian guideline development group are listed in Annex 1.

The Monash University NHMRC Centre for Research Excellence in Women’s Reproductive Health (CRE WHIRL) then undertook to adapt the Guideline for the Australian context using the ADAPTE process (ADAPTE working Group) and to seek approval (not yet provided), to endorse that the guidelines meet the NHMRC standard for clinical practice guidelines, are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for healthcare professionals.. This document includes the ESHRE original and Australian adapted content. Methods used to ADAPTE this guideline align with international best practice, and follow comprehensive evidence-based guideline development processes and criteria including the Appraisal of Guidelines for
GUIDELINE SCOPE AND PURPOSE

Knowledge gaps were identified and prioritised during the ESHRE UI Guideline development with CRE WHiRL input and stakeholder consultation.

The aims of this guideline are:

- To provide clinicians with evidence-based information on the optimal diagnostic work-up for infertile couples based on the examinations and procedures available to date, to correctly establish the diagnosis of UI.
- To provide clinicians with evidence-based information on the optimal therapeutic approach considering issues like live birth rates, safety, patient compliance, and individualisation.
- To adapt these recommendations for the Australian context

This guideline aims to assist healthcare professionals and couples in decision making about appropriate and effective management of all cases of UI. This could inevitably lead to a certain degree of generalisation. Beyond evidence-based recommendations, the GDG, including members of the Australian NHMRC CRE WHiRL, acknowledges that each medical decision needs to consider individual characteristics, preferences, beliefs and values. Similarly, even if the guideline is applicable in both high- and low-income settings, all recommendations need to be contextualised, based on different socio-geographical areas, regulations and economic resources.

Even if not specifically and/or comprehensively addressed in this guideline, some aspects of the pre-conception care were included, due to the overlap between the phase of diagnosis/treatment of infertility and the interventions aimed at improving the pregnancy and child-health outcomes.

The guideline consists of four chapters. The first chapter reviews the ICMART definition of UI. The second chapter is about diagnostic tests. Since UI is a diagnosis by exclusion, the GDG first reviewed basic fertility tests. This part is applicable to all patients under investigation for infertility. The GDG also reviewed additional tests to facilitate the diagnosis of UI (section II.9 and II.10). The studied population in these sections is couples with UI specifically. The third chapter covers treatment. The studied population in these sections is couples with UI specifically. In the fourth chapter, the GDG investigated whether there is a difference in quality of life between couples with explained or unexplained infertility.

GUIDELINE FUNDING

The Australian NHMRC funded guideline development through the Centre for Research Excellence in Women’s Health in Reproductive Life (CRE-WHiRL) (APP1171592) led by Monash University, Australia.

TARGET USERS OF THE GUIDELINE AND TRANSLATION

The target users of this guideline include but are not limited to general practitioners, gynaecologists, andrologists, infertility specialists, and reproductive surgeons and those with UI. A patient leaflet is available on the ESHRE website (www.eshre.eu/guideline/UI) with further translation planned by CREWHiRL

PATIENT POPULATION AND LANGUAGE

The current guideline focuses on couples with UI.

This guideline, in line with original peer reviewed ESHRE Guideline, the research, terminology and discussion in UI, is focused on couples composed of females and males. The guideline group recognises that there are single women, same sex couples or individuals who are transgender, who do not
menstruate, who do not have a uterus or who do not identify with the terms used in the literature. For the purposes of this guideline, we use the terms “couples with unexplained infertility”, “women or females with unexplained infertility” and “men or males with unexplained infertility”, however, it is not intended to isolate, exclude, or diminish any individual’s experience nor to discriminate against any group.

In the Australian adaptation process, specific populations were considered including Aboriginal and Torres Strait Islanders, Culturally and Linguistically Diverse populations and regional, rural and remote populations. Evidence was specifically sought on these populations and UI with little evidence found. The experience and consensus of the GDG including Indigenous representation had input into GRADE evidence to decision templates to consider these populations for each question. These populations will also be considered in the Guideline translation, dissemination and implementation program.

INTEGRITY ASSESSMENT
Applicable studies (namely randomised controlled trials) underwent an integrity check following the Research Integrity in Guideline Development (RIGID) framework. Details of the RIGID framework and integrity assessment outcomes are provided in the technical report at https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation.

COMMUNITY AND CONSUMER ENGAGEMENT
Addressing unmet needs of those with UI was a key driver for this work. We adopted the International Association for Public Participation (IPA), Public Participation Spectrum framework, in which the consumer’s capacity to participate was built and enhanced throughout the process. Consumers were engaged in all phases as active contributors within a distributed decision-making approach, ensuring that the lived experiences of those with UI had a voice at the table.

In Australia, consumer representatives were informed about the process of participation, were remunerated for time spent in preparation and at meetings including all Guideline Development Group meetings to embed consumer perspectives within the GRADE decision-making process. Consumer groups were engaged in feedback and public consultation processes and will be engaged in codesign of the implementation, translation and dissemination program.

GUIDELINE LANGUAGE: We have considered inclusive language

GUIDELINE GOVERNANCE; Governance for the Australian ADAPTE process included a Steering and Reference Group, a Guideline Development Group and an Integrity group (see Figure 1 and Annex 1)
INTERPRETING THE RECOMMENDATIONS

Detailed methods for stakeholder engagement and guideline development can be found in Annex 4, the administrative and technical reports. In summary, in developing and interpreting the guideline in both the ESHRE and Australian ADAPTE process, evidence was evaluated alongside multidisciplinary health professional expertise and consumer perspectives in all stages from conceptualisation, development, review and translation. Variability in resources, health systems and access to healthcare professionals, investigations and therapies was considered across international settings and across Australia in the adaptation.

To assist in interpreting guideline recommendations, these are presented by category, terms used, GRADE and quality of evidence. The category of the recommendations includes evidence-based recommendations and have accompanying relevant practice points as described in table 1. When sufficient evidence was available in UI, an evidence-based recommendation was made, where there was insufficient evidence, evidence in general or relevant populations was considered. Notably, evidence was limited for many questions and general population evidence was of little relevance. Where evidence was inadequate on systematic review, both ESHRE and the Australian Guideline made research recommendations. Practice points highlight important clinical and implementation issues arising from GDG consideration of evidence-based recommendations.

Table 1: Categories of the PCOS guideline recommendations

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR</td>
<td>Evidence based recommendations: Evidence sufficient to inform a recommendation made by the guideline development group.</td>
</tr>
<tr>
<td>PP</td>
<td>Practice Points: Evidence not sought. A practice point has been made by the guideline development group where important issues arose from discussion of evidence-based recommendations.</td>
</tr>
</tbody>
</table>

Aligned to the ESHRE Guideline we did not employ consensus recommendation terminology.

The Australian Adaptation of the Guideline was also reviewed by two independent methodologists, one prior to public consultation and a second during the consultation to optimise alignment to NHMRC requirements.
Aligned to the terms used by ESHRE and the required methodology for NHMRC recommendation terms used in this adaptation include “should”, “could”, “probably is not” or “is not”. These terms are informed by the nature of the recommendation, the GRADE framework and evidence quality and are independent descriptors reflecting the judgement of multidisciplinary GDG including consumers. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. “Should” is used where benefits of the recommendation exceed harms, and where the recommendation can be trusted to guide practice. “Could” is used where either the quality of evidence was limited or the available studies demonstrate little clear advantage of one approach over another, or the balance of benefits to harm was unclear. “Probably is not” is used where there is no clear advantage of one option over another or the option is probably not recommended. “Is not recommended” is used where the evidence against the test or intervention suggests the harms may outweigh the benefits.

The GRADE of the recommendation was determined by the GDG from structured, transparent consideration of the GRADE framework including desirable effects, undesirable effects, balance of effects, resource requirements and cost effectiveness, equity, acceptability and feasibility and includes:

- Conditional recommendation against the option;
- Conditional recommendation for either the option or the comparison;
- Conditional recommendation for the option;
- Strong recommendation for the option.

Quality of the evidence is categorised according to:
- information about the number and design of studies addressing the outcome
- judgments about the quality of the included studies and/or synthesised evidence, such as risk of bias, inconsistency, indirectness, imprecision and any other considerations that may influence the quality of the evidence
- key statistical data
- and classification of the importance of the outcomes

The quality of evidence reflects the extent to which our confidence in an estimate of the effect is adequate to support a particular recommendation and was largely determined by the expert evidence synthesis team.

Quality (certainty) of evidence categories (adapted from GRADE)

- High
  Very confident that the true effect lies close to that of the estimate of the effect
- Moderate
  Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is different
- Low
  Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect
- Very Low
  Very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

GRADE notes that quality of evidence is a continuum; any discrete categorisation involves a degree of arbitrariness. Nevertheless, advantages of simplicity, transparency, and vividness outweigh these limitations.
The recommendations summary below applies the category, descriptive terms, GRADE of the recommendations and the quality of the evidence. Within the body of the guideline, we outline the clinical need for the question, the clinical question, the evidence summary, the recommendation and practice points and a summary of the justification developed by the GDG and modified by ESHRE international and Australian peer review. The comprehensive evidence reviews, profiles and GRADE frameworks supporting each recommendation, can be found in the supplementary Technical Report.

**TERMINOLOGY AND DEFINITIONS**

The current guideline applies the terms and definitions as described in the international glossary on Infertility and Fertility Care (Zegers-Hochschild, et al., 2017). Specifically, the term medical assisted reproduction (MAR) refers to reproduction brought about through various interventions, procedures, surgeries and technologies to treat different forms of fertility impairment and infertility. These include ovulation induction, ovarian stimulation, ovulation triggering, all ART procedures, uterine transplantation and intra-uterine, intracervical and intravaginal insemination with semen of husband/partner or donor. A list of further abbreviations can be found in Annex 2.

**OUTCOMES FOR THE GUIDELINE**

The guideline focuses on outcomes of relevance, accuracy, acceptability, reliability, feasibility, value (in terms of cost-benefit ratio) for the diagnostic tools.

The guideline focuses on outcomes of efficacy, safety and patient-related outcomes for the treatment.

The critical outcomes in this guideline are: live full-term singleton birth, live birth, ongoing pregnancy rate, multiple pregnancies/multiple births.

The important outcomes in this guideline are: clinical symptoms, patient satisfaction, health-related quality of life, cost – effectiveness value.

Other outcomes are: clinical pregnancy rate, adverse pregnancy outcome (including miscarriage, ectopic, stillbirth, preterm delivery), ovarian hyperstimulation syndrome, fetal abnormalities, feasibility, acceptability.

**REFERENCES**


Evidence-based treatments for couples with unexplained infertility: a guideline. Fertility and sterility 2020;113: 305-322.


**PRINCIPLES AGREED TO DURING THE AUSTRALIAN ADAPTE PROCESS**

In following the ADAPTE process for this ESHRE guideline to the Australian setting, several principles were agreed by the GDG including:

- Access to diagnostic assessments, treatment and monitoring of UI are adversely impacted by regionality and rurality in Australia, which represents an equity issue and needs to be considered in making recommendations and in informing policy on fertility care in Australia (https://doi.org/10.1093/humrep/deac205)
- Australian Aboriginal and Torres Strait Islander people are disproportionately represented in regional settings, acknowledging that most do live in urban areas, and are disproportionately affected by a range of risk factors for infertility warranting education, healthcare models, policy change and further research to ensure accessible, timely and equitable care. (https://doi.org/10.1186/s12913-021-06714-8, DOI: 10.1002/ijgo.13920)
- Inadequate or misinformation is common in infertility, with an imperative for evidence-based care, across diagnosis, treatment and monitoring, and with a need for resources, tools, and education to enable informed shared decision making between patients and healthcare professionals.
- Cost effectiveness data is limited in the Australian setting on comparisons between expectant management and different fertility options, yet health professionals should be aware of, inform and enable shared decision making encompassing direct and indirect costs to enable shared decision making. https://doi.org/10.1007/s40258-022-00764
# List of all recommendations

<table>
<thead>
<tr>
<th>1 Definition</th>
<th>Type/GRADE</th>
<th>Evidence certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defining infertility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>It is recommended that at least 12 months of regular, unprotected sexual intercourse is recommended before initiating fertility interventions.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>In Australia, it is recognised that clinical investigation may commence earlier in the case of a couple who are older or may want more than one child.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>Defining infertility and frequency of intercourse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whilst frequency of intercourse should not affect the definition of infertility, in couples seeking to conceive, it could be reasonable to advise to increase sexual intercourse to at least every 2-3 days within the fertility window to the extent that such suits their own preference.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>Infertility and age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female age is a consideration in UI, with male age a less significant factor, at more extreme age.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>Female and male factor infertility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health professionals are recommended to routinely take a medical, reproductive and sexual history from both the male and female partners.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>A regular menstrual cycle should be considered to be 21 to 35 days and up to 8 days in duration with shortest to longest cycle variation of less than 7 to 9 days.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>Mild male factor is excluded from the diagnosis of unexplained infertility</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>2 Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Confirmation of Ovulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In women with regular menstrual cycles, tests for confirmation of ovulation are not routinely recommended.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>2.1.1 In women with regular menstrual cycles, if confirmation of ovulation is warranted, tests such as urinary LH measurements, ultrasound monitoring or mid-luteal progesterone measurement could be used.</td>
<td>EBR</td>
<td>☽☼☼☼</td>
</tr>
<tr>
<td>2.2 Oocyte/corpus luteum quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2.1 In women with regular menstrual cycles, it is suggested not to routinely measure mid-luteal serum progesterone levels.</td>
<td>EBR against</td>
<td>☼☼☼</td>
</tr>
<tr>
<td>2.2.2 In women investigated for infertility, endometrial biopsy for histological examination is not recommended in the absence of other indications.</td>
<td>EBR against</td>
<td>☼☼☼</td>
</tr>
</tbody>
</table>
### 2.3 Ovarian reserve

#### 2.3.1
In women with regular menstrual cycles, ovarian reserve testing is not required to identify the aetiology of infertility or to predict the probability of spontaneous conception over 6 to 12 months.

**EBR against** ☠️

### 2.4 Tubal factor

#### 2.4.1
Hystero-contrast-sonography (HyCoSy) and hysterosalpingography (HSG) should be recommended as valid tests for tubal patency, compared to laparoscopy and chromopertubation.

**EBR against** ☠️

#### 2.4.2
Chlamydia antibody testing for tubal patency could be considered a non-invasive test to differentiate between patients at low and at high risk for tubal occlusion.

**EBR against** ☠️

### 2.5 Uterine factor

#### 2.5.1
Ultrasound, preferably 3D, could be recommended to exclude uterine anomalies in women with unexplained infertility.

**EBR against** ☠️

#### 2.5.2
MRI is not recommended as a first-line test to confirm a normal uterine structure and anatomy in females with unexplained infertility.

**EBR against** ☠️

#### 2.5.3
If ultrasound assessment of the uterine cavity is normal, no further evaluation is probably needed.

**EBR against** ☠️

### 2.6 Laparoscopy

#### 2.6.1
Routine diagnostic laparoscopy is probably not recommended for the diagnosis of unexplained infertility.

**EBR against** ☠️

### 2.7 Cervical/ vaginal factor

#### 2.7.1
The post-coital test is probably not recommended in couples with unexplained infertility.

**EBR against** ☠️

### 2.8 Male genito-urinary anatomy

#### 2.8.1
Testicular imaging is probably not recommended when semen analysis according to WHO criteria is normal.

**EBR against** ☠️

### 2.9 Male additional tests

#### 2.9.1
Testing for anti-sperm antibodies in the semen is probably not recommended when semen analysis according to WHO criteria is normal.

**EBR against** ☠️

#### 2.9.2
Testing for sperm DNA fragmentation is probably not recommended when semen analysis according to WHO criteria is normal.

**EBR against** ☠️
### 2.9.3 Sperm chromatin condensation test
- EBR against

### 2.9.4 Sperm aneuploidy screening
- EBR against

### 2.9.5 Serum hormonal testing
- EBR against

### 2.9.6 HPV testing of semen
- EBR against

### 2.9.7 Microbiology testing of semen
- EBR against

#### 2.10 Additional tests for systemic conditions

| 2.10.1 | Testing for anti-sperm antibodies in serum of either males or females with unexplained infertility is probably not recommended. | EBR against |
| 2.10.2 | Testing for coeliac disease in women with unexplained infertility could be recommended. | EBG |
| 2.10.3 | Testing for thyroid antibody and other autoimmune conditions (apart from coeliac disease) in women with unexplained infertility is probably not recommended. | EBG against |

- TSH measurement is considered good practice in pre-conception care.
- PP

| 2.10.4 | No additional thyroid evaluation in the female is recommended, if TSH is within the normal range and there is no underlying history of thyroid disease. | EBR against |
| 2.10.5 | Testing for thrombophilia in the female is probably not recommended. | EBR against |

- Measurement of oxidative stress in semen of males with unexplained infertility should only be considered in the context of research. Research only

| 2.10.6 | Measurement of oxidative stress in females with unexplained infertility is not recommended. | EBR against |
| 2.10.7 | Genetic or genomic tests are probably not recommended in couples with unexplained infertility. | EBR against |
| 2.10.8 | Testing for vitamin D deficiency in females is probably not recommended for diagnosis of unexplained infertility. | EBR against |
| 2.10.9 | Prolactin testing in the female without clinical features of hyperprolactinemia, is probably not recommended. | EBR against |

- BMI evaluation in the female is considered good practice in pre-conception care.

| 3.1 Expectant management |

| 3.1.1 | IUI with ovarian stimulation could be recommended as a first-line treatment for couples with unexplained infertility. | EBR |

- It is advised to base the decision to start active treatment on prognosis in couples with unexplained infertility.

- PP
### 3.2 Active treatment

| 3.2.1 | IUI with ovarian stimulation could be recommended as a first-line treatment for couples with unexplained infertility. | EBR | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.2.2 | To avoid multiple pregnancies and ovarian hyperstimulation syndrome, care is needed by using gonadotrophin treatment only in a low-dose regimen with adequate monitoring. | PP |
| 3.2.3 | IVF is probably not recommended over IUI with ovarian stimulation in couples with unexplained infertility. | EBR either | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.2.4 | It is expected that the decision to use IVF is individualised by patient characteristics such as age, duration of infertility, previous treatment and previous pregnancy. | PP |
| 3.2.5 | ICSI is not recommended over conventional IVF in couples with unexplained infertility. | EBR either | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |

### 3.3 Mechanical-surgical procedures

| 3.3.1 | Hysteroscopy for the detection and possible correction of intrauterine abnormalities not seen at routine imaging requires further research. | Research only |
| 3.3.2 | HSG (i.e., tubal flushing) with an oil-soluble contrast medium should be considered over a water-soluble contrast medium. Risks and benefits of tubal flushing with oil-soluble contrast medium should be discussed with all couples with unexplained infertility. | EBR | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.3.3 | If incidental minimal to mild endometriosis is found at laparoscopy, this is not further considered unexplained infertility. | PP |
| 3.3.4 | Endometrial scratching should probably not be recommended for unexplained infertility. | EBR against | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |

### 3.4 Alternative therapeutic approaches

| 3.4.1 | Adjunct oral antioxidant therapy to females undergoing fertility treatment is probably not recommended. | EBR against | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.4.2 | Adjunct oral antioxidant therapy to males undergoing fertility treatment is probably not recommended. | EBR against | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.4.3 | Acupuncture in females undergoing fertility treatment is probably not recommended. | EBR against | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| 3.4.4 | Inositol supplementation in women undergoing fertility treatment is probably not recommended. | EBR against | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
| | Psychological support, including psychotherapy, is recommended for patients when needed. | PP |
| | A healthy diet and regular exercise, supported by behavioural therapy, when necessary, are recommended. | PP |

### 3.5 Psychological support

| 3.5.1 | Psychological support, including psychotherapy, is recommended for patients when needed. | PP |

### 4 Quality of Life

| 4.1.1 | Healthcare professionals should be aware that there is probably no difference in QoL between women with unexplained infertility versus women in couples with known causes of infertility, except when the cause of infertility is PCOS, when QoL is lower. | EBR | ⊕⊕⊕⊕ ⊙⊙⊙⊙ |
Healthcare professionals should be aware that QoL could be higher in men from a couple with unexplained infertility compared to men from a couple with known causes of infertility except when the cause of infertility is men with a partner with PCOS, then the men from a couple with unexplained infertility have a lower QoL.

It should be acknowledged that couples with UI may experience considerable impact on their QoL and they can be offered support and therapeutic counselling.

**CONSIDERING PROGNOSIS** - Please see the Guideline Treatment section on considering prognosis when assessing and treating UI.

**IMPACT:**

Given the limited evidence-based guidance currently available on UI, the contribution of this work is expected to be significant in informing practice, shared decision-making and providing guidance to other stakeholders. The ESHRE and Australian adapted UI Guidelines have followed best practice processes and sought to provide consistent guidance based on available evidence, multidisciplinary clinical consensus and consumer perspectives. The low certainty of evidence here has also highlighted the vital importance of further research.

The recommendations provided have the potential to simplify diagnosis and screening, reduce cost and optimise equity by avoiding complex testing that is not indicated, based on lack of evidence. Prognostic factors may also be considered when advising treatment. Treatments may be streamlined and simplified, potentially reducing cost and increasing equity, with many treatments not supported by evidence. Implementation, education and evaluation of the impact of these Guidelines will be important moving forward to meet the aims of improving health outcomes for Australian couples with UI.
1. Definition

This section relied on narrative reviews, and given the nature of the questions and the evidence, aligned to NHMRC methods, the recommendations in this section were converted into practice points in the Australian Guideline.

**NARRATIVE QUESTION: AFTER HOW MANY MONTHS OF UNPROTECTED INTERCOURSE SHOULD A COUPLE BE DEFINED AS INFERTILE?**

Based on a wide-ranging analysis of 237 studies of unexplained infertility (UI), 85 of these related to the time of unprotected intercourse in their definition of UI; 46.5% specified 1 year, 39.5% specified 2 years and 14%, 3 years.

According to the International Committee for Monitoring Assisted Reproductive Technology (ICMART) definition of infertility, couples should have at least 12 months of regular, unprotected sexual intercourse before fertility interventions may be initiated (Zegers-Hochschild et al., 2017).

In Australia, it was recognised that clinical investigations may commence earlier in the case of a couple who are older or who may want more than one child.

**Recommendation**

| It is recommended that at least 12 months of unprotected intercourse is required before initiating fertility interventions. | PP |
| In Australia, it is recognised that clinical investigation may commence earlier in the case of a couple who are older or may want more than one child. | PP |

**NARRATIVE QUESTION: SHOULD FREQUENCY OF SEXUAL INTERCOURSE AFFECT THE DEFINITION OF UI?**

The definition of infertility includes a broad reference to “regular” unprotected sex, albeit without specifying what this term entails. In fact, the concept of “regular” coital frequency is extremely variable and particular to each couple, fluctuating not only over time, but also influenced by multiple factors including age, education, race, working status, exercise and mood, amongst others (Gaskins et al., 2018). Hence, applying strict bounds to define regular unprotected sex is not only unfeasible, but also unadvisable and could cause unnecessary stress in those seeking to conceive.

In their seminal study, Wilcox et al. assessed prospectively in 221 women whether sexual frequency within the six days preceding ovulation could affect the probability of conception (Wilcox et al., 1995). The authors found that predicted conception rates did not alter significantly when comparing women who perform sexual intercourse daily, every other day or twice during the fertility window. However, the number of conception cycles were indeed lower in those who had intercourse only once within the before mentioned timeframe. These results seem to reiterate that more frequent ejaculations do not seem to decrease overall male fertility and, in fact, may even be beneficial (Agarwal et al., 2016). Hence, in couples seeking to conceive, it could be reasonable to advise to increase sexual intercourse to at least every 2-3 days within the fertility window to the extent that such suits their own preference.
In couples seeking to conceive, it could be reasonable to advise to increase sexual intercourse to at least every 2-3 days within the fertility window to the extent that such suits their own preference.

The ESHRE and Australian guideline development groups (GDG) acknowledged that giving the indication of having sexual intercourse at least every 2-3 days can sometimes be stressful for individuals.

**Recommendation**

| Whilst frequency of intercourse should not affect the definition of infertility, in couples seeking to conceive, it could be reasonable to advise to increase sexual intercourse to at least every 2-3 days within the fertility window to the extent that such suits their own preference. |

**Narrative Question: Should female or male partner's age affect the definition of UI?**

Based on the analysis of 237 studies of UI, only 49 related to upper age limits of the female partner. Of these, 12 studies referred to 35 years, 8 studies to age 38 and 16 studies to 40 years old. The rest were fairly well distributed in small numbers between 36, 37, 39 and 42 years.

The ICMART definition of UI only refers to the clinical diagnosis without any reference to the duration of unprotected intercourse or female partner’s age (Zegers-Hochschild, et al., 2017). This definition could well be further defined for practical purposes by adding 40 years old as the limit of the female partner’s age. This was illustrated in a mathematical model, showing that after 2 years of regular unprotected intercourse, the false positive diagnosis of UI is 10% in women under 35 years of age, and increases to 80% in women over 40 years of age (Broer et al., 2011, Somigliana et al., 2016).

To a much lesser extent and at more extreme ages, male age could affect fertility potential (du Fossé et al., 2020, Johnson et al., 2015, Laurentino et al., 2020).

**Recommendation**

| Female age is a consideration in UI, with male age a less significant factor, at more extreme age. |

**Narrative Question: Should couples with mild infertility factors be included in the definition of UI?**

**Male**

Contextualising the ICMART definition of UI, GDG considers that the initial fertility evaluation of the male should include at least one basic semen examination (strictly adhering to WHO 6\textsuperscript{th} edition manual for the examination and processing of human semen) from a laboratory subscribed to an external quality control programme and a reproductive (including sexual history) and medical history. The results of the basic semen examination should be interpreted in conjunction with the findings in clinical examination and history. WHO has developed detailed guidance for history taking (reproductive, medical, sexual) and physical examination of the infertile man (WHO, 2000).

The lower fifth percentile of data from men in the reference population, as described in the WHO manual for the examination and processing of human semen represents the level under which only
results from 5% of the men who achieve conception within 12 months in the reference population were found (WHO, 2021). The GDG proposes that results from a basic semen examination below the lower 5th percentile reference limit (and its 95% confidence interval) should be considered as clinically relevant for decision making about further clinical investigation. However, anything outside this reference excludes unexplained infertility.

### Table 1: The lower fifth percentile of data from men in the reference population (WHO, 2021).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>5th percentile</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semen volume</td>
<td>1.4 ml</td>
<td>1.3-1.5 ml</td>
</tr>
<tr>
<td>Sperm concentration</td>
<td>16 x 10^6 per ml</td>
<td>15-18 x 10^6 per ml</td>
</tr>
<tr>
<td>Total sperm number</td>
<td>39 x 10^6 per ejaculate</td>
<td>35-40 x 10^6 per ejaculate</td>
</tr>
<tr>
<td>Total motility (PR+NP)</td>
<td>42%</td>
<td>40-43%</td>
</tr>
<tr>
<td>Progressive motility (PR)</td>
<td>30%</td>
<td>29-31%</td>
</tr>
<tr>
<td>Non-progressive motility (NP)</td>
<td>1%</td>
<td>1-1%</td>
</tr>
<tr>
<td>Immotile spermatozoa (IM)</td>
<td>20%</td>
<td>19-20%</td>
</tr>
<tr>
<td>Vitality</td>
<td>54%</td>
<td>50-56%</td>
</tr>
<tr>
<td>Normal forms</td>
<td>4%</td>
<td>3.9-4.0%</td>
</tr>
</tbody>
</table>

Current expert position on the question of repeated basic semen examination is that one single (high quality) ejaculate examination should be sufficient to decide on the following actions of male fertility investigation (Barratt et al. 2017; WHO 2000). However, it is also recommended that semen analysis should be repeated if one or more abnormalities is found (Barratt et al. 2017; WHO 2000).

Going by the ICMART definition of UI which states an apparently normal testicular function and a normal ejaculate (Zegers-Hochschild, et al., 2017), mild male factor is excluded from the diagnosis of unexplained infertility.

The GDG acknowledges some studies of unexplained UI have been heterogeneous in the inclusion of thresholds for various semen analysis parameters.

### FEMALE

Going by the ICMART definition of UI which states an apparently normal ovarian function, fallopian tubes, uterus, cervix and pelvis (Zegers-Hochschild, et al., 2017), presence of any female factors excludes the diagnosis of unexplained infertility.

### CONCLUSION

The GDGs defined unexplained infertility as: infertility in couples with apparently normal ovarian function, fallopian tubes, uterus, cervix and pelvis, age ≤ 40 years and with adequate coital frequency; and apparently normal testicular function, genito-urinary anatomy and a normal ejaculate. As per ICMART definition of infertility, couples should generally have at least 12 months of regular, unprotected sexual intercourse before investigations are started.

The GDG recommends routinely taking a medical, reproductive and sexual history for both the male and female partners.

The ESHRE GDG considered a regular menstrual cycle to be < 38 days, up to 8 days in duration and shortest to longest cycle variation of < 7 to 9 days (Munro et al., 2018).

The Australian GDG acknowledged that the definition of normal menstrual cycle length is controversial. FIGO regards abnormal uterine bleeding as cycles > 38 days in length, largely from a 2018 Delphi consensus (Munro et al., 2018). Yet a recent large study showed that ovulation can occur after day 21, but is uncommon with 8.6 % of women having cycles >35 days (Greiger, J et al 2020). The 2023 International PCOS guidelines defines a normal ovulatory cycle as <35 days (Teede,
H et al 2023). It was therefore considered that if a cycle is > 35 days, an underlying ovulatory disturbance should be considered and appropriate investigation and treatment instituted at the discretion of the clinician, and that this should not be considered as UI, acknowledging the need for more research.

The GDG recommends at least one basic semen examination according to WHO criteria by a laboratory subscribed to an external quality control program. If the result from first analysis falls out of the lower 5th percentile reference limit as per WHO 6th edition, perform a second analysis after a 3-month interval.

**Recommendation**

| Health professionals are recommended to routinely taking a medical, reproductive and sexual history for both the male and female partners. | PP |
| A regular menstrual cycle should be considered to be 21 to 35 days and up to 8 days in duration with shortest to longest cycle variation of less than 7 to 9 days. | PP |
| Mild male factor is excluded from the diagnosis of unexplained infertility | PP |

**REFERENCES**


Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaec Obstetrics: 2018;143: 393-408.


2. Diagnosis

2.1 Confirmation of ovulation

**PICO QUESTION: Which is the reliability and convenience of methods to confirm regular ovulation?**

**Menstrual history**

**Evidence**

No relevant papers were identified that compare menstrual history with other methods to predict/confirm ovulation.

**Menstrual history + one progesterone/ultrasound/luteinizing hormone urinary measurement**

**Evidence**

In a cohort study, including 101 infertile women with regular menstrual cycles, the accuracy of urinary luteinizing hormone (LH) and serum progesterone tests for the prediction/confirmation of ovulation were determined with ultrasound monitoring as reference standard. The agreement between ultrasound and urinary LH test was 97%. Sensitivity, specificity, and accuracy for LH readings were 100%, 25%, and 97%, respectively. The accuracy of progesterone measurement on day six with ultrasound as reference was 79%, sensitivity and specificity were 80% and 71%, respectively (Guermandi et al., 2001).

**Luteinizing hormone (LH) urinary measurement**

**Evidence**

In a cohort study, including 101 infertile women with regular menstrual cycles, the accuracy of urinary LH tests was compared with ultrasound for the prediction/confirmation of ovulation. In 100/101 (97%) cycles, the LH test was in agreement with the ultrasound monitoring, resulting in a sensitivity of 100%, with a specificity of 25% and an accuracy of 97% (Guermandi, et al., 2001).

A cohort study, including 32 spontaneously ovulating women, investigated the agreement between quantitative (assay, plasma) and qualitative (colour, urine) LH tests. A high correlation was found between both assays (r=0.688) (Bischof et al., 1991).

A cohort study including 99 spontaneous cycles investigated the agreement between LH urinary test and ultrasound monitoring to predict/confirm ovulation. Positive test results, presumably reflecting the occurrence of a urinary LH surge above 50 IU/L, were observed in 97 (98%) spontaneous cycles (Martinez et al., 1991).

Another cohort study including 55 women with normal ovulatory menstrual cycles investigated the agreement between the LH urinary test and ultrasound monitoring to predict/confirm ovulation. In 39/55 cases (70.91%), ovulation occurred within 24h after positivity of the LH-test (Gregoriou et al., 1990).
**SERIAL BASAL BODY TEMPERATURE (BBT)**

**Evidence**

In a cohort study, including 101 infertile women with regular menstrual cycles, the accuracy of basal body temperature (BBT) was compared with ultrasound for the prediction/confirmation of ovulation. In 67/101 cycles, the BBT was in agreement with the ultrasound monitoring, resulting in a sensitivity of 77%, with a specificity of 33% and an accuracy of 74% (Guermandi, et al., 2001).

A cohort study including 99 spontaneous cycles investigated the agreement between the thermal nadir and LH test decolouration to predict/confirm ovulation. The BBT nadir correlated with the day of the positive test in 30% of spontaneous cycles (Martinez, et al., 1991).

Another cohort study including 55 women with normal ovulatory menstrual cycles investigated the agreement between the thermal nadir and LH test decolouration to predict/confirm ovulation. In 20/55 (36.36%) of the cases, the thermal nadir was noted on the day of decolouration, whereas in 22 (40%) and 13 (23.6%) patients the thermal nadir occurred on days -1 and +1 and on days -2 and days +2 of the LH surge, respectively (Gregoriou, et al., 1990).

**CHANGES IN THE CHARACTERISTICS OF CERVICAL MUCUS**

**Evidence**

No relevant papers were identified that compare changes in the characteristics of cervical mucus with other methods to predict/confirm ovulation.

**ULTRASOUND**

**Evidence**

In the relevant papers identified for this PICO question, follicular growth and rupture monitoring by ultrasound was defined as the gold standard. No relevant papers were identified that investigated the accuracy of ultrasound to predict/confirm ovulation.

**OVERALL RECOMMENDATION**

**Evidence**

In the four studies included, follicular growth and rupture monitoring by ultrasound was performed and also defined as the gold standard for this evidence synthesis. In the studies evaluating urinary LH measurements, both the agreement (98-100%) and accuracy (97%) with ultrasound monitoring were very high (Bischof, et al., 1991, Gregoriou, et al., 1990, Guermandi, et al., 2001, Martinez, et al., 1991). Meanwhile, BBT and luteal-phase serum progesterone measurements were shown to have estimated accuracies between 70% and 80% (Gregoriou, et al., 1990). No studies of sufficient quality in this population could be retrieved to access the predictive value of self-reported menstrual history or changes in cervical mucus to confirm regular ovulation. Moreover, convenience was not formally assessed in any of the studies included.

**Recommendation**

<table>
<thead>
<tr>
<th>In women with regular menstrual cycles, tests for confirmation of ovulation are not routinely recommended.</th>
<th>PP</th>
</tr>
</thead>
<tbody>
<tr>
<td>In women with regular menstrual cycles, if confirmation of ovulation is warranted, tests such as urinary LH measurements, ultrasound monitoring or mid-luteal progesterone measurement could be used.</td>
<td>EBR</td>
</tr>
</tbody>
</table>

**ADAPTED Australian Unexplained Infertility Guideline 2023**
Justification
Pregnancy would be the most straightforward way to determine if ovulation occurred. However, studies considering pregnancy as reference were not available. Therefore, follicular rupture, evidenced by ultrasound, was chosen as the reference test. All included studies presumed that included women had regular cycles which is implicit in the context of unexplained infertility.

In clinical practice, ovulation is seldomly confirmed during basic fertility work-up. If confirmation of ovulation is warranted, all strategies presented a reasonable accuracy to confirm ovulation and may therefore be used. BBT presented with a lower accuracy and was found to be less acceptable to patients. While one may postulate that self-administered testing strategies may be deemed as more convenient for patients, this hypothesis is yet to be adequately tested in the infertile population. Regardless, it is also important to note that the documentation of an ovulation episode in one specific menstrual cycle is not a surrogate marker of regular ovulation.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES

2.2 Oocyte/corpus luteum quality

PICO QUESTION: WHAT IS THE RELIABILITY OF PARAMETERS DETECTING GOOD OOCYTE/ CORPUS LUTEUM QUALITY?

Mid-luteal phase progesterone levels

Evidence
A cohort study, including 138 cycles from 72 women with no physical cause for infertility investigated the association between midluteal serum progesterone and conception and reported that the lowest progesterone threshold for conception cycles was 8.5 ng/ml (equals 27 nmol/L) (Hull et al., 1982).

Recommendation

| 2.2.1 | In women with regular menstrual cycles, it is suggested not to routinely measure midluteal serum progesterone levels. | EBR against | ⚫⚫⚫⚫ |
Justification
There was only one study, which identified midluteal progesterone levels in natural conception and reported the lowest progesterone level to obtain pregnancy. There are no studies conclusively documenting a minimum midluteal serum progesterone level required for the occurrence of pregnancy. Even if the presence of a threshold of midluteal serum progesterone level below which pregnancy and live birth rates are decreased is assumed, there is no evidence showing an increase in live birth rates with exogenous progesterone administration in any form.

On the other hand, recent data from studies on frozen embryo transfer in a natural cycle and one study involving women with UI undergoing ovarian stimulation (OS) and intrauterine insemination (IUI) suggest an association between luteal phase progesterone levels and probability of a pregnancy and live birth (Gaggiotti-Marre et al., 2020, Hansen et al., 2018). Given the limited information on an association between luteal progesterone levels and spontaneous pregnancy this is an area that requires further research.

Further information
Details of the literature study and evidence tables are available in the technical report.

ENDOMETRIAL BIOPSY

Evidence
In an RCT, 287 ovulatory female partners of infertile couples and 332 fertile controls were randomised to undergo histological examination of an endometrial biopsy in the midluteal or late luteal phase of the menstrual cycle. The prevalence of out of phase endometrial biopsy results were similar between fertile and infertile women in adjusted analyses. Receiver operating characteristics (ROC) curves showed less than 0.5 area under the curve (AUC) values for endometrial biopsy to differentiate fertile and infertile women (Coutifaris et al., 2019).

In a cohort study, including 20 women with UI and 21 fertile controls, midluteal endometrial biopsies were performed. Women in the UI group showed similar endometrial maturation as the fertile control group (Edi-Osagie et al., 2004).

Recommendation

| 2.2.2 | In women investigated for infertility, endometrial biopsy for histological examination is not recommended in the absence of other indications. | EBR against | ⭕⎬⎬🚫 |

Justification
Two studies, one with a large sample size, show that endometrial dating does not discriminate between fertile and infertile women. There is no justification for an invasive test in the context.

This recommendation does not apply to women having an indication for endometrial biopsy, such as endometrial hyperplasia.

The GDG is aware of other methods to assess the endometrium, however, these were not investigated.

Further information
Details of the literature study and evidence tables are available in the Technical Report.
FERTILISATION FAILURE

Evidence

No relevant papers could be identified investigating the reliability of fertilisation failure to determine good oocyte or corpus luteum quality.

EUPLOID EMBRYO RATE WITH PGT-A

Evidence

No relevant papers could be identified investigating the reliability of euploid embryo rate (determined by PGT-A) to determine good oocyte or corpus luteum quality.

REFERENCES


2.3 Ovarian reserve

PICO QUESTION: SHOULD ONE OR MORE TESTS OF OVARIAN RESERVE BE INCLUDED IN THE DIAGNOSTIC WORK-UP?

ANTI-MÜLLERIAN HORMONE (AMH)

Evidence

In a cohort study, female partners of 148 couples with unexplained infertility (UI) and females from 112 couples with male factor infertility were prospectively compared. Women with serum FSH levels >10 IU/L were excluded. While a multivariate analysis adjusted for age suggested lower anti-Müllerian hormone (AMH) levels being significantly associated with UI, antral follicle count (AFC) was not found to be associated with UI (Yücel et al., 2018).

Women between 30 and 44 years of age, who were trying to conceive for less than three months or were about to start trying to conceive, were prospectively observed in a cohort study. Analyses adjusted for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, showed that women with low AMH values (<0.49pmol/L, n = 84) had a similar predicted probability of conceiving by six cycles of attempt (65%, 95% CI 50-75%) compared with women (n = 579) with normal values (62%, 95% CI 57-66%) or by 12 cycles of attempt (84% (95% CI 70-91%) vs. 75% (95% CI 70-79%),
respectively). Likewise, women with high serum FSH values (>10 IU/L, n = 83) had similar predicted probability of conceiving after six cycles of attempt (63%, 95% CI 50-73%) compared with women (n = 654) with normal values (62%, 95% CI 57-66%) or after 12 cycles of attempt (82% (95% CI 70-89%) vs. 75% (95% CI 70-78%), respectively). The study excluded women <30 years of age. Male partners not having provided a semen sample can be considered as a limitation if women with low ovarian reserve would be more likely to have partners with impaired semen. While all women were not enrolled in their first three cycles of attempt; findings were similar when less than 10% of women who entered after their third cycle of attempt were excluded (Steiner et al., 2017).

In another cohort study, 102 women, aged 18 to 46 years, were prospectively followed for 12 cycles. Analyses adjusted for age showed no predictive value of AMH, basal FSH or the AFC for time to ongoing pregnancy (hazard ratio (HR) 1.43, 95% CI 0.84-2.46; HR 0.96, 95% CI 0.86-1.06 and HR 1.03, 95% CI 1.00-1.07, respectively) (Depmann et al., 2017).

Similar AMH levels and AFC were reported in 382 female partners of infertile couples and 350 women with no history of infertility. Moreover, the proportion of women with very low serum AMH levels (with two different cut-offs of serum AMH <5pmol/L or AFC <7) was similar in two cohorts. The findings were similar when the analyses were restricted to women with UI. All analyses were adjusted for age and other relevant factors (Hvidman et al., 2016).

In a small cohort study, 83 women with UI were prospectively followed for 6 cycles. Serum AMH and FSH levels, as well as AFC were similar between 14 women who achieved a spontaneous pregnancy during the observation period and 69 women who did not. AUC values for AMH, FSH and AFC for prediction of a spontaneous pregnancy were 0.39 (95% CI 0.25-0.52), 0.42 (95% CI 0.25-0.58) and 0.42 (95% CI 0.26-0.57), respectively. Moreover, pregnancy and live birth rates were similar between women with AMH levels <0.75 ng/mL and above (Casadei et al., 2013).

In a small cohort study, cycle day 2 AMH levels were compared between 42 women with UI and 29 women with male factor infertility. Median serum AMH levels were similar between UI and male factor groups (19.3 pmol/L (range 1.3-60.8 pmol/L; vs. 21.1 pmol/L (range 5.3-60.8, respectively)). AMH alone was a poor predictor of live birth in five years (Murto et al., 2013).

In a cohort study, 186 couples who attempted pregnancy for six menstrual cycles were prospectively observed. Women were between 20 and 35 years old. Compared with women in medium serum AMH levels (quintiles 2 – 4 of the study population), women with low AMH levels (lowest quintile) had similar fecundability (HR 0.81, 95% CI 0.44-1.40), while women with high AMH (in quintile 5) had lower fecundability (HR 0.62, 95% CI 0.39-0.99). Analyses were adjusted for female age, BMI, smoking, diseases affecting fecundability, and oligozoospermia. When women with irregular cycles were excluded the high AMH group still had lower fecundability rate (FR, i.e., monthly probability of conceiving) (FR 0.48, 95% CI 0.27–0.85) (Hagen et al., 2012).

In a cross-sectional study, AMH, FSH and AFC were compared between 227 women with strictly defined UI and 226 control women. Women were aged between 25 and 40 years and required to have a serum FSH level <12 IU/L on cycle day 3 within the previous year. Analyses adjusted for age, race, BMI, smoking status and recruitment site showed similar AMH levels and AFC in the two groups. It should be noted that inclusion of women with FSH >12 IU/L during the previous year, might have yielded different results (Greenwood et al., 2017).
In a retrospective study including 325 couples who presented for assessment of infertility and did not have an absolute indication for IVF/ICSI (e.g., bilateral tubal blockage), serum AMH level was not a significant predictor of natural conception in a Cox regression analysis adjusted for female age, type of infertility (primary or secondary), duration of infertility, and percentage of motile sperm (Nguyen et al. 2022). However, the addition of AMH level into the Hunault model was found to improve the accuracy of the model to some extent (Hunault et al., 2004, Nguyen et al., 2022).

**ANTRAL FOLLICLE COUNT (AFC)**

**Evidence**

A cohort study, including 83 women with UI undergoing six months of expectant management, reported a spontaneous pregnancy rate of 17% (14/83). Antral follicle count (AFC) was not predictive of spontaneous pregnancy with an AUC of 0.418 ± 0.08 (95% CI 0.26-0.57) (Casadei, et al., 2013).

In another cohort study, 102 women, aged 18 to 46 years, were prospectively followed for 12 cycles. Analyses adjusted for age showed no predictive effect of AMH, basal FSH or the AFC for time to ongoing pregnancy (HR 1.43, 95% CI 0.84-2.46; HR 0.96, 95% CI 0.86-1.06 and HR 1.03, 95% CI 1.00-1.07, respectively) (Depmann, et al., 2017).

Similar AMH levels and AFC were reported in 382 female partners of infertile couples and 350 women with no history of infertility. Moreover, the proportion of women with very low serum AMH levels (with two different cut-offs of serum AMH <5 pmol/L or AFC <7) was similar in two cohorts. The findings were similar when the analyses were restricted to women with UI. All analyses were adjusted for age and other relevant factors (Hvidman, et al., 2016).

A cohort study compared cycle day 2-4 AFC in 148 women with UI and 112 women with male factor infertility. Women with UI had lower AFC than the male factor group (9 (3-16) vs. 10 (3-23) respectively). Log regression with infertility as the dependent showed that AFC was not significantly associated with UI, after adjusting for age (Yücel, et al., 2018).

Rosen et al. compared 881 women with UI with 771 women with regular ovulatory cycles from a community study. Women aged between 25 and 40 years in the UI group had significantly lower AFC than similarly aged women in the community group, women between 40 and 45 years had similar AFC in both groups. Serum FSH levels were significantly higher in UI women who were 31–35 years of age and show a tendency to be higher in UI women who were 25–30 years of age. There were no differences in FSH concentrations between groups in women who were 36–40 or 41–45 years of age. However, the authors employed bivariate comparisons for 5-year age brackets rather than using a multivariate model adjusting for significantly lower age in the community group (Rosen et al., 2011).

In a cross-sectional study, AMH, FSH and AFC were compared between 227 women with strictly defined UI and 226 control women. Women were aged between 25 and 40 years and required to have a serum FSH level <12 IU/L on cycle day 3 within the previous year. Analyses adjusted for age, race, BMI, smoking status and recruitment site showed similar AMH levels and AFC in the two groups. It should be noted that inclusion of women with FSH >12 IU/L during the previous year, might have yielded different results (Greenwood, et al., 2017).
**DAY 3 FSH AND OESTRADIOL**

**Evidence**
A cohort study, including 750 women without infertility, found no difference in cumulative probability of conception for women with FSH>10 IU/L (HR 1.22, 0.92-1.62) after adjusting for confounding factors (Steiner, et al., 2017).

A cohort study compared cycle day 2-4 FSH in 148 women with UI and 112 women with male factor infertility. Women with UI had similar FSH compared to the male factor group (7.52 (range 4.21-9.88) IU/L vs. 6.96 (range 5.1-9.37) IU/L respectively). Likewise, oestradiol levels were similar in UI and male factor (169.95 (range j89 -284) pmol/l vs. 143.5 (range 28.3 -7234 pmol/l) (Yücel, et al., 2018).

**CLOMIPHENE CITRATE CHALLENGE TEST (CCCT)**

**Evidence**
A cohort study including 236 women from the general ovulating infertility population found that 52% of women with UI (12/32) had an abnormal Clomiphene citrate challenge test (CCCT) as compared to 17.4% for oligo/anovulation, 8.7% for male factor, 4.3% for tubal factor, 4.3% for endometriosis, and 0% for pelvic adhesions. Women with an abnormal CCCT were less likely to conceive as compared to women with a normal result (Scott et al., 1993).

**OVARIAN VOLUME, OVARIAN BLOOD FLOW, INHIBIN B**

**Evidence**
A cohort study, including 750 women without infertility, found no association of inhibin B levels and cumulative probability of conception (HR 0.999, 0.997-1.001, per 1 pg/ml increase in inhibin B level) after adjusting for confounding factors (age, body mass index, race, current smoking status, and recent hormonal contraceptive use) (Steiner, et al., 2017).

A cohort study compared cycle day 2-4 ovarian volume in 148 women with UI and 112 women with male factor infertility. Women with UI had similar ovarian volume as compared to the male factor group (6.2 ml (range 3.2-10.96) vs. 6.06 ml (range 3.3-12.2) respectively). Likewise, inhibin B levels were similar in UI and male factor (119 pg/ml (range 40-145) vs. 120 pg/ml (range 52-150)) (Yücel, et al., 2018).

In a small cohort study cycle day 2-5 inhibin B levels were compared between 42 women with UI and 29 women with male factor infertility. Median serum inhibin B levels were similar between UI and male factor groups (37.1 (range 7.0-95.4) vs. 47.5 (range 13-138.4) pg/ml respectively). Inhibin B alone was a poor predictor of live birth in 5 years (Murto, et al., 2013).

**OVERALL RECOMMENDATION**

| 2.3.1 | In women with regular menstrual cycles, ovarian reserve testing is not required to identify the aetiology of infertility or to predict the probability of spontaneous conception over 6 to 12 months. | EBR against | ☀️☀️☀️ |
Justification
The term “ovarian reserve” often refers to the quantity of primordial follicles in the ovaries at a given time. Although the term has also been used in a broader sense to include quality of oocytes, it is difficult to assess oocyte quality during the diagnostic work up.

The purpose of diagnostic work up is to identify any factor preventing pregnancy or decreasing spontaneous fecundity and to inform management strategy.

For the first aim, ovarian reserve would be relevant if regularly ovulating women in different categories of ovarian reserve, i.e., low, normal or high, have different conception rates when every other factor is similar, chronological age in particular. Since women cannot be randomised to different categories of ovarian reserve, this question can be answered by two different study designs: comparing conception rates between women with different ovarian reserve (prospective cohort study or cross-sectional study) or comparing ovarian reserve between fertile women and women with UI (case-control study).

Most of the listed studies consistently show that ovarian reserve status is not predictive of spontaneous conception over the subsequent 6-12 months. As long as they maintain regular menstrual cycles, women with decreased ovarian reserve seem to have a similar spontaneous pregnancy rate with women of similar age who have normal ovarian reserve. These observations effectively exclude decreased ovarian reserve per se as a reason for infertility. Thus, an ovarian reserve test (ORT) is not required from a diagnostic standpoint.

ORT would be relevant for choice of management if ovarian reserve status is a determinant of the probability of pregnancy with expectant management, OS-IUI or IVF. Studies reviewed above do not suggest that ovarian reserve status would determine the probability of a spontaneous pregnancy in 6-12 months, so ORT may not be informative to predict the success of expectant management over such a period. While one retrospective study suggests improved accuracy of the Hunault model used to categorise couples based on their anticipated chance of spontaneous conception, it needs to be validated prospectively and for other settings where referral by primary care is not required before consulting a fertility specialist (Hunault, et al., 2004, Nguyen, et al., 2022). While a retrospective study including 3019 women younger than 35 years old, who underwent IUI in a natural or stimulated cycle, reported similar cumulative live birth rates up to seven IUI cycles between women with serum AMH levels less than 1 ng/ml and higher than 1 ng/ml (Tiegs et al., 2020), another retrospective study including 1861 gonadotropin stimulated IUI cycles without an age limit reported that women in the lower 25th percentile of the study population for serum AMH levels, or women with serum AMH level < 0.7 ng/ml were significantly less likely to achieve a clinical pregnancy over six cycles as compared with women higher AMH levels (Vagios et al., 2021). Another retrospective study including 195 couples also reported a positive correlation between serum AMH level and cumulative pregnancy rate over three OS-IUI cycles (Bakas et al., 2015). It should be noted that the study populations were not limited to UI in the latter two studies and a variety of OS protocols have been used. In addition to the limitations of retrospective design, these features introduce some heterogeneity and limit generalisability of findings to UI. It is uncertain whether ovarian reserve status determines the probability of pregnancy with OS-IUI cycles, where the aim should be to limit the number of growing follicles to 2 – 3 to prevent multiple pregnancies. It may be inappropriate to exclude women from OS-IUI based on ovarian reserve status.

On the other hand, ovarian response, hence ovarian reserve, is a major determinant of cumulative probability of live birth per OS cycle in IVF. Women with decreased ovarian reserve will have lower
pregnancy/live birth rate per cycle with IVF (because of a low number of oocytes/stimulation) compared to women with similar characteristics but higher ovarian reserve. Thus, diverting women with low ovarian reserve directly or rapidly to IVF is questionable.

The Australian GDG determined that this PICO question cannot be determined by an RCT and is reliant on observational cohort studies which are automatically rated as lower quality. Hence this was determined as a strong recommendation considering the benefits of risks versus harms as uptake would increase if this was conditional. One GDG member did not vote to retain this as a strong recommendation.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES


Greenwood EA, Cedars MI, Santoro N, Eisenberg E, Kao CN, Haisenleder DJ, Diamond MP, Huddleston HG. Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility. Fertility and sterility 2017;108: 1070-1077.


Tiegs AW, Sun L, Scott RT, Jr., Goodman LR. Comparison of pregnancy outcomes following intrauterine insemination in young women with decreased versus normal ovarian reserve. *Fertility and sterility* 2020;113: 788-796.e784.


Yücel B, Kelekci S, Demirel E. Decline in ovarian reserve may be an undiagnosed reason for unexplained infertility: a cohort study. *Archives of medical science* : AMS 2018;14: 527-531.

### 2.4 Tubal factor

**PICO QUESTION: WHAT IS THE ACCURACY OF COMMONLY USED TESTS OF TUBAL PATENCY?**

**HYSTERO-CONTRAST-SONOGRAPHY (HyCoSy/HyFoSy) VS. LAPAROSCOPY AND CHROMOPERTUBATION TEST**

**Evidence**

A systematic review and meta-analysis including 1977 patients with subfertility in 21 studies investigated the sensitivity and specificity of hystero-contrast-sonography (HyCoSy/HyFoSy) in the diagnosis of tubal pathology using laparoscopy with chromopertubation as the reference standard (Alcázar et al., 2020). For 2D-HyCoSy the pooled sensitivity and specificity were 0.86 (95% CI 0.80–0.91) and 0.94 (95% CI 0.90–0.96), respectively. The likelihood ratio (LR) for detecting tubal occlusion with 2D-HyCoSy were 0.14 (95% CI 0.08–0.23) for LR+ and 0.14 (95% CI 0.1–0.2) for LR−, respectively. High heterogeneity was found for sensitivity (p<0.001) and for specificity (p<0.001). For 3D/4D-HyCoSy the pooled sensitivity and specificity were 0.95 (95% CI 0.89–0.98) and 0.89 (95% CI 0.82–0.94), respectively. The LR for detecting tubal occlusion with 3D/4D-HyCoSy were 0.09 (95% CI 0.05–0.16) for LR+, and 0.06 (95% CI 0.03–0.13) for LR−, respectively. Both sonography methods had almost identical areas under the curve (0.96 for 2D-HyCoSy and 0.97 for 3D/4D-HyCoSy) (Alcázar, et al., 2020).

Another systematic review and meta-analysis including 1553 patients in 23 studies investigated the sensitivity and specificity of 3D- and 4D-HyCoSy for tubal patency using laparoscopy as the gold standard. The pooled estimates of sensitivity and specificity were 0.92 (95% CI 0.90–0.94) and 0.92 (95% CI 0.89–0.93), respectively. The area under the ROC curve was 0.97 (95% CI 0.95–0.98) (Wang and Qian, 2016).

Table 1 includes all other studies included as for evidence on the comparison between HyCoSy and laparoscopy and chromopertubation that were not included in the meta-analyses. True and false positive and true and false negative data were extracted from the included publications, followed by calculations on sensitivity, specificity, predictive values and likelihood ratios by the GDG. The unadjusted pooled accuracy of HyCoSy showed a sensitivity of 0.87 (95% CI 0.74–1.00) and a specificity of 0.83 (95% CI 0.77–0.90) (Table 1).
Table 1: Accuracy of HyCoSy compared to gold standard laparoscopy and chromopertubation for tubal patency testing. True and false positive and true and false negative data were extracted from the included publications followed by calculations on sensitivity, specificity, predictive values and likelihood ratios by the GDG. PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Method</th>
<th>No of patients</th>
<th>Clinical background</th>
<th>True positive</th>
<th>False positive</th>
<th>True negative</th>
<th>False negative</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>LR+</th>
<th>LR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Chen et al., 2019)</td>
<td>4D-HyCoSy contrast medium</td>
<td>34</td>
<td>Not specified</td>
<td>23</td>
<td>4</td>
<td>32</td>
<td>3</td>
<td>0.88</td>
<td>0.89</td>
<td>0.85</td>
<td>0.91</td>
<td>7.96</td>
<td>0.13</td>
</tr>
<tr>
<td>(Cimen et al., 1999)</td>
<td>HyCoSy contrast medium</td>
<td>47</td>
<td>No patients included with a suspicion of acute or chronic PID</td>
<td>9</td>
<td>3</td>
<td>22</td>
<td>2</td>
<td>0.82</td>
<td>0.88</td>
<td>0.75</td>
<td>0.92</td>
<td>6.82</td>
<td>0.21</td>
</tr>
<tr>
<td>(Liang et al., 2019)</td>
<td>3D-HyCoSy contrast medium</td>
<td>83</td>
<td>Not specified</td>
<td>86</td>
<td>8</td>
<td>58</td>
<td>10</td>
<td>0.90</td>
<td>0.88</td>
<td>0.91</td>
<td>0.85</td>
<td>7.39</td>
<td>0.12</td>
</tr>
<tr>
<td>(Malek-Mellouli et al., 2013)</td>
<td>HyCoSy saline</td>
<td>40</td>
<td>No vaginal, cervical, or pelvic infection</td>
<td>21</td>
<td>8</td>
<td>44</td>
<td>7</td>
<td>0.75</td>
<td>0.85</td>
<td>0.72</td>
<td>0.86</td>
<td>4.88</td>
<td>0.30</td>
</tr>
<tr>
<td>(Radić et al., 2005)</td>
<td>saline contrast medium</td>
<td>37</td>
<td>No patients with any signs of pelvic infection</td>
<td>47</td>
<td>30</td>
<td>58</td>
<td>0</td>
<td>1.00</td>
<td>0.66</td>
<td>0.61</td>
<td>1.00</td>
<td>2.93</td>
<td>0.00</td>
</tr>
<tr>
<td>(Shahid et al., 2005)</td>
<td>HyCoSy contrast medium</td>
<td>15</td>
<td>History suggestive of ovulatory factors (PCO), pelvic inflammatory disease and endometriosis was noted</td>
<td>7</td>
<td>0</td>
<td>7</td>
<td>1</td>
<td>0.88</td>
<td>1.00</td>
<td>1.00</td>
<td>0.88</td>
<td>N/A</td>
<td>0.13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19</td>
<td></td>
<td>7</td>
<td>0</td>
<td>2</td>
<td>12</td>
<td>0.29</td>
<td>1.00</td>
<td>1.00</td>
<td>0.14</td>
<td>N/A</td>
<td>0.71</td>
</tr>
<tr>
<td>(Zhou et al., 2012)</td>
<td>3D-HyCoSy contrast medium</td>
<td>75</td>
<td>No acute or subacute inflammation of the reproductive system</td>
<td>72</td>
<td>10</td>
<td>63</td>
<td>5</td>
<td>0.94</td>
<td>0.86</td>
<td>0.88</td>
<td>0.93</td>
<td>6.83</td>
<td>0.08</td>
</tr>
</tbody>
</table>
**Hysterosalpingography (HSG) vs. Laparoscopy and Chromopertubation Test**

**Evidence**

A systematic review and meta-analysis including seven studies with 4521 women investigated the sensitivity and specificity of hysterosalpingography (HSG) in the diagnosis of tubal pathology using laparoscopy with chromopertubation as the reference standard (Broeze et al., 2011). The sensitivity of HSG for any tubal pathology ranged between 46% and 100% and specificity between 73% and 100% across the studies. The unadjusted pooled accuracy of HSG showed a sensitivity of 0.70 (95% CI 0.66–0.74) and a specificity of 0.78 (95% CI 0.75–0.80). After imputation of missing laparoscopy results (for 2632 women), these rates were 0.53 (95% CI 0.50–0.57) and 0.87 (95% CI 0.86–0.88) for sensitivity and specificity, respectively. In women with a low-risk clinical history (no previous pelvic inflammatory disease (PID) and with negative chlamydia antibody testing result), the sensitivity of HSG for detecting unilateral tubal pathology was 38% versus 61% in women with a high-risk history (previous PID and with negative chlamydia antibody testing result). For bilateral tubal pathology, sensitivity ranged between 0% and 100% and specificity ranged between 87% and 97% across the individual studies. The pooled estimates for sensitivity and specificity were 0.66 (95% CI 0.55–0.75) and 0.91 (95% CI 0.89–0.93), respectively. After imputation of laparoscopy results, these rates were 0.46 (95% CI 0.41–0.51) and 0.95 (95% CI 0.94–0.95) (Broeze, et al., 2011).

Table 2 includes 18 studies from the evidence review by the GDG that were not included in the systematic review and meta-analysis by Broeze et al. Only studies were included that had data available to calculate test performance by the GDG. True and false positive and true and false negative data were extracted from the included publications followed by calculations on sensitivity, specificity, predictive values and likelihood ratios. To support the systematic review by Broeze et al. showing high sensitivity and specificity for HSG, the pooled sensitivity and specificity of these additional 18 studies were 0.86 (95% CI 0.78–0.94) and 0.79 (95% CI 0.72–0.86), respectively.
Table 2: Accuracy of HSG compared to gold standard laparoscopy and chromopertubation for tubal patency testing. True and false positive and true and false negative data were extracted from the included publications followed by calculations on sensitivity, specificity, predictive values and likelihood ratios by the GD. PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio.

<table>
<thead>
<tr>
<th>Reference</th>
<th>No of patients</th>
<th>Clinical background</th>
<th>True positive</th>
<th>False positive</th>
<th>True negative</th>
<th>False negative</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>LR+</th>
<th>LR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Adelusi et al., 1995)</td>
<td>104</td>
<td>Not specified</td>
<td>42</td>
<td>21</td>
<td>33</td>
<td>8</td>
<td>0.84</td>
<td>0.61</td>
<td>0.67</td>
<td>0.80</td>
<td>2.16</td>
<td>0.26</td>
</tr>
<tr>
<td>(Agrawal and Fayyaz, 2019)</td>
<td>103</td>
<td>No active genitourinary infection</td>
<td>38</td>
<td>31</td>
<td>34</td>
<td>0</td>
<td>1.00</td>
<td>0.52</td>
<td>0.55</td>
<td>1.00</td>
<td>2.10</td>
<td>0.00</td>
</tr>
<tr>
<td>(Berker et al., 2015)</td>
<td></td>
<td>Bilateral</td>
<td>25</td>
<td>9</td>
<td>175</td>
<td>1</td>
<td>0.96</td>
<td>0.95</td>
<td>0.74</td>
<td>0.99</td>
<td>19.66</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unilateral</td>
<td>13</td>
<td>30</td>
<td>175</td>
<td>2</td>
<td>0.87</td>
<td>0.85</td>
<td>0.30</td>
<td>0.99</td>
<td>5.92</td>
<td>0.16</td>
</tr>
<tr>
<td>(Chang et al., 1987)</td>
<td>1267</td>
<td>Not specified</td>
<td>944</td>
<td>95</td>
<td>171</td>
<td>57</td>
<td>0.94</td>
<td>0.64</td>
<td>0.91</td>
<td>0.75</td>
<td>2.64</td>
<td>0.09</td>
</tr>
<tr>
<td>(Dabekausen et al., 1994)</td>
<td>34</td>
<td>Not specified</td>
<td>7</td>
<td>5</td>
<td>17</td>
<td>5</td>
<td>0.58</td>
<td>0.77</td>
<td>0.58</td>
<td>0.77</td>
<td>2.57</td>
<td>0.54</td>
</tr>
<tr>
<td>(Foroozanfard and Sadat, 2013)</td>
<td></td>
<td>All</td>
<td>62</td>
<td>10</td>
<td>35</td>
<td>8</td>
<td>0.53</td>
<td>0.78</td>
<td>0.47</td>
<td>0.81</td>
<td>2.38</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral</td>
<td>9</td>
<td>10</td>
<td>35</td>
<td>8</td>
<td>0.53</td>
<td>0.78</td>
<td>0.47</td>
<td>0.81</td>
<td>2.38</td>
<td>0.61</td>
</tr>
<tr>
<td>(Gündüz et al., 2021)</td>
<td>208</td>
<td>No chronic disease or history of abdominal surgery</td>
<td>61</td>
<td>47</td>
<td>86</td>
<td>14</td>
<td>0.81</td>
<td>0.65</td>
<td>0.56</td>
<td>0.86</td>
<td>2.30</td>
<td>0.29</td>
</tr>
<tr>
<td>(Hamed et al., 2009)</td>
<td>88</td>
<td>No pelvic infections or organic lesions</td>
<td>36</td>
<td>16</td>
<td>54</td>
<td>8</td>
<td>0.82</td>
<td>0.77</td>
<td>0.69</td>
<td>0.87</td>
<td>3.58</td>
<td>0.24</td>
</tr>
<tr>
<td>(Hiroi et al., 2007)</td>
<td></td>
<td>Bilateral</td>
<td>18</td>
<td>15</td>
<td>192</td>
<td>12</td>
<td>0.60</td>
<td>0.93</td>
<td>0.55</td>
<td>0.94</td>
<td>8.28</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unilateral</td>
<td>15</td>
<td>11</td>
<td>192</td>
<td>39</td>
<td>0.28</td>
<td>0.95</td>
<td>0.58</td>
<td>0.83</td>
<td>5.13</td>
<td>0.76</td>
</tr>
<tr>
<td>(Ismajovich et al., 1986)</td>
<td>215</td>
<td>Not specified</td>
<td>53</td>
<td>34</td>
<td>88</td>
<td>40</td>
<td>0.57</td>
<td>0.72</td>
<td>0.61</td>
<td>0.69</td>
<td>2.04</td>
<td>0.60</td>
</tr>
<tr>
<td>(Keltz et al., 2006)</td>
<td>210</td>
<td>9.04% of patients reported a prior history of Chlamydia infection or PID</td>
<td>40</td>
<td>3</td>
<td>19</td>
<td>11</td>
<td>0.78</td>
<td>0.86</td>
<td>0.93</td>
<td>0.63</td>
<td>5.75</td>
<td>0.25</td>
</tr>
<tr>
<td>(Loy et al., 1989)</td>
<td>77</td>
<td>Not specified</td>
<td>16</td>
<td>16</td>
<td>41</td>
<td>4</td>
<td>0.80</td>
<td>0.72</td>
<td>0.50</td>
<td>0.91</td>
<td>2.85</td>
<td>0.28</td>
</tr>
<tr>
<td>(Ngowa et al., 2015)</td>
<td></td>
<td>Bilateral</td>
<td>208</td>
<td>3</td>
<td>27</td>
<td>24</td>
<td>0.51</td>
<td>0.90</td>
<td>0.89</td>
<td>0.53</td>
<td>5.10</td>
<td>0.54</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Distal</td>
<td>59</td>
<td>26</td>
<td>19</td>
<td>9</td>
<td>0.87</td>
<td>0.42</td>
<td>0.69</td>
<td>0.68</td>
<td>1.50</td>
<td>0.31</td>
</tr>
<tr>
<td>Reference</td>
<td>No of patients</td>
<td>Clinical background</td>
<td>True positive</td>
<td>False positive</td>
<td>True negative</td>
<td>False negative</td>
<td>Sensitivity</td>
<td>Specificity</td>
<td>PPV</td>
<td>NPV</td>
<td>LR+</td>
<td>LR-</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>(Rice et al., 1986)</td>
<td>143</td>
<td>Not specified</td>
<td>58</td>
<td>11</td>
<td>62</td>
<td>12</td>
<td>0.83</td>
<td>0.85</td>
<td>0.84</td>
<td>0.84</td>
<td>5.50</td>
<td>0.20</td>
</tr>
<tr>
<td>(Tan et al., 2021)</td>
<td>644</td>
<td>20.97% (n = 181) of patients had a history of previous pelvic surgery.</td>
<td>477</td>
<td>3</td>
<td>143</td>
<td>21</td>
<td>0.96</td>
<td>0.98</td>
<td>0.99</td>
<td>0.87</td>
<td>46.61</td>
<td>0.04</td>
</tr>
<tr>
<td>(Tshabu-Aguemon et al., 2014)</td>
<td>96</td>
<td>patients investigated for tubal infertility</td>
<td>45</td>
<td>11</td>
<td>20</td>
<td>20</td>
<td>0.69</td>
<td>0.65</td>
<td>0.80</td>
<td>0.50</td>
<td>1.95</td>
<td>0.48</td>
</tr>
<tr>
<td>(Tvarijonaviciene and Nadisauskiene, 2008)</td>
<td>149</td>
<td>No previous laparoscopic or abdominal tubal surgery related to infertility.</td>
<td>48</td>
<td>47</td>
<td>43</td>
<td>11</td>
<td>0.81</td>
<td>0.48</td>
<td>0.51</td>
<td>0.80</td>
<td>1.56</td>
<td>0.39</td>
</tr>
</tbody>
</table>
Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR</th>
<th>PP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4.1 Hystero-contrast-sonography (HyCoSy) and hysteron-salpingography (HSG) should be recommended as valid tests for tubal patency, compared to laparoscopy and chromopertubation.</td>
<td>⊕⊕⊕</td>
<td>⊙⊙⊙⊙</td>
</tr>
<tr>
<td>2.4.2 HSG and HyCoSy are comparable in diagnostic capacity, thus selection of the technique depends on the preference of the clinician and the patient.</td>
<td>PP</td>
<td></td>
</tr>
<tr>
<td>2.4.2 Chlamydia antibody testing for tubal patency could be considered a non-invasive test to differentiate between patients at low and high risk for tubal occlusion.</td>
<td>⊕</td>
<td>ØØØØ</td>
</tr>
<tr>
<td>In patients at high-risk for tubal abnormality, visual demonstration of tubal patency is necessary.</td>
<td>PP</td>
<td></td>
</tr>
</tbody>
</table>

Justification

High risk for tubal occlusion includes past chlamydia infection, PID, peritonitis, known endometriosis and/or pelvic surgery including salpingectomy for ectopic pregnancy. As for the evidence, not all studies described whether the test was done in low/high-risk population. In most of the cases the population was selected to be of low-risk, and this has to be taken into consideration in the recommendation formulated by the GDG. The mechanical tubal flushing has been considered as “treatment” and has been evaluated for evidence in section III.3 mechanical-surgical procedures.

In the Australian adaptation, access for underserved populations and regional and rural settings was noted as a barrier to care that needs to be considered. These recommendations are considered to increase access to care including in Indigenous populations and others living in regional areas. However, it was noted that while a higher proportion of Indigenous individuals reside in rural areas, substantial absolute numbers still inhabit urban centres, underscoring the significance of achieving accessible, timely, and equitable care across diverse geographical contexts.

HyCoSy

The current evidence for HyCoSy compared to laparoscopy and chromopertubation, consisting of two systematic reviews and meta-analyses including 44 cohort studies and eight additional cohort studies not included in the meta-analysis, showed that HyCoSy is a valid test for tubal patency. Even though there was high variation in data, there was overall high specificity and sensitivity for HyCoSy. All sonography types (2/3/4D) performed well.

The GDG cannot formulate a recommendation on the use of contrast medium, foam or saline due to too little studies. It has to be noted that the evidence synthesis included studies including contrast medias that are off-label use and some are no longer at the market. A recent systematic review and meta-analysis investigated the frequency of severe pain perception during HyCoSy with different contrast agents (contrast media, saline or foam) and found similar occurrence of mild, moderate and severe pain for all types of contrast during the procedure (Boned-López et al., 2021).

HSG

The current evidence, consisting of a systematic review and meta-analysis including seven cohort studies and 14 additional cohort studies not included in the meta-analysis, showed that HSG is a valid test for tubal patency and less costly and harmful than laparoscopy. The risk for HSG (oil or water-based
contrast media) has been evaluated to be low in a recent study by Roest et al. including 3289 HSG cases; overall complication risk was 5.1% for oil-based HSG and 1.8% for water based HSG (Roest et al., 2020). The same study also reported intravasation in 4.8% of cases for oil-based contract and 1.3% for the water-based (Roest, et al., 2020). Procedure-related PID was rare (0.3% for oil-based contracts and 0.4% for water-based) and no pulmonary embolism or deaths were reported. Clinical history increases the accuracy of HSG testing although as a limitation, HSG has very limited possibility to detect abdominal adhesions compared to laparoscopy.

HyCoSy (using saline or foam) is less harmful than laparoscopy or HSG, given that the women going through HyCoSy can be assessed immediately after ultrasound, allowing the evaluation of the fallopian tubes and uterine cavity in one test. Furthermore, there is no need for general anaesthesia or exposure to radiation with the use of HyCoSy/HyFoSy.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

CHLAMYDIA ANTIBODY TESTING VS. LAPAROSCOPY AND CHROMOPERTUBATION TEST

Antibodies against Chlamyida Trachomatis (CT), can be maintained in sera for at least 10 years after infection (Horner et al., 2013, Horner et al., 2016) and are the only available means for determining prior CT infection.

Evidence
A systematic review and meta-analysis including 2729 patients with subfertility in 23 studies investigated the sensitivity and specificity of Chlamydia antibody titres in the diagnosis of tubal pathology using laparoscopy with chromopertubation as the reference standard (Mol et al., 1997). The sensitivity of Chlamydia antibody testing (CAT) for tubal pathology varied between 0.21 and 0.90, with the specificity varying between 0.29 and 1. There was substantial heterogeneity between studies also with regards to the method used for verifying tubal pathology. The discriminative capacity of CAT was significantly different between studies using micro immunofluorescence (MIF) or immunofluorescence (IF) and ELISA or immunoperoxidase (IP) with MIF/IF and ELISA performing equally and IP showing the lowest performance in the estimated summary ROC curve (Mol, et al., 1997).

The 13 studies that were not included in the systematic review and meta-analysis by Mol et al. (Table 3), showed similar results, pooled sensitivity was quite low 0.61 (95% CI 0.54-0.67), but specificity was as high as 0.83 (95% CI 0.78-0.88). This also reflected the positive and negative predictive value for the antibody testing (pooled PPV 0.58 and NPV 0.85). Combining medical history or transvaginal ultrasound (TVUS) with CAT increased the test performance (Akande et al., 2003, Coppus et al., 2007, Logan et al., 2003). Moreover, quantitative titre threshold could also reveal severity of damage (Akande, et al., 2003).

Recommendation

<table>
<thead>
<tr>
<th>2.4.2</th>
<th>Chlamydia antibody testing for tubal patency could be considered a non-invasive test to differentiate between patients at low and at high risk for tubal occlusion.</th>
<th>EBR</th>
<th>PP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In patients at high-risk for tubal abnormality, visual demonstration of tubal patency is necessary.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Justification
The current evidence, consisting of a systematic review and meta-analysis including 23 cohort studies, and an additional 13 cohort studies that were published after the systematic review, showed CAT could be considered a non-invasive test to differentiate between patients at low and at high risk for tubal occlusion. However, although the techniques were not compared head-to-head, the sensitivity versus laparoscopy is lower compared to HSG and HyCoSy. The specificity seems to be good across different tests. It has to be noted that the validity of the test varies according to the assay used. This was investigated in a cohort study that reported a discrepancy in 21% of patients between MIF and ELISA assays for IgG (Gijsen et al., 2002). Moreover, CAT does not allow evaluation of the degree of occlusion or occlusions due to other infections than CT.

The reviewed data suggests a role (although limited) for CAT in clinical practice. Given the low false negative rate in testing, a negative result combined with low-risk medical history could be considered specific for tubal patency. Given the somewhat low PPV for the CAT, both a positive test as well as a negative test combined with a high-risk medical history should be confirmed with visual methods like HyCoSy, HSG or laparoscopy depending on the assessments needed. To highlight the role for medical history, Hubacher et al. reported tubal pathology (confirmed by laparoscopy) in 84.3% of patients with a high-risk medical history (based on a logistic regression model using past pelvic inflammatory disease symptoms, previous history of a lower genital tract infection, previous vaginal discharge, and antibodies to Chlamydia trachomatis) (Hubacher et al., 2004). Since the systematic review by Mol et al., newer antibodies and more specific CAT have emerged with improved performance of these tests, however, limitations especially with sensitivity still remain (Horner et al., 2021).

Further information
Details of the literature study and evidence tables are available in the Technical Report

Overall, in the Australian setting, the urgent national requirement for further research on epidemiology diagnosis and management of infertility in Indigenous Australian populations was recognised, especially in relation to tubal patency.
Table 3: Accuracy of Chlamydia antibody testing compared to gold standard laparoscopy and dye for tubal patency testing. IF: immunofluorescence, MIF: micro immunofluorescence. True and false positive and true and false negative data were extracted from the included publications followed by calculations on sensitivity, specificity, predictive values and likelihood ratios by the GDG. PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Method</th>
<th>No of patients</th>
<th>Clinical background</th>
<th>True positive</th>
<th>False positive</th>
<th>True negative</th>
<th>False negative</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>LR+</th>
<th>LR-</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Babay and Al-Meshari, 1993)</td>
<td>Iodine stain</td>
<td>75</td>
<td>History of urinary tract infection, history of PID, history of previous pelvic surgery was recorded</td>
<td>33</td>
<td>16</td>
<td>21</td>
<td>5</td>
<td>0.87</td>
<td>0.57</td>
<td>0.67</td>
<td>0.81</td>
<td>2.01</td>
<td>0.23</td>
</tr>
<tr>
<td>(Akande, et al., 2003)</td>
<td>IF</td>
<td>434</td>
<td>Not specified</td>
<td>358</td>
<td>192</td>
<td>380</td>
<td>76</td>
<td>0.82</td>
<td>0.66</td>
<td>0.65</td>
<td>0.83</td>
<td>2.46</td>
<td>0.26</td>
</tr>
<tr>
<td>(Sönmez et al., 2008)</td>
<td>IF</td>
<td>152</td>
<td>No patients with history of pelvic surgery, endometriosis, tuberculosis</td>
<td>18</td>
<td>18</td>
<td>62</td>
<td>27</td>
<td>0.40</td>
<td>0.78</td>
<td>0.50</td>
<td>0.70</td>
<td>1.78</td>
<td>0.77</td>
</tr>
<tr>
<td>(Veenemans and van der Linden, 2002)</td>
<td>IF</td>
<td>277</td>
<td>Women with only one tube or tuboperitoneal abnormality not caused by CT</td>
<td>28</td>
<td>50</td>
<td>60</td>
<td>7</td>
<td>0.80</td>
<td>0.55</td>
<td>0.36</td>
<td>0.90</td>
<td>1.76</td>
<td>0.37</td>
</tr>
<tr>
<td>(den Hartog et al., 2004)</td>
<td>MIF</td>
<td>313</td>
<td>No previous pelvic surgery</td>
<td>32</td>
<td>20</td>
<td>234</td>
<td>27</td>
<td>0.54</td>
<td>0.92</td>
<td>0.62</td>
<td>0.90</td>
<td>6.89</td>
<td>0.50</td>
</tr>
<tr>
<td>(den Hartog et al., 2005)</td>
<td>MIF IgG</td>
<td>313</td>
<td>No previous pelvic surgery</td>
<td>32</td>
<td>20</td>
<td>234</td>
<td>27</td>
<td>0.54</td>
<td>0.92</td>
<td>0.62</td>
<td>0.90</td>
<td>6.89</td>
<td>0.50</td>
</tr>
<tr>
<td></td>
<td>EIA IgA</td>
<td>313</td>
<td>No previous pelvic surgery</td>
<td>21</td>
<td>21</td>
<td>233</td>
<td>38</td>
<td>0.36</td>
<td>0.92</td>
<td>0.50</td>
<td>0.86</td>
<td>4.31</td>
<td>0.70</td>
</tr>
<tr>
<td>(Ng et al., 2001)</td>
<td>MIF</td>
<td>110</td>
<td>No history of any pelvic surgery</td>
<td>17</td>
<td>11</td>
<td>68</td>
<td>14</td>
<td>0.55</td>
<td>0.86</td>
<td>0.61</td>
<td>0.83</td>
<td>3.94</td>
<td>0.52</td>
</tr>
<tr>
<td>(Logan, et al., 2003)</td>
<td>EIA</td>
<td>207</td>
<td>No previous laparoscopy or tubal surgery</td>
<td>23</td>
<td>17</td>
<td>127</td>
<td>40</td>
<td>0.37</td>
<td>0.88</td>
<td>0.58</td>
<td>0.76</td>
<td>3.09</td>
<td>0.72</td>
</tr>
<tr>
<td>(Rantsi et al., 2019)</td>
<td>EIA TroA IgG</td>
<td>116</td>
<td>No prior pelvic surgery</td>
<td>17</td>
<td>11</td>
<td>40</td>
<td>11</td>
<td>0.61</td>
<td>0.78</td>
<td>0.61</td>
<td>0.78</td>
<td>2.81</td>
<td>0.50</td>
</tr>
<tr>
<td></td>
<td>EIA HtrA IgG</td>
<td></td>
<td></td>
<td>16</td>
<td>11</td>
<td>40</td>
<td>12</td>
<td>0.57</td>
<td>0.78</td>
<td>0.59</td>
<td>0.77</td>
<td>2.65</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td>ELISA MOMP IgG</td>
<td></td>
<td></td>
<td>15</td>
<td>17</td>
<td>34</td>
<td>13</td>
<td>0.54</td>
<td>0.67</td>
<td>0.47</td>
<td>0.72</td>
<td>1.61</td>
<td>0.70</td>
</tr>
<tr>
<td>(Coppus, et al., 2007)</td>
<td>ELISA</td>
<td>207</td>
<td>No previous tubal testing or surgery</td>
<td>23</td>
<td>17</td>
<td>127</td>
<td>40</td>
<td>0.37</td>
<td>0.88</td>
<td>0.58</td>
<td>0.76</td>
<td>3.09</td>
<td>0.72</td>
</tr>
<tr>
<td>(Singh et al., 2016)</td>
<td>ELISA</td>
<td>200</td>
<td>Not specified further</td>
<td>10</td>
<td>0</td>
<td>150</td>
<td>40</td>
<td>0.20</td>
<td>1.00</td>
<td>1.00</td>
<td>0.79</td>
<td>N/A</td>
<td>0.80</td>
</tr>
<tr>
<td>(Tanikawa et al., 1996)</td>
<td>ELISA</td>
<td>131</td>
<td>No previous pelvic surgery</td>
<td>24</td>
<td>27</td>
<td>60</td>
<td>20</td>
<td>0.55</td>
<td>0.69</td>
<td>0.47</td>
<td>0.75</td>
<td>1.76</td>
<td>0.66</td>
</tr>
<tr>
<td>(van Dooremalen et al., 2020)</td>
<td>ELISA</td>
<td>890</td>
<td>Not specified further</td>
<td>44</td>
<td>75</td>
<td>710</td>
<td>61</td>
<td>0.42</td>
<td>0.90</td>
<td>0.37</td>
<td>0.92</td>
<td>4.39</td>
<td>0.64</td>
</tr>
</tbody>
</table>
REFERENCES


Keltz MD, Gera PS, Moustakis M. Chlamydia serology screening in infertility patients. *Fertility and sterility* 2006;85: 752-754.


2.5 Uterine factor

**PICO Question:** Which diagnostic procedures should be performed to confirm a normal uterine structure/anatomy, uterine wall/myometrium?

**3D Ultrasound vs. 2D Ultrasound**

**Evidence**

In a prospective cohort study, 117 women were examined with 2D and 3D ultrasound (US) to detect the most common congenital uterine anomalies. In the study, distinction was also made between an initial 2D-US and expert 2D-US. In the overall diagnosis of uterine anomalies, 3D-US found to be a significantly better technique than both initial and expert 2D-US. Accuracy of 3D-US was 97.1% versus 51.4% for initial 2D-US and 82.9% for expert 2D-US, compared with combined hysteroscopy and laparoscopy (Ludwin et al., 2013).

In a prospective cohort study, 108 women with suspected congenital Mullerian abnormalities were evaluated with 2D- and 3D-US. Compared to 2D-US, the sensitivity and specificity of real-time 3D-US were significantly higher in both the follicular phase (3D-US sensitivity 94.7% and specificity 75% vs. 30.2% and 78.1%, respectively) and the luteal phase (3D-US sensitivity 100% and specificity 93.7% vs. 42.1% and 81.2%, respectively). In the follicular phase, PPV for 3D-US was 90% vs. 76.6% for 2D-US and NPV 85.7% vs. 32%. In the luteal phase, PPV for 3D-US was 97.4% vs. 84.2% for 2D-US and NPV 100% vs. 37.1% (Caliskan et al., 2010).

In a prospective cohort study, 2D- and 3D-US were compared for the assessment of uterine anatomy and detection of congenital anomalies in 61 women with a history of recurrent miscarriage or infertility and who had previously been investigated by HSG. In 95.1% good quality images were obtained by 3D-US. In comparison with 2D-US, 3D-US had 98% specificity (vs. 88% for 2D-US), 100% sensitivity (vs. 94%), 100% PPV (vs. 97%) and 94% NPV (vs. 75%) (Jurkovic et al., 1995).

**Recommendation**

| 2.5.1 | Ultrasound, preferably 3D, could be recommended to exclude uterine anomalies in women with unexplained infertility. | EBR | ⭐⭐⭐⭐ |

**Justification**

Current evidence comparing 2D- to 3D-US is limited. Despite 2D-US is shown to be a valid diagnostic tool to exclude uterine anomalies, 3D-US showed superior results. Furthermore, comparing 2D- and 3D-US, cost per scan are the same, and the test is not more painful or more invasive for patients. The GDG acknowledges that 3D-US may not be available in every clinic. In the Australian context this was downgraded in recommendation strength, given the very low certainty of evidence. Accessibility issues in regional areas were also noted for 3D ultrasound.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.
MRI

Evidence

No relevant studies were identified investigating the use of MRI compared to 2D-ultrasound to confirm a normal uterine structure and anatomy in women with UI.

Recommendation

| 2.5.2 | MRI is not recommended as a first-line test to confirm a normal uterine structure and anatomy in females with unexplained infertility. | EBR against 🗿️ | 🌛️ |

Justification

We have found no evidence on the usefulness of MRI as a first-line test in confirming a normal uterine structure. Furthermore, MRI is expensive and time-consuming and should therefore be considered as a second-line diagnostic tool for the diagnosis of specific conditions. In the Australian context access to MRI will also be limited.

PICO QUESTION: WHICH ADDITIONAL DIAGNOSTIC PROCEDURES SHOULD BE PERFORMED TO CONFIRM AN ANATOMICALLY NORMAL UTERINE CAVITY?

Evidence

An RCT including 678 asymptomatic sub fertile women with normal 2D-US and no previous hysteroscopy were assessed for uterine pathologies in an office hysteroscopy prior to their first IVF treatment. The study reported 11% of women with normal 2D-US having abnormal findings on hysteroscopy; 6% had polyps (only 1 case with polyp >1cm), 2% intrauterine adhesions, 2% septa, 1% myomas. The authors concluded that the second-line hysteroscopy findings were few. Moreover, given the cost for routine hysteroscopy versus for example HyCoSy that is also widely available, they did not recommend routine hysteroscopy as a second-line assessment (Fatemi et al., 2010).

A retrospective study investigated 1726 infertile women with normal uterine cavity on 2D-US with subsequent office hysteroscopy for uterine abnormalities. 15.1% of all women had intrauterine lesions; 6% polyps, 5.7% adhesions, 1.5% isthmocele, 0.5% unicornsate uterus, 0.5% endometritis, 0.2% myoma, and 0.1% septum. History of abnormal uterine bleeding or previous dilatation and curettage were indicative for uterine abnormality in hysteroscopy (Yang et al., 2019).

A prospective cohort study evaluated the usefulness of hysteroscopy in 2017 infertile women who had been previously investigated to have normal uterine cavity on US or HSG. 31.8% of women had intrauterine lesions on hysteroscopy: 12.9%, septum, 12%, polyps, 5.5% submucosal myoma, and 1.4% adhesions (Bakas et al., 2014).

A prospective cohort of 100 women with UI (confirmed ovulation, patent tubes, normal semen analysis) were assessed for uterine abnormalities. After confirming assessment of the uterine cavity with 2D transvaginal US, 93% of women went through hysteroscopy. 86% of the women had some abnormality detected in the cervix, endometrium, or uterine wall. The most common finding was an endometrial polyp (31%) or hyperplasia (15%). The NPV for 2D-US for endometrial polyp was 0.84, for submucosal myoma 0.97, whereas PPV for these were as good as 1.0. compared to hysteroscopy. 2D-US was able to detect the thick endometrial lining in cases with polyp or hyperplasia (Makled et al., 2014).
A retrospective cohort study investigated in 294 women the value of routine HyCoSy with saline as contrast agent after normal 2D-US finding compared to targeted HyCoSy with saline. The study group consisted of 124 women with normal US finding whereas the control group consisted of 170 women with reported uterine abnormality in 2D-US. 10.4% of women with normal US finding showed a uterine abnormality in HyCoSy. However, only 23% of these were confirmed in hysteroscopy and none of these were confirmed by pathology. As for targeted investigations, 67.7% of abnormal HyCoSy findings were confirmed in hysteroscopy and of these 83.3% were further confirmed by pathology (Almog et al., 2011).

Recommendation

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR</th>
<th>J</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5.3 If ultrasound assessment of the uterine cavity is normal, no further evaluation may be needed.</td>
<td>against</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Justification

Even though there were some additional uterine findings in subsequent hysteroscopy or HyCoSy procedures in women with normal ultrasonography findings, most of the diagnosis were polyps or a septum that likely will not have a major effect on pregnancy outcomes especially if they present without any symptoms. The reproductive outcomes were, indeed, described in the Cochrane review that was not able to show any benefit for routine hysteroscopy (Kamath et al., 2019). None of the studies introduced 3D as one option and given that some of the papers were already quite old, the ultrasonography technology may not represent the latest 2D/3D performance. Moreover, as a practical point, given the evidence on the good performance, availability and cost profile of HyCoSy compared to hysteroscopy, these methods should be prioritised in cases where further assessment for uterine cavity is needed.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES


2.6 Laparoscopy

PICO Question: Should women undergo a laparoscopy before being diagnosed with UI?

Evidence

In a retrospective cohort study of patients with a normal HSG or suspected unilateral pathology on HSG and in whom both HSG and laparoscopy were performed, the diagnostic benefit of laparoscopy was assessed. Among 63 patients who were assigned to ovulation induction and IUI, 60 patients were found to have laparoscopic findings that did not necessitate any change in the original treatment plan. In three patients (4.8%), abnormalities discovered at laparoscopy were of such an extent that a change in the original treatment plan and referral to IVF was needed. The conclusion of the authors was that laparoscopy may be omitted in women with normal HSG or suspected unilateral tubal pathology on HSG, since it was not shown to change the original plan indicated by HSG in 95% of the patients (Lavy et al., 2004).

Another study evaluated the accuracy of diagnostic laparoscopy prior to IUI and included 495 women with a normal HSG. In 124 women (25%), the laparoscopy changed the initial treatment plan of IUI. Of these 21 (4%) had severe abnormalities that resulted in a change to in vitro fertilisation or open surgery. The remaining 103 (21%) patients had fertility enhancing surgical interventions. However, because it is unclear if treating the abnormalities such as minimal and mild endometriosis or milder adhesions increases success of subsequent IUI, the authors recommended a randomised trial (Tanahatoe et al., 2003).

The same group later published a randomised controlled trial including 154 women with UI. In this RCT, 77 women were assigned to have a diagnostic laparoscopy performed with ablation or resection of stage I/II endometriosis lesions or adhesiolyis if needed before IUI and 77 women were assigned to have six cycles of IUI followed by diagnostic laparoscopy in case of no pregnancy. The overall pregnancy rate was not significantly different between groups: 44% (34/77) after immediate laparoscopy and 49% (38/77) after immediate IUI (OR 1.2, 95% CI 0.7-2.3), of which 12 vs. 16 spontaneous and 22 vs. 22 IUI pregnancies. There were no complications as a result of laparoscopy (Tanahatoe et al., 2005).

Recommendation

2.6.1 Routine diagnostic laparoscopy may not be recommended for the diagnosis of unexplained infertility. EBR against
Consideration should be given to discussing the benefits and harms of laparoscopy for diagnosing minimal to mild endometriosis.

Justification

Although different tests exist to reliably detect tubal patency, laparoscopy is the only method for directly visualising the pelvic anatomy and diagnosing peritoneal factors such as minimal or mild endometriosis or subtle tubal abnormalities. The presence of subtle tubal abnormalities was reported to be present in 103 of 208 patients (54.3%) with infertility and consisted of anatomical lesions such as tubal diverticula, Morgagni hydatids, accessory fallopian tubes, tubal phimosis, agglutination and sacculatation (Guan and Watrelot, 2019). However, it is unknown to what extent these abnormalities contribute to infertility and there are no randomised trials that address the effectiveness of correction of these subtle lesions. The trial by Tanahatoe et al (2005) was small but showed no benefit of a diagnostic laparoscopy before treatment of UI in women with proven patent tubes on HSG (Tanahatoe, et al., 2005).

One might argue that some patients would like to have a diagnostic laparoscopy to exclude all pelvic pathology, even though there is limited or no clinical benefit. Considering the fact that a diagnostic laparoscopy is not risk-free and requires a dedicated theatre team, general anaesthesia and operating time, time off work for the patient, costs are higher than the benefits. A formal cost-effectiveness analysis has not been performed.

Routine laparoscopy is not recommended in infertile women at low risk for tubal pathology but should be reserved for women with an abnormal HSG or those at risk for tubo-peritoneal disease due to a history of PID, previous ectopic pregnancy or clinically suspected or known endometriosis.

In the Australian context, prevalence of endometriosis is high and diagnosis often difficult. Australia is the first country to have a National Action Plan on Endometriosis and increased awareness and advocacy in one of the main pillars of the plan, hence the GDG highlighted that the role of laparoscopy in this context warrants discussion.

REFERENCES

2.7 Cervical/ vaginal factor

**PICO Question:** What is the need for female lower genital tract investigations?

**Post-coital test (PCT)**

**Evidence**

A systematic review and meta-analysis, including 4007 women from 11 studies, reported that the predictive values of normal and abnormal post-coital test (PCT) were 0.37-0.92 and 0.58-0.85 respectively. Sensitivity ranged between 0.10 and 0.90 and specificity ranged between 0.30 and 0.97. Likelihood ratios for normal and abnormal PCT were 0.77 and 1.85 respectively (Oei et al., 1995).

In a randomised controlled trial, 444 women were randomised to undergo a PCT or not. Fertility treatments were given more often in the intervention group compared to the control group (54% vs. 41%). However, cumulative pregnancy rates at 24 months were similar with and without PCT (49% (42-55%) vs. 48% (42-55%) (Oei et al., 1998).

In a retrospective cohort study, including 2476 patients with UI, the long-term overall pregnancy rates after a positive or a negative PCT were compared. The spontaneous and overall (OI, IUI, IVF) pregnancy rates were 37.7% and 77.5%, respectively, after a positive PCT which was significantly higher compared to 26.9% and 68.8% after a negative test (Hessel et al., 2014).

A retrospective study, including 200 couples who underwent a PCT as part of their routine fertility work-up, investigated the predictive value of normal and abnormal PCTs on pregnancy rates. The predictive values of normal and abnormal PCTs were 0.54 and 0.58 overall and 0.74 and 0.47 if only untreated women were considered. Sensitivity and specificity were, respectively, 0.47 and 0.65 for all women and 0.54 and 0.68 for untreated women only. Likelihood ratios for normal and abnormal PCTs were 0.83 and 1.32 overall and 0.67 and 1.72 in untreated women (Oei et al., 1996).

In a retrospective re-analysis of 207 couples originally studied between 1982 and 1983, it was found that in couples with less than 3 years of infertility and positive PCT, 68% conceived within 2 years compared with 17% of those with negative result. After 3 years of infertility, corresponding rates were 14% and 11% (Glazener et al., 2000).

**Recommendation**

<table>
<thead>
<tr>
<th>2.7.1</th>
<th>The post-coital test is probably not recommended in couples with unexplained infertility.</th>
</tr>
</thead>
</table>

**EBR against**

| ▼ | ▼ | ▼ |

**Justification**

The meta-analysis showed that PCT has poor discriminating capacity. Cumulative pregnancy rates seem to be similar after a positive or a negative test. Importantly, it is an invasive test for the patient and does not change further management. Therefore, PCT is not recommended in infertility investigations. In Australia this was downgraded due to low certainty of evidence.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.
VAGINAL MICROBIOTA TESTING

Evidence
In a case-control study, gut and vaginal microbiota were compared between women with UI (n=10) and fertile controls (n=11). Firmicutes accounted for the vast majority of the vaginal bacteria, with higher relative abundance in UI than controls (69.7 vs. 53). *Fusobacteria* (18% vs.0.14) and *Bacteroidetes* (4.1% vs. 0.92) were relatively more abundant in the controls than in the UI group. Within the genus of *Lactobacillus*, *L. jensenii* and *L. vaginalis* were only detected in the UI group (Patel et al., 2022).

Another case-control study compared vaginal and endometrial microbiota between women with UI (n=26) and fertile controls (n=26). In the vaginal samples, the lactobacilli-impaired microbiota proportion was significantly higher in women with UI compared to fertile women (76.9% vs. 26.9%). Similarly, the *Mycoplasma hominis* flora increment or pathogenic microorganism growth rate was significantly higher in women with UI compared to fertile women (34.6% vs. 7.7%). The amount of lactobacilli per total bacterial mass mean proportion in the vaginal samples, was significantly lower in women with UI compared to fertile women (38.2% vs. 76.3%) (Sezer et al., 2022).

In a prospective cohort study, including 25 couples with UI, the association between vaginal microbiota and pregnancy outcome after IUI was investigated. Five out of 23 women achieved a clinical pregnancy, and this was associated with a more evident *Lactobacillus spp* domination, comparable to that observed in controls. Furthermore, a significantly lower Shannon index was found in pregnant women compared to non-pregnant women (0.8 ± 0.9 vs. 1.5 ± 1.1) (Amato et al., 2020).

In a prospective cohort study, including 47 (25 unexplained and 22 explained infertility) couples undergoing ART, the difference in vaginal microbiota between unexplained and explained infertility was investigated. There were no significant differences in alpha or beta diversity metrics between explained and unexplained infertility couples. In comparison with the unexplained group, there was a decrease in lactobacilli in the vaginal lavage of women with explained infertility (Campisciano et al., 2020).

In a case-control study, the microbiome of 96 cervical-vaginal samples (27 infertile women and 69 fertile controls) was compared. Compared to controls, the idiopathic infertility group showed the highest biodiversity of species (Simpson’s reciprocal indexes, 1.5±0.5 vs. 2.43±1.19) (Campisciano et al., 2017).

In a case-control study, the incidence of bacterial etiological factors causing inflammation of the upper and lower reproductive tract in women treated for infertility with no clinical parameters of acute inflammation of the vagina and/or the cervix was assessed. Normal bacterial vaginal flora was confirmed in 80 women (79%) treated for infertility and 51 women (85%) from the control group. Bacterial vaginosis was confirmed (based on pH, Nugent score and quantitative culture results) in 7 women (7%) treated for infertility, and none from the control group (Tomusiak et al., 2013).

**Recommendation**

| Vaginal microbiota testing could be considered in couples with unexplained infertility only in a research setting. | Research only |

**Justification**
It is very difficult to compare studies investigating the role of vaginal microbiota, due to the different detection methods used (wet mount microscopy, modified Spiegel criteria, Nugent scores, qPCR assays.
for common bacteria in bacterial vaginosis). Additionally, the vaginal swabs were taken at different time points of the menstrual cycle in different studies (before and during ovarian stimulation, at oocyte retrieval or at embryo transfer). The lactobacillus dominance is also defined differently between papers. There is currently insufficient evidence of a role of abnormal vaginal microbiota in UI. Furthermore, there is currently no evidence suggesting that correcting abnormal vaginal microbiota improves fertility outcomes.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES


2.8 Male genito-urinary anatomy

PICO QUESTION: SHOULD MEN UNDERGO ADDITIONAL DIAGNOSTIC PROCEDURES TO CONFIRM NORMAL GENITO-URINARY ANATOMY BEFORE BEING DIAGNOSED WITH UI?
Evidence
Mean testicular volume (TV) was positively associated with sperm concentration ($r=0.315$, $p<0.0001$ unadjusted, $r=0.274$ $p<0.0001$ after adjustment for confounding factors) and total sperm count ($r=0.219$, $p=0.001$ unadjusted, $r=0.278$ $p<0.0001$ after adjustment for confounding factors). Subjects with testicular inhomogeneity (defined as an echotexture score, ranging from 0 (regular pattern) to 5 (tumour suspected)) showed a lower sperm vitality compared with the rest of the sample, while those with any parenchymal calcification had lower sperm concentration and total count. Intratesticular artery peak systolic velocity was positively associated with sperm normal morphology ($r=0.226$, $p=0.017$ unadjusted, adjusted $r=0.240$ $p<0.008$). Epididymal mean head size was positively associated with normal sperm morphology ($r=0.385$, $p<0.0001$, adjusted $r=0.233$, $p=0.002$) and vas deferens mean size was positively associated with progressive motility ($r=0.214$, $p=0.004$, adjusted $r=0.235$, $p=0.001$). Subjects with a mixed antiglobulin reaction (MAR) test $\geq 1\%$ showed a higher prevalence of epididymal tail echotexture inhomogeneity (OR 5.75, 95% CI 1.35-24.1), and a higher mean size of vas deferens and of epididymal body and tail, as compared with the rest of the sample (Lotti et al., 2021).

Recommendation

| 2.8.1 | Testicular imaging is probably not recommended when semen analysis according to WHO criteria is normal. | EBR against | ⬤⬤⬤⬤ |

Justification
There is no additional benefit in performing scrotal colour Doppler ultrasound (CDUS) on male partners with normal semen parameters and having undergone physical examination. CDUS may aid physical examination in assessment of ultrasound patterns of testicular anatomy and structure. It can thus be helpful to identify scrotal abnormalities and to assist in better understanding the pathophysiology of sperm abnormalities and male infertility. Though CDUS shows some association with semen parameters, it would not be beneficial to replace gold standard WHO semen analysis for CDUS. This recommendation was downgraded in strength in Australia due to low certainty of evidence.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES

2.9 Male additional tests

**PICO Question:** *Is there added value of additional tests in the male with normal WHO semen analysis?*

The GDG acknowledges that presently unexplained infertility (UI) is a diagnosis by exclusion. The GDG supports the urgent need to develop robust standardised methods for establishing etiological diagnosis...
in the male partner (Barratt et al., 2017, Björndahl, 2022). In some patients underlying sperm dysfunction may not be detected during a routine semen assessment of the ejaculate, which may appear to be normal regarding basic semen parameters (WHO, 2021). The GDG considers that some adverse reproductive outcomes that have been identified during medical and reproductive history examination may indicate the use of further tests procedures specified in the WHO 6th ed chapters 3 and 4 to assess sperm function. However, these tests have a research status only or are not regarded for routine use in clinical practice until sound evidence is developed (WHO, 2021).

**ANTI-SPERM ANTIBODIES (ASA)**

Evidence

A case-control study investigated the effect of anti-sperm antibodies (ASA) in 1060 normozoospermic infertile men with female partners with no abnormalities found after full investigation and 107 normozoospermic fertile men (control group). Significantly more ASA was found in the infertile group compared to the controls (Mixed antiglobulin reaction (MAR) ≥50% in 15.6% (166/1060)) vs. 1.9% (2/107) and the mean ASA titre was higher. The relative infertility risk for MAR ≥50% was 8.38, which increases starting from MAR-IgG >25%. Also, in ASA-positive men, acrosome reaction was decreased, DNA fragmentation increased and higher reactive oxygen species (ROS) were found (Bozhedomov et al., 2015).

In a cohort study, including 84 men with positive MAR test, the occurrence of natural pregnancies and the effectiveness of IUI were analysed in connection with the degree of sperm autoimmunisation. In men with 100% MAR test, natural live birth rate was 2/44 (4.5%), 14/38 (36.8%) after IUI and 7/15 (46.7%) after ICSI. In males with moderate (50-99%) MAR test, the natural live birth rate was 12/40 (30%), 7/26 (26.9%) after IUI and 5/6 (83.3%) after ICSI. Multiple regression analysis showed that the percentage of MAR test positivity was an independent predictor of natural live birth rate (β −0.06 (95% CI −0.10 to −0.02)) (Barbonetti et al., 2020).

In a small case-control study pregnancy rates were compared in IVF couples with ASA positive males and couples without ASA. Pregnancy rates were not significantly different between couples with ASA positive males (11% (1/9)) and couples without ASA (44% (4/9)) (Vazquez-Levin et al., 1997).

In a cohort study, men with anti-sperm antibodies (MAR assay) undergoing ICSI or conventional IVF were compared to an ICSI control group with male infertility without anti-sperm antibodies. Clinical pregnancy rates were 46% with ICSI (13/28), 30% (11/37) with conventional IVF and 30% (6/20) in the control group. Five miscarriages occurred in the ICSI group, compared to three in the IVF and none in the control group (Lähteenmäki et al., 1995).

In a cohort study couples were divided into three categories according to their sperm MAR test results, and fertilisation and pregnancy rate (per embryo transfer) were compared in those groups (weakly
positive, >0 and <40%; positive, >40 and <90%; strongly positive, >90%). Pregnancy rate as per MAR category were not significantly different: 43% versus 45% versus 33% (Lähteenmäki, 1993).

In a cohort study, couples with UI were divided into couples with >50% sperm antibody bound and couples with <50% sperm antibody bound. There was a significant higher pregnancy rate found in couples with <50% sperm antibody bound, 66.7% (6/9) compared to 15.3% (4/26) in couples with >50% sperm antibody bound (Ayvaliotis et al., 1985).

**Recommendation**

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9.1 Testing for anti-sperm antibodies in the semen is probably not recommended when semen analysis according to WHO criteria is normal.</td>
</tr>
</tbody>
</table>

**EBR against ⊕◯◯◯**

**Justification**

There is insufficient evidence to suggest the benefit of anti-sperm antibodies tests in couples with UI. The quality of data is very low (old and underpowered studies, some with old methodologies, methods not following standard procedures, not sufficient or lacking inclusion criteria, most of them analysing couples undergoing MAR). Cut-off values are inconsistent and differ between studies, thresholds are not validated. Furthermore, currently there are no evidence-based reference values for antibody-bound spermatozoa in the MAR test of semen from fertile men (WHO, 2021). In some of the available studies male partners had different degrees of abnormal semen parameters, including impaired motility which can influence the validity of ASA tests (tests should be performed on motile spermatozoa). This recommendation was downgraded in strength in Australia due to low certainty of evidence.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.

**DNA fragmentation test**

*It is important to emphasise that sperm DNA fragmentation (SDF) assays cannot be used interchangeably as they have often been in literature. Each SDF assay currently used in clinical practice is based on specific technical methodology which defines its capacity to measure different structural aspects of sperm DNA damage (WHO, 2021).*

**Evidence**

In a prospective cohort study including couples undergoing their first ICSI cycles for UI, the effect of sperm DNA fragmentation (SDF; by acridine orange test) on reproductive outcomes was investigated. Cumulative live birth rate was significantly higher in the low versus high SDF group (60.8% (59/97) vs. 41.7% (20/48)). Subgroup analysis by fresh or frozen embryo transfer showed that live birth was significantly different between groups with fresh embryo transfer (ET), but no difference was found with frozen ET (Repalle et al., 2022).

In a prospective cohort study, including couples undergoing their first IVF with ICSI cycle, the influence of SDF (by sperm chromatin dispersion test) on reproductive outcomes was investigated. A significantly higher miscarriage rate (17.8% vs. 39.9%) was observed in cycles with SDF above the cut-off (30%), however, there was no difference in clinical pregnancy rate (32.4% vs. 30.3%) (Borges et al., 2019).
In a retrospective cohort study, including couples with UI and poor IUI outcome, couples were assigned to either IVF or ICSI, based on the results of their SDF testing (sperm chromatin structure assay (SCSA) or TUNEL). Thirty-one couples with normal sperm DNA fragmentation underwent IVF, resulting in a clinical pregnancy rate of 12.7%. The remaining 343 couples underwent ICSI, resulting in a cumulative pregnancy rate of 18.7% (O’Neill et al., 2018).

Recommendation

<table>
<thead>
<tr>
<th>2.9.2</th>
<th>Testing for sperm DNA fragmentation is probably not recommended when semen analysis according to WHO criteria is normal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR</td>
<td>against</td>
</tr>
</tbody>
</table>

Justification

Data from meta-analyses in recent years indicate that SDF may adversely affect reproductive success in natural and assisted conception (Osman et al., 2015, Simon et al., 2017, Sugihara et al., 2020, Tan et al., 2019). Some evidence suggests increased sperm DNA damage in infertile men compared to fertile men (Evenson et al., 1999, Spanò et al., 2000), and similar degree of SDF in ejaculates from infertile men with abnormal semen parameters and infertile men with semen parameters in the reference range (Saleh et al., 2002).

Several meta-analyses have shown that different SDF assays have different predictive accuracy for pregnancy and each assay had a different predictive value for IVF and ICSI (Cissen et al., 2016, Zhao et al., 2014). Furthermore, each test has different clinical thresholds validated by the laboratories performing the test. The methodology and the cut-offs are not standardised worldwide, nor is there a consensus on which test is preferred. Differences in cut-offs between available studies might falsely re-categorise patients into those at risk of adverse reproductive outcome. Clinical relevance for performing SDF test in couples with UI is questionable since available data on reproductive outcomes (pregnancy rate, live birth rate, miscarriage) is predominantly based on couples undergoing IVF/ICSI. The quality and heterogeneity (including parental age and previous MAR treatments) of the available data from three cohort studies does not allow conclusive recommendation on the benefit of performing SDF testing in males from couples with UI who have normal semen parameters. Published studies so far have not directly tested the effect of SDF testing on the clinical management of infertile couples (i.e., that the fertility outcomes of those who had testing are different from those who did not), which does not support a recommendation for its routine use in the initial evaluation of the male. Upcoming evidence might show benefit of specific tests, when validated. This recommendation was downgraded in strength in Australia due to low certainty of evidence.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

**Sperm chromatin condensation test**

**Evidence**

*No studies were identified to answer this PICO question.*

**Recommendation**

<table>
<thead>
<tr>
<th>2.9.3</th>
<th>Sperm chromatin condensation test is probably not recommended when semen analysis according to WHO</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR</td>
<td>against</td>
</tr>
</tbody>
</table>

criteria is normal.

Justification
Abnormal sperm chromatin structure may cause sperm DNA damage, such as double or single DNA strand breaks, because of poor chromatin condensation (i.e., defects in histone replacement by protamines) (WHO, 2021). Abnormal sperm chromatin remodelling has been detected in infertile men (Zhang et al., 2006). Depending on the assay used for DNA fragmentation, some studies have shown an association between abnormal sperm histone retention and/or protamination anomalies and sperm DNA fragmentation in infertile men with abnormal semen analysis (Simon et al., 2014, Tavalaee et al., 2009, Torregrosa et al., 2006).

Currently, we found no published evidence to suggest the clinical significance of routine sperm chromatin condensation testing in men with UI. Published studies either did not assess men with UI, assessed the test inappropriately in relation to clinical outcomes, or the sperm chromatin condensation test was evaluated together or in association with other methods for sperm quality. Furthermore, published studies so far have not directly tested the effect of sperm chromatin condensation testing on the clinical management of infertile couples (i.e., that the fertility outcomes of those who had testing are different from those who did not) which does not support a recommendation for its routine use in the initial evaluation of the male. Instead, sperm chromatin condensation is usually assessed in studies that investigate its associations with aneuploidy and other methods to evaluate sperm chromatin integrity (i.e., SDF). Thus, there is not enough strong evidence to suggest that assessing sperm chromatin structure integrity solely by sperm chromatin condensation test can be reliably predictive of reproductive outcomes or how it can be used to guide clinical decision making (Barratt et al., 2010). This recommendation was downgraded in strength in Australia due to low certainty of evidence.

**SPERM ANEUPLOIDY SCREENING**

Evidence

No studies were identified to answer this PICO question.

Recommendation

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR against</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9.4 Sperm aneuploidy screening is probably not recommended when semen analysis according to WHO criteria is normal.</td>
<td>⊖</td>
<td>⊕ ⊕ ⊕ ⊕</td>
</tr>
</tbody>
</table>

Justification

At least 15% of human male factor infertility can be attributed to genetic factors that underlie the major categories of male infertility – spermatogenic quantitative defects, ductal obstruction or dysfunction, hypothalamic–pituitary axis disturbances, and spermatogenic qualitative defects (reviewed in (Krausz and Riera-Escamilla, 2018)). Azospermia is the aetiological category with the highest frequency of known genetic factors (25%) contributing to male infertility (Krausz and Riera-Escamilla, 2018), but the number of identified genes linked with other seminal phenotypes and male infertility aetiological categories is constantly expanding (Houston et al., 2021, Riera-Escamilla et al., 2022). The risk of men being carriers of genetic anomalies progressively decreases with increasing sperm output (Krausz, 2011).
The incidence of sperm aneuploidy is rare in fertile men (WHO, 2021). Abnormal levels of aneuploid sperm are most commonly observed in men with spermatogenic failure, oligozoospermia or oligoasthenozoospermia, and among normozoospermic men who are partners in couples with recurrent pregnancy loss (Ramasamy et al., 2015, WHO, 2021). Thus, based on current state-of-the-art knowledge about prevalence and male infertility aetiologies underlined by chromosomal abnormalities, aneuploidy is not indicated for routine testing in men with normal semen parameters. This recommendation was downgraded in strength in Australia due to low certainty of evidence.

**HORMONAL TESTING**

**Evidence**

*No studies were identified to answer this PICO question.*

**Recommendation**

| 2.9.5 | Serum hormonal testing is probably not recommended when semen analysis according to WHO criteria is normal. | EBR against | ☧️〇〇〇 |

**Justification**

Semen analysis as performed according to WHO Laboratory Manual for the Examination and Processing of Human Semen standards (WHO, 2021) is used to assess male reproductive function and genital tract patency. In this context, semen analysis is the cornerstone in the evaluation of the reproductive hormonal status for men. In cases of abnormal sperm parameters (oligozoospermia and azoospermia), potential hypogonadism is ruled out by reproductive hormone (testosterone and gonadotropins) testing which provide a functional readout of the hypothalamic-pituitary-testicular axis. Thus, the hormonal profile will be helpful in following extended examination to accurately diagnose underlying pathological conditions associated with abnormal semen parameters. However, no evidence was found supporting endocrine testing as a first line of investigation for males with UI and results from a basic semen examination in the reference range according to the WHO criteria.

Currently, endocrine testing is not recommended as a primary first line of investigation for males with UI and results from a basic semen examination in the reference range according to the WHO criteria (Minhas et al., 2021, Schlegel et al., 2021, WHO, 2000). However, given the essential role of FSH for the initiation and maintenance of full spermatogenesis, increasing research emphasis has been given to single nucleotide polymorphisms in FSH beta (FSHB) and FSH receptor (FSHR) genes and their effects on male infertility (Ferlin et al., 2011, Grigorova et al., 2011, Schubert et al., 2019, Schubert et al., 2022, Tamburino et al., 2017a, Tamburino et al., 2017b, Tüttelmann et al., 2012). This recommendation was downgraded in strength in Australia due to low certainty of evidence.

**HUMAN PAPILLOMA VIRUS (HPV)**

**Evidence**

*No studies were identified to answer this PICO question.*

**Recommendation**

| 2.9.6 | HPV testing of semen is probably not recommended when semen analysis according to WHO criteria is normal. | EBR against | ☧️〇〇〇 |
Justification
There are over 200 HPV subtypes and most people will test positive for an HPV type at some point during life. Furthermore, HPV is a transient infection which most often clears spontaneously, but it is unknown how fast infectious HPV is cleared in males and females (Depuydt et al., 2019, Giuliano et al., 2011). There is some evidence showing reduced pregnancy rates in donor IUI cycles and autologous IUI cycles with moderate male factor infertility in HPV positive semen versus HPV negative (Depuydt et al., 2018, Depuydt, et al., 2019). Conflicting data on association between semen HPV presence and alteration of sperm parameters (Luttmer et al., 2016), as well as the effects of semen HPV infection on reproductive outcomes makes it impossible to recommend routine screening of HPV in a diagnostic setting in assisted reproduction. Therefore, HPV testing could be discussed with couples scheduled for an IUI cycle only in research settings. Further information on the management of HPV in couples undergoing MAR can be found in the ESHRE guideline “Medically assisted reproduction in patients with a viral infection or disease” (ESHRE Guideline Group on Viral infection/disease et al., 2021). This recommendation was downgraded in strength in Australia due to low certainty of evidence.

MICROBIOLOGY TEST

Evidence
No studies were identified to answer this PICO question.

Recommendation

<table>
<thead>
<tr>
<th>2.9.7</th>
<th>Microbiology testing of semen is probably not recommended when semen analysis according to WHO criteria is normal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR against</td>
<td>◯◯◯</td>
</tr>
</tbody>
</table>


Borges E, Jr., Zanetti BF, Setti AS, Braga D, Provenza RR, Iaconelli A, Jr. Sperm DNA fragmentation is correlated with poor embryo development, lower implantation rate, and higher miscarriage rate in reproductive cycles of non-male factor infertility. Fertility and sterility 2019;112: 483-490.


Depuydt CE, Donders G, Verstraete L, Vanden Broeck D, Beert J, Salembier G, Bosmans E, Dhot TN, Van Der Auwera I, Vandenborne K et al. Time has come to include Human Papillomavirus (HPV) testing in sperm donor banks. Facts, views & vision in ObGyn 2018;10: 201-205.


Lähteenmäki A. In-vitro fertilization in the presence of antisperm antibodies detected by the mixed antiglobulin reaction (MAR) and the tray agglutination test (TAT). *Human reproduction (Oxford, England)* 1993;8: 84-88.


2.10 Additional tests for systemic conditions

**PICO QUESTION:** SHOULD THERE BE ADDITIONAL EVALUATIONS OF POSSIBLE SYSTEMIC CAUSE OF UI IN THE COUPLE?

**Auto-immunity**

Evidence

Anti-sperm antibodies (ASA) in serum

A study, including 42 couples with unexplained infertility (UI), investigated the presence of serum anti-sperm antibodies (ASA) and their association with UI. The prevalence of ASA was 14.3% (6/42) among all couples, 9.5% (4/42) among males and 4.8% (2/42) among females. Of the 42 couples, 22 couples were managed with IVF-ICSI, and it was found that no relation between ASA status and the successfulness of IVF-ICSI exists (Yasin et al., 2016).
In a study, including 30 men and 24 women with UI, presence of ASA was compared to fertile controls (45 men and women) and their association with UI was investigated. With the indirect immunofluorescence technique 22/54 patients tested positive for ASA and 3/45 controls. With ELISA, 20/54 patients tested positive and 4/45 controls. This suggested a strong correlation between UI and ASA (Monem and Moalla, 2003).

A study including 44 couples where the only detectable cause of infertility was the presence of ASA in the female, looked at pregnancy rates after IVF in these couples. After IVF, fertilisation rates were slightly lower in couples where the only detectable cause of infertility was the presence of ASA in the female than in patients with other infertility aetiologies but was successful in 45% without the need for ICSI (Mardesic et al., 2000).

In a study, including 698 couples with UI, prevalence of ASA was investigated, and their impact on pregnancy rates. In the study 16.5% of the men and 21.6% of the women had serum ASA. The overall incidence of immobilising antibodies was 5.6% for men and 6.4% for women. In men, the pregnancy rate dropped significantly from 42.7% to 7.1% at high agglutinin titres >1:16. In women at high titters ≥1:16 the incidence of pregnancy was only 4.0%, compared with 46.2% in the negative group (Menge et al., 1982).

**Female coeliac disease**

In a systematic review and meta-analysis, the risk of coeliac disease in UI was investigated in 586 patients and 5088 controls without risk factors, from 7 case-control studies. The OR for coeliac disease was 5.06 (95% CI 2.13–11.35) in patients with UI (Tersigni et al., 2014).

A small cohort study in 65 couples with UI also investigated the role of coeliac disease in UI. Overall, 7.9% of patients tested positive for antigliadin, anti-endomysial or tissue transaminase antibodies. In these cases, an intestinal biopsy was performed, however, only one male and one female tested positive for coeliac disease (Karaca et al., 2015).

**Thyroid antibodies**

In a prospective cohort study, 69 patients with UI were screened for anti-thyroid antibodies and their effect on IVF outcome. Patients were divided in 3 groups, group 1 consisted of infertile patients without thyroid pathology (n=31), group 2 consisted of infertile patients with normal thyroid function and anti-thyroid antibodies (n=23), and group 3 consisted of infertile patients euthyroid by medical therapy and anti-thyroid antibodies (n=15). Clinical pregnancy rate was significantly lower in thyroid antibody positive groups (groups 2 and 3) compared to controls (30.4% vs. 13.3% vs. 41.9% respectively) (Kilic et al., 2008).

A small cross-sectional study, including 14 women with UI, reported no cases of subclinical hypothyroidism and 3/14 (21.4%) women with thyroid antibodies, which was not significantly different from findings in the control group (Abalovich et al., 2007).

In another cross-sectional study including 73 patients with UI and 100 controls (randomly selected, parous women) thyroid dysfunction and auto-immunity in infertility was investigated. The percentage of patients with positive thyroid peroxidase-antibodies (>100 kU/L) was 7% in UI patients, which was not significantly different from controls (8%) (Poppe et al., 2002).

**Other auto-immune tests**
A number of publications were identified examining other auto-immune tests, such as anti-endometrial antibodies (Palacio et al., 1997), anti-ovarian antibodies (Luborsky et al., 2000), zona pellucida antibodies (Hovav et al., 1994) or combinations of several auto-immune tests (Aoki et al., 1995, Bellver et al., 2008, Kovács et al., 2012, Luborsky et al., 1999, Radojičić et al., 2004, Witkin et al., 1984). However, data was too sparse to draw conclusions.

Recommendation

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.10.1 Testing for anti-sperm antibodies in serum of either males or females</td>
<td>EBR</td>
<td>Current evidence indicates that the benefit of testing for ASA is low. However, the studies are relatively small and, apart from one, somewhat dated. Patients value explanations for UI but uncertainty about the evidence, no clear treatment shown to be effective and potential risks of treatment limit value of treatment. There is no clear benefit of ASA testing for health equity and the current evidence shows no feasibility of treatment in case of a positive test.</td>
</tr>
<tr>
<td>with unexplained infertility is probably not recommended.</td>
<td></td>
<td>The benefits of testing for coeliac disease may be considerable depending on the test used. If blood testing for antibodies, the patients would value investigation at small cost with an easy intervention, i.e., a dietary change.</td>
</tr>
<tr>
<td>2.10.2 Testing for coeliac disease in women with unexplained infertility</td>
<td>EBG</td>
<td>Testing for thyroid antibodies and other autoimmune diseases appears to have little benefit, but may reassure the patient that a full investigation has been implemented. Costs would be relatively small but in the absence of treatment, efficacy would be of little value. Some of these recommendations were downgraded in strength in Australia, due to low certainty of evidence.</td>
</tr>
<tr>
<td>could be recommended.</td>
<td></td>
<td>Further information</td>
</tr>
<tr>
<td>2.10.3 Testing for thyroid antibody and other autoimmune conditions</td>
<td>EBG</td>
<td>Details of the literature study and evidence tables are available in the Technical Report.</td>
</tr>
<tr>
<td>(apart from coeliac disease) in women with unexplained infertility is probably</td>
<td></td>
<td>THYROID HORMONES</td>
</tr>
<tr>
<td>not recommended.</td>
<td></td>
<td>Evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In a case-control study, the role of altered thyroid hormones in UI was investigated in 44 women with UI and 44 fertile controls. Both thyroid stimulating hormone (TSH) and T4 were found to be slightly higher in women with UI than controls (1.49±0.76 vs. 1.12±0.54 mIU/L and 10.48±1.89 vs. 9.18±1.53 (µg/dl) (Rehman et al., 2020).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In a cross-sectional study, the association between thyroid hormones and UI was investigated in 187 women with UI and compared with 52 women with male infertility. Median TSH levels were significantly higher in the UI group compared to the male factor infertility group (1.95 (IQR 1.54 – 2.61 vs. 1.66 (IQR 1.25 – 2.17) mIU/L. Also, more women with UI had levels &gt;2.5mIU/L (26.9 vs. 13.5%). Thyroid</td>
</tr>
</tbody>
</table>
peroxidase antibodies (TPO) were significantly lower in UI women compared to male factor infertility (13.3 (IQR 10.2 – 18) vs. 90.4 (IQR 18.4 – 2994.3) IU/mL) (Orouji Jokar et al., 2018).

In a case-control study, the prevalence of thyroid hormone and thyroid antibody abnormalities were investigated in 25 women with UI and 45 normal controls. The fT4 levels were significantly higher in the UI group compared to controls (1.14±0.13 vs. 0.88±0.11 pmol/L), and the fT3 was significantly lower (3.48±0.46 vs. 4.7±2.52 pmol/L). No difference in thyroid autoimmune antibodies (TAI) was found between groups (Duran et al., 2013).

In a cross-sectional analysis of a prospective cohort study, the role of thyroid hormone and thyroid antibody abnormalities in UI were investigated in 95 women with UI and compared to women with male factor infertility. There were no differences in the thyroid hormones but in the UI group, 86% were TAI negative and 14% positive, which was not significantly different from controls (Unuane et al., 2013).

**Recommendation**

| 2.10.4 | TSH measurement is considered good practice in pre-conception care. |
| PP | EBR against |
| No additional thyroid evaluation in the female is recommended, if TSH is within the normal range and there is no underlying history of thyroid disease. |

**Justification**

According to Endocrine Society guidelines (De Groot et al., 2012), TSH should be measured in pre-conception care.

The results of the studies were heterogenous but there is little evidence that additional thyroid testing is required despite widely available testing and cheap intervention with thyroid preparations. Additional measurement of thyroid antibodies does not appear to help further diagnosis of UI despite patient acceptance of simple thyroid replacement. Despite low certainty of evidence in UI, the strong evidence in the general population was considered.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.

**THROMBOPHILIA**

**Evidence**

A small cross-sectional study, including 31 patients with UI and 32 controls, investigated the role of thrombophilia (antithrombin III deficiency, protein C and/or S deficiency, FVL, FII mutation, MTHFR C677T mutation, hyperhomocysteinemia, Lupus anticoagulant) in UI. No significant differences were detected between UI and controls for any of the isolated or combined thrombophilia markers (Bellver, et al., 2008).

In a large case-control study, 594 women with UI were screened for common prothrombotic polymorphisms (Factor V Leiden (FVL), prothrombin G20210A and activated protein C resistance (APCR)), and/or antiphospholipid antibodies (anticardiolipin IgG, beta 2 glycoprotein I antibodies, Lupus anticoagulant). APCR and/or FVL were significantly more prevalent in UI women vs. fertile women with
previous spontaneous pregnancy (7.9% vs. 3.8%, OR 2.18, 95% CI 1.28-3.72). The prevalence of prothrombin G20210A or antiphospholipid antibodies was not different between the study group and fertile women (prothrombin 3.1% vs. 4.2%, OR 0.73, 95% CI 0.39-1.37; lupus/anticardiolipin 3.3% vs. 4.7%, OR 0.70, 95% CI 0.38-1.28). The presence of thrombophilia was not significantly associated with lower fertility success rate. Rather, women who had APCR and/or factor V Leiden or had antiphospholipid antibodies had significantly higher live birth rates in comparison to women who were tested negative (Steinvil et al., 2012).

In a case-control study, the frequency and SNP-SNP interactions between FVL G1691A, prothrombin G20210A mutation, and C677T MTHFR and PAI-1 4G/5G gene polymorphisms was evaluated in 105 women with UI and 120 fertile controls. Significant differences were found between UI women and controls only in the frequency of the MTHFR C677T CC genotype (19.1% vs. 40.8%), CT genotype (60% vs. 45.8%), and TT genotype (20.9% vs. 13.3%). Interaction of MTHFR plus FVL was associated with UI (Milenkovic et al., 2020).

In a case-control study, 230 women with UI and 240 fertile women were screened for the presence of congenital inherited thrombophilia (FVL mutation, prothrombin gene G20210A polymorphism, and deficiencies in protein S and C and AT). A significant higher prevalence of thrombophilia was found in women with UI compared to controls (13% vs. 7.1%). A significantly higher prevalence of prothrombin gene mutation was found in the UI group compared to controls (5.7% vs. 2.1%, OR 2.82, 95% CI 1.02-8.03). The presence of FVL and anticoagulant protein deficiencies was not significantly higher (4.8% vs. 3.8% and 2.6% vs. 1.2%) (Fatini et al., 2012).

In a case-control study including 100 women with UI and 200 apparently healthy women without infertility and with previous term pregnancies, screening was performed for mutations of the FVL, G20210A in prothrombin, and of MTHFR C677 T. There was no significant difference between UI and control groups for any of the thrombophilia: MTHFR OR 1.28 (95% CI 0.68-2.4), Factor V Leiden OR 1.0 (95% CI 0.36-2.75), prothrombin OR 0.85 (95% CI 0.22-3.37) (Casadei et al., 2010).

In a case-control study, the frequency of inherited thrombophilia’s (FVL G1691A, FVL H1299R (R2), factor II prothrombin G20210A, factor XIII V34L, b-fibrinogen -455G>A, PAI-1 4G/5G, HPA1 a/b (L33P), MTHFR C677T, and MTHFR A1298C) was investigated among 92 women with UI and 60 fertile control women. MTHFR C677T was the only gene to show a significant difference between women with UI (22%) and controls (0%) (Coulam and Jeyendran, 2009).

In a case-control study, 36 women with UI and 62 healthy, fertile controls were screened for the presence of thrombophilic mutations (FVL G1691A, MTHFR C677T, and FII G20210A). Significantly more mutations in FVL were found in the UI group compared to controls (30.6% vs. 0%), however, no significant differences were found in MTHFR or FII mutations (50% vs. 38.7% and 2.8% vs. 3.2%) (Behjati et al., 2006).

In a case-control study, 115 women with UI and 107 fertile women were screened for the PAI-1 4G - 675 allele. A significant difference in allele frequency was found between UI and fertile controls. Of the UI group 22.6% (26/115) was 5G/5G compared to 39.3% (42/107) of controls, and 77.4% (89/115) was either 4G/5G or 4G/4G compared to 60.7% (64/107) of controls (Kydonopoulou et al., 2017).
Recommendation

| 2.10.5 | Testing for thrombophilia in the female is probably not recommended. | EBR against | ☐ ☐ ☒ ☒ ☒ |

Justification

All included studies are small and the results are heterogenous, the evidence is therefore considered of very low quality. Furthermore, comprehensive testing for thrombophilia can be expensive, given the multiple alleged effects. While patients may value thorough exclusion of thrombophilia, the cost is large compared to the potential benefit. Comprehensive testing may not be available globally, is expensive and affects accessibility. In the absence of any proof of effective treatment, investigation is of low value to a desired outcome. This recommendation was downgraded in strength in Australia, due to low certainty of evidence.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

Oxidative Stress

Evidence

Male

In a prospective cohort study the role of oxidative stress (DNA fragmentation, reactive oxygen species (ROS), malondialdehyde (MDA), protein carbonyl group (PC), nitrotyrosine (NT), total thiol group (SH) levels and ferric reducing antioxidant power (FRAP)) in 28 males with UI was investigated and compared to 14 fertile sperm donors. A significantly higher percentage of DNA fragmentation and ROS formation was found in the UI group compared to controls (72% vs. 4.2%; and 56% vs. 4.7% respectively). Furthermore, seminal plasma MDA, PC, and NT levels were significantly elevated in UI versus control group (8.6 vs. 5.2 nmol/ml, 0.78 vs. 0.46 nmol/mg protein and 234 vs. 148 nmol/L respectively) (Aktan et al., 2013).

In a prospective cohort study, the effects of DNA damage and oxidative stress (ROS, total antioxidant capacity (TAC), SCSA DNA damage) in semen were investigated in 23 males with UI and 16 fertile controls. No significant differences were found in isolated ROS or TAC between the UI group and controls. However, the ROS-TAC score was significantly lower in UI vs. control groups (47 (IQR 25th and 75th percentile 45-51) vs. 53 (IQR 50-58)). Also, the DNA fragmentation index (DFI) was significantly higher in the UI group compared to controls (23% (IQR 15-32) vs. 15% (IQR 11-21)). ROS negatively correlated with fertilisation (r=-0.59) and embryo quality (r=-0.89); DFI negatively correlated with fertilisation (r=-0.70) and embryo quality (r=-0.70) (Saleh et al., 2003).

In a case-control study, oxidative stress markers (ROS and lipid peroxidation, mitochondrial membrane potential, DFI, antioxidant capacity) were investigated in 23 men with UI and 34 fertile controls. Only ROS was significantly increased in UI males compared to fertile controls (121.2±29.9 vs. 71.7±8.7) (Mayorga-Torres et al., 2017).

In a case-control study, oxidative DNA damage to sperm cells was investigated in 30 males with UI and 22 fertile males. When comparing UI males with controls, seminal MDA (9.68±2.87 µM vs. 6.63±2.99 µM); serum MDA (12.55±3.17 µM vs. 7.7±2.37 µM), serum nitric oxide (NO; 19.26±7.81 µM vs.
11.18±5.61 µM), serum 8-OhdG/106dG (1.55±0.61 vs. 1.03±1.03) and leukocyte 8-OhdG/106dG (1.25±0.37 vs. 0.77±0.27) were significantly higher in UI males (Taken et al., 2016).

In a case-control study, ROS in semen were compared between 43 men with UI and 17 fertile controls. ROS was significantly higher in UI males compared to controls, both in neat and washed semen (0.79 (IQR 0.41-2.01) vs. 0.03 (IQR 0.014-0.11) 10^4 RLU/min/20 million sperms and 2.35 (IQR 0.91-23.1) vs. 0.24 (IQR 0.12-0.38) 10^4 RLU/min/20 million sperms) (Venkatesh et al., 2011).

In a case-control study, lipid peroxidation (2-thiobarbituric acid-reactive substances (TBARS) as substitute for MDA, arachidonic acid (AA), docosahexaenoic acid (DHA)) in semen was evaluated in 12 males with UI and 17 controls. TBARS and AA levels in blood plasma were found to be significantly higher in the UI males group compared to controls (Oborna et al., 2010).

In a case-control study, ROS in semen were compared between 54 men with UI and 51 fertile sperm donors. Significant higher ROS levels were found in semen of UI patients compared to controls (0.35 ± 0.67 vs. 0.01 ± 0.02 x10^6 cpm/20x10^6 sperm) (Desai et al., 2009).

In a case-control study, DNA damage and oxidative stress (total antioxidant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI)) measured by Comet assay in semen of 30 males with UI and 20 fertile donors was investigated. No significant differences were found between UI and control males for TAO, TOS, OSI or sperm DNA damage (Verit et al., 2006).

In a case-control study, metabolomic analysis was performed on the urine of 71 UI and 47 fertile males. The study was able to distinguish significant differences between the two groups with respect to a number of purported biomarkers (Zhang et al., 2014).

Female

In a prospective cohort study, oxidative stress markers were evaluated in the serum and follicular fluid of 31 women with UI and compared to 40 women with male factor infertility. Serum Fas, follicular fluid MDA and follicular fluid TAC levels were found to be significantly lower in women with UI compared to controls (sFAS 2.85±0.44 vs. 2.90±1.01 pg/ml; fMDA 3.19±0.21 vs. 3.47±0.30 µM and fTAC 0.88±0.16 vs. 1.31±0.63 mmol/L respectively). Serum and follicular fluid superoxide dismutase (SOD) levels were found to be significantly higher in women with UI compared to controls (3.59±0.45 vs. 3.47±0.68 U/mL and 4.66±1.64 vs. 3.14±0.91 U/mL) (Pekel et al., 2015).

In a case-control study, including 20 women with UI and 20 controls undergoing ICSI for male-factor infertility, the association between oxidant status (TOS, TAS, and OSI) and infertility and outcomes after ICSI was investigated. TOS and OSI in follicular fluid of the UI patients were statistically higher than the control group (10.14±6.69 vs. 6.54±3.52 µmol H2O2 Eq/L and 0.94±0.5 vs. 0.62±0.33 arbitrary units, respectively). The systemic TOS and OSI were also significantly increased in the UI group compared to the control group (9.63±6.16 vs. 5.51±4.27 µmol H2O2 Eq/L and 0.82±0.5 vs. 0.47±0.35 arbitrary units, respectively). No significant difference in implantation, clinical PR or LBR (Şentürk et al., 2021).

In a case-control study, including 145 infertile women with different infertility diagnosis and 35 controls, the association between follicular fluid metabolites and infertility was investigated. The concentrations of 27 metabolites in follicular fluid were found to be significantly different between infertile females and controls. The pattern of alterations in the aforementioned metabolites was different according to different infertility diagnoses (Lazzarino et al., 2021).
In a case-control study, oxidative stress (MDA, serum nitrite and FRAP) was evaluated in 13 women with UI and compared to 25 fertile controls. Serum nitrite was lower in UI compared to controls (3.0±0.43 vs. 5.0±0.52 µmol/L). Serum MDA levels were significantly higher in UI compared to controls (3.28±0.10 vs. 2.82±0.15 nmol/L) (Veena et al., 2008).

**Couple**

In a case-control study, the role of superoxide dismutase (SOD) 2 and nitric oxide synthase (NOS) polymorphisms in UI was evaluated. Sixty-nine fertile patients (34 men and 35 women) and 110 infertile patients with UI (52 men and 58 women) were enrolled. Comparing fertile and infertile groups, a significant difference was noted only for the eNOS gene. Homozygosity for the 894G-eNOS allele was associated with a significant increased risk of infertility (OR 1.91, 95% CI 1.04-3.54). For males with UI, the Ala-MnSOD allele was found in 59% of UI males vs. 41% of controls, and associated with infertility (OR 2.94, 95% CI 1.14-7.60) (Faure et al., 2014).

**Recommendation**

<table>
<thead>
<tr>
<th>Measurement of oxidative stress in semen of males with unexplained infertility should only be considered in the context of research.</th>
<th>Research only</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.10.6 Measurement of oxidative stress in females with unexplained infertility is not recommended.</td>
<td>EBR against</td>
</tr>
</tbody>
</table>

**Justification**

The included studies point towards an increase in ROS in males with UI. However, studies described have used many different methods, some of which are not readily available, limiting access and equity. The evidence for male testing is low and would benefit from further research. Patients would value a simple blood test if treatment was available and effective. In the absence of this, testing of oxidative stress should be standardised across research studies and treatment benefits compared with the work and expenses involved in testing. In females, there is good evidence that testing is not valuable, at least for serum, while follicular fluid is difficult to obtain before fertility treatment. Again, there is no evidence of any treatment being effective thereby limiting investigation and the cost of testing. This recommendation was downgraded in strength in Australia, due to low certainty of evidence.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.

**GENETIC/GENOMIC TESTS**

**Evidence**

In a retrospective cohort study, 4345 (2261 male and 2084 female) individuals with reproductive disorders (11% of patients with UI) underwent karyotype testing. Abnormalities were found in 3% of patients with UI, compared with 2.2% for ART failure and 1.6% for recurrent miscarriage. No statistical analysis was performed (Ertosun et al., 2022).

In a prospective cohort study, genetic polymorphisms in the FSHB gene were evaluated in 36 females with UI and 169 healthy women without known fertility problems. Carriers of the FSHB-211 T-allele had significantly higher serum FSH and LH concentrations, and this allele was enriched among infertility
patients, and even nearly doubled in women with UI (23.6% vs. 12.4%). Frequency of TT homozygosity was increased threefold (5.6% vs. 1.8%) (Rull et al., 2018).

In a prospective cohort study, 98 couples with UI were screened for genetic polymorphisms in the PPAR gamma gene. No relationship was found between pregnancy rate and the studied polymorphisms (Sahmani et al., 2011).

In a prospective cohort study, 19 women with UI were screened for genetic polymorphisms of CIAS1, an inflammasome component. Frequency was not significantly different between groups, 18.4% in unexplained vs. 17% in male infertility (Witkin et al., 2010).

In a case-control study, sperm miRNA expression levels were evaluated in 8 males with UI and 10 fertile controls. Overall, 115 miRNAs were found to be ubiquitous in all normospermic infertile individuals, while 59 miRNAs were not detected. In addition, 57 miRNAs were found to be differentially expressed; of which 20 are regulated by a host promoter and 3 of these comprised genes involved in fertility (Salas-Huetos et al., 2016).

In a case-control study, 28 normozoospermic men with female partners with UI were screened for chromosomal polymorphisms. Chromosomal polymorphisms were found in 9/28 normozoospermic men (Suganya et al., 2015).

In a case-control study, 206 males with UI and 230 healthy controls were screened for genetic polymorphisms of MTHFR. No significant differences in allele frequencies between males with UI and controls were found (Vani et al., 2012).

In a study, including 1206 normovulatory sub fertile women, the association between chromosome abnormalities and infertility was investigated. The cause of infertility was not associated with the prevalence of chromosome abnormalities in the patients analysed. However, a significantly higher prevalence of chromosome abnormalities was observed in women with secondary infertility (1.25%) compared to those with primary infertility (0.25%) (Papanikolaou et al., 2005).

A study including 50 couples with UI investigated the association between chromosome abnormalities and infertility. Significantly more micronucleated cells were found in infertile couples compared to controls (14.66±5.21 vs. 10.60±2.57) (Trková et al., 2000).

**Recommendation**

| 2.10.7 | Genetic or genomic tests are probably not recommended in couples with unexplained infertility. | EBR against | ☭○○○ |

**Justification**

Many tests are described in literature, but there is little evidence of a specific benefit in UI, as opposed to the general infertility population. Genetic testing is expensive, and there is currently no association between specific genes and UI. While background rates of chromosomal analysis vary between studies, there is little evidence of an increase in UI in either men or women. Patients would value knowing their karyotype is normal, but a routine karyotype may not be sufficient to exclude genetic contributions to infertility. Selection of specific genes contributing to UI has not shown any benefit and the cost is large relative to the benefit. Assessment of any abnormality will need advice from a genetic specialist and
expensive intervention via IVF and PGT-A, depending on the particular genetic condition. This recommendation was downgraded in strength in Australia, due to low certainty of evidence.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

VITAMIN D DEFICIENCY

Evidence
In a study including 58 men with UI and 50 age- and BMI-matched fertile men, vitamin D levels were compared between groups. Compared with the fertile group, male patients in couples with UI had significantly lower vitamin D levels (27.00 ng/mL (12.63-39.30) vs. 23.66 ng/mL (7.50-55.00)) (Güngör et al., 2022).

A retrospective cohort study, including women undergoing their first IVF cycle, investigated the association between vitamin D and live birth rates. The cumulative live birth rate in the vitamin D-deficient group was significantly lower compared to the non-deficient group (43.9%, 208/474 vs. 50.9%, 325/639, OR 0.755, 95% CI 0.595–0.959). The clinical/ongoing pregnancy rate, live birth rate and miscarriage rate in the fresh cycle did not show significant differences between the vitamin D deficient and non-deficient groups (Ko et al., 2022).

In a sub-analysis of a randomised controlled trial, the association between vitamin D deficiency and UI was investigated in 647 women. Overall, 25% of patients met the criteria for vitamin D deficiency. In patients with vitamin D deficiency the live birth rate was not significantly different from those who were not vitamin D deficient (32 vs. 29%, OR 1.1, 95% CI 0.7–1.7) (Butts et al., 2019).

In a retrospective cohort study, the influence of vitamin D levels on IVF outcomes was investigated in 22 women with UI. Overall, 14/22 women had vitamin D levels >30 ng/ml, 4 had levels 20-30 ng and 4 had levels <20 ng/ml. There was no specific effect on UI but vitamin D deficiency was associated with lower pregnancy rates in non-Hispanic white females but not in Asian females (Rudick et al., 2012).

In a case-control study, the prevalence of vitamin D deficiency was evaluated in 26 women with UI and compared to 15 women with male factor infertility. Vitamin D levels were not significantly different between women with UI and women with male factor infertility (23.3 ± 8.6 vs. 26.2 ± 9.2 ng/ml) (Lopes et al., 2017).

Recommendation

| 2.10.8 | Testing for vitamin D deficiency in females is probably not recommended in couples with unexplained infertility. | EBR against | ⬤⬤⬤⬤ |

Justification
In the context of UI, no role of vitamin D has been found. The evidence is of relatively low quality, but generally against specific testing outside of other medical or environmental indications. Testing for an individual is relatively inexpensive and widely available with easy dietary remediation, but treatment efficacy is unproven. This recommendations was downgraded in strength in Australia, due to low certainty of evidence.
Further information
Details of the literature study and evidence tables are available in the Technical Report.

PROLACTIN

Evidence
In a cross-sectional study, the association between prolactin and UI was investigated. 84 women with UI and 44 healthy fertile women were enrolled and ROC curves were calculated. Prolactin levels were significantly higher (2-fold elevated) in serum of women with UI compared to controls. Using prolactin, MCP-1 and leptin in a predictive model, a significant receiver operating curve (ROC of 0.89) was obtained for prediction of UI (Qu et al., 2020).

In a prospective cohort study, the role of prolactin in UI was investigated in 12 women with UI and 12 fertile controls. Midcycle bioactive prolactin (34.2±8.3 vs. 19.2±3.4 ng/ml) but not immunoactive (26.9±4.3 vs. 22.1±2.6 ng/mL) were different in women with UI compared to controls (Subramanian et al., 1997).

In a cross-sectional study, the association between prolactin and UI was investigated in 187 women with UI and compared with 52 women with male infertility. Prolactin levels were not significantly different in the UI group compared to the male factor infertility group (10.4 ng/mL (IQR 7.7-13.4) vs. 11 ng/mL (IQR 8.5-13.7) (Orouji Jokar, et al., 2018).

In a case-control study, prolactin levels were no different in 13 women with UI compared to 25 fertile controls. Lactate dehydrogenase (LDH) was also evaluated and were significantly higher in serum in UI compared to controls (83.40±4.81 vs. 67.9±3.53 U/L) (Veena, et al., 2008).

Recommendation

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR against</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.10.9 Prolactin testing in the female without clinical features of hyperprolactinemia, is probably not recommended.</td>
<td>✍</td>
</tr>
</tbody>
</table>

Justification
The included studies are small and the quality of the data is very poor and heterogenous. In addition, current evidence is unable to show a benefit to measuring prolactin levels in asymptomatic women with UI. While the testing is cheap and widely available, the evidence is low and the cost benefit relationship poor.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

BMI

Evidence
In an epidemiologic survey study, the association of dietary status and UI was evaluated in 198 women with UI and 59 pregnant controls. There was a significant difference in caloric intake between women with UI and controls (2688.64±580.78 vs. 2115.44±326.63 calories), with a lower intake of carbohydrates and vitamins and higher intake of fats in women with UI. Of the women with UI 33% reported daily physical exercise compared to 69% of controls (Noventa et al., 2016).
In an epidemiologic survey study, the effect of body weight on the success rate of IVF in 1828 women with UI was studied. A significantly higher live birth rate per cycle was found in women with normal weight (BMI ≥20–25 kg/m²) and slight overweight (BMI 25–27 kg/m²) compared with women with a BMI ≥27 kg/m². The unfavourable effect of overweight was largest for women with UI (Lintsen et al., 2005).

In a study, the effect of BMI on oestradiol, progesterone and LH values in females who received IUI treatment was analysed in women with UI. Oestradiol on the day of hCG was lower in overweight/obese (natural and stimulated cycles) where patients were <35 years but not in over 35 years. In older women, oestradiol, progesterone and LH were lower in woman with greater weight (Wang et al., 2020).

Recommendation

| BMI evaluation in the female is considered good practice in pre-conception care as it affects fertility and reproductive outcomes. | PP |

Justification

Although there is little evidence of a specific association between BMI and UI specifically, reproductive outcomes are known to be impaired in men and women with low and high BMIs. The standard advice and medical investigation and interventions apply equally to patients with UI as to any other causes of infertility. Patients generally value advice about lifestyle and healthy alternatives to maximise fertility in the context of their social and cultural environment. While healthy lifestyle intervention may improve spontaneous conception, active weight loss treatment in assisted reproduction has not yet shown a benefit in getting pregnant.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

REFERENCES


Coulam CB, Jeyendran RS. Thrombophilic gene polymorphisms are risk factors for unexplained infertility. *Fertility and sterility* 2009;91: 1516-1517.


Ko JKY, Shi J, Li RHW, Yeung WSB, Ng EHY. 100 YEARS OF VITAMIN D: Effect of serum vitamin D level before ovarian stimulation on the cumulative live birth rate of women undergoing in vitro fertilization: a retrospective analysis. *Endocrine connections* 2022;11.


Yasin AL, Yasin AL, Basha WS. The Epidemiology of Anti-Sperm Antibodies Among Couples with Unexplained Infertility in North West Bank, Palestine. *Journal of clinical and diagnostic research : JCDR* 2016;10: Qc01-03.

3. Treatment

When to start treatment

It is known that couples presenting with unexplained infertility (UI) can achieve spontaneous pregnancy. The chances of natural conception in couples with UI can be predicted from prognostic factors, which have been integrated into prognostic models (Hunault CC et al 2019 and Van der Steeg JW et al 2007). Typically, such models use a validated set of prognostic factors shown to impact the chance of spontaneous pregnancy and consider the weight or importance of the prognostic factors. The most important prognostic factors include parameters such as age, duration of infertility, previous treatment and previous pregnancy.

Several tools are available and in use in some countries with the potential to guide clinical practice including at policy, reimbursement and individualised shared decision-making levels. For example, in couples with a 12-month chance of natural conception of 30% or higher, using published parameters, expectant management has been suggested as appropriate, depending on factors such as aspirational family size (Wang, R et al 2019). In couples with a 12-month chance of natural conception below 30%, timely treatment may be indicated. There is also evidence of variable efficacy of treatments based on prognosis (Wessel et al 2022, Farquhar C, et al 2017, Bensdorp AJ 2017), suggesting that individual prognosis could inform in which patients treatment is effective and in which it is not. This in turn could enable personalized medicine and shared decision making, side effects, may optimise treatment outcomes and facilitate a cost-effective use of resources.

Reciprocally, it is important to note that the currently available prediction models are not fully evolved and have only been validated for select populations including the Canadian and the Dutch population. Also, some can only be used once: at the point of diagnosis, when couples first present with infertility. More evolved dynamic models, which can be used more than once to provide updated estimates of chances of natural conception over 6-12 months have been developed (McLernon et al., 2019, van Eekelen et al., 2017). Although these have undergone initial validation in Dutch and Scottish populations, these are not yet widely adopted and have yet to be validated using data from other settings or implemented in clinical practice.

As shown in the next two chapters, the perception that a treatment is either effective or not effective (changed "does not apply" to applies differently in UI as this did not make sense with the section that follows

Namely, one RCT comparing ovarian stimulation and IUI to expectant management in good-prognosis patients found no difference in live birth rate (Steures et al., 2006), while another RCT investigating the same treatment comparison in poor-prognosis patients reported a striking benefit of treatment (ovarian stimulation and IUI) over expectant management (Farquhar et al., 2018). Therefore, young women with a short duration of infertility have a high prognostic index and the added benefit of active treatment is small. However, with longer duration of infertility and older age, the prognostic index decreases and the benefit of active treatment increases.

Prognostic models can help the decision-making on a treatment plan in couples with UI, however, it is also important to take patient preferences into account, including factors such as aspirational family size, when deciding on treatment options.
REFERENCES


3.1 Expectant management

**PICO QUESTION: What is the value of expectant management compared to active treatment for patients with UI?**

For this chapter, the GDG considered timed intercourse without hormonal stimulation part of expectant management and not as an active treatment, hence the comparison of timed intercourse without hormonal stimulation versus expectant management is not included in the guideline.

**Clomiphene citrate with timed intercourse (+/- ovulation trigger) vs. expectant management**

**Evidence**

One RCT including 385 patients with unexplained infertility (UI), compared six months of expectant management (n=167) with clomiphene citrate (CC) and timed intercourse (n=173). Cumulative birth rate was 16% (26/167) with expectant management compared to 13% (23/173) with active treatment. Compared with expectant management, the adjusted hazard ratio (HR) for the time to a pregnancy leading to a live birth was 0.83 (99% CI 0.42-1.63) (Bhattacharya et al., 2008). The cost-benefit study using this data by the same group also found no cost-benefit of clomiphene citrate over expectant management (Wordsworth et al., 2011).

In a four-arm RCT, including 155 couples with UI, timed intercourse with CC for ovarian stimulation (OS), with or without hCG for final oocyte maturation, was compared to timed intercourse and placebo, with or without hCG for final oocyte maturation. Pregnancy rates were significantly higher after timed intercourse with CC and hCG compared to placebo without hCG (7/37 (19%) vs. 0/36 (0%) (Fisch et al., 1989).

**Letrozole with timed intercourse (+/- ovulation trigger) vs. expectant management**

**Evidence**

No relevant studies were identified comparing letrozole with timed intercourse (+/- ovulation trigger) with expectant management in couples with UI.

**Gonadotropins with timed intercourse (+/- ovulation trigger) vs. expectant management**

**Evidence**

No relevant studies were identified comparing OS with gonadotropins and timed intercourse (+/- ovulation trigger) with expectant management in couples with UI.

**Intra-uterine insemination (IUI) in a natural cycle vs. expectant management**

**Evidence**

One RCT compared IUI in a natural cycle with expectant management in couples with UI. Live birth rate was not significantly different between IUI and expectant management (38/165 (23%) vs. 26/167 (16%) (Bhattacharya, et al., 2008).
**Ovarian Stimulation with IUI vs. Expectant Management**

**Evidence**
A systematic review and meta-analysis compared OS combined with IUI and expectant management in couples with UI. The OR for cumulative live birth rate in couples with poor prognosis was 4.48 (95% CI 2.00-10.01, 1 RCT, 201 women). The OR for live birth rate in couples with moderate prognosis was 0.82 (95% CI 0.45-1.49; 1 RCT, 253 women). The OR for multiple pregnancy rate was 3.01 (95% CI 0.47-19.28; 2 RCTs, 454 women) (Ayeleke et al., 2020).

**IVF vs. Expectant Management**

**Evidence**
A systematic review and meta-analysis compared IVF with expectant management. The OR for live birth with 1 cycle of IVF compared to three months of expectant management was 22.0 (95% CI 2.56-189.38, 51 women, 1 RCT). The OR for clinical pregnancy with 1 cycle of IVF compared to 3-6 months of expectant management was 3.24 (95% CI 1.07-9.80, 2 RCTs, 86 women). Although the evidence is of low quality and insufficient, IVF is presently associated with a higher live birth rate than expectant management (Pandian et al., 2015).

In a retrospective cohort study, 635 couples with UI and female age ≥39 years were included. Couples undergoing immediate IVF treatment (n= 359) were compared to couples waiting for about 1 year to start IVF treatment (n=276). No significant difference was found in live birth rate between immediate IVF treatment and waiting for about a year (70/359 (19%, 11 natural conception and 59 after IVF) vs. 57/276 (20.7%, 37 natural conception and 20 after IVF) (Carosso et al., 2022).

**Overall Recommendation**

<table>
<thead>
<tr>
<th>3.1.1</th>
<th>IUI with ovarian stimulation could be recommended as a first-line treatment for couples with unexplained infertility.</th>
<th>EBR</th>
<th>PP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>It is advised to base the decision to start active treatment informed by prognosis in couples with unexplained infertility.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Justification**
The context of prognosis was emphasised as a consideration in the Australian context.

The first mentioned RCT (Bhattacharya, et al., 2008) is by far the largest and latest and shows no significant evidence that CC is either more efficient or cheaper than expectant treatment. Similar findings were reported for IUI in a natural cycle versus expectant management. Although only one RCT is available, it is of sufficient quality and size to suggest that the live birth rate following IUI in a natural cycle is not significantly superior to that following expectant management.

The weight of evidence strongly suggests that IUI with OS is recommended in preference to expectant management, particularly for couples with poor prognosis. Although IUI involves obviously more invasive treatment, the difference in live birth rates between these two alternatives provides justification for its use. The latest (mainly European) studies suggest that only a low-dose regimen should be employed when using gonadotrophins for OS, since it can greatly reduce the multiple pregnancy rate without significantly reducing the live birth rate.
For the comparison of IVF to expectant management, the evidence is scarce. The current evidence seems to point towards a higher efficacy for IVF than expectant management, leading to the conclusion that IVF is recommended over expectant management. The GDG regards this as indirect evidence for the effectiveness of IVF and regards it unlikely that direct evidence from trials comparing IVF vs. expectant management will emerge in the future due to several factors. These include whether equipoise exists for such a trial is controversial, secondly the proper comparator of IVF is unclear, i.e., how many cycles of expectant management. Also, IVF comes with high physical and psychological burdens. In the absence of direct evidence for effectiveness and or additional benefit of IVF in different patient profiles, the practice point was that the decision to use IVF should be based on patient characteristics and preferences. In the Australian context, cost was considered noting that IUI is higher cost than expectant management, but not as high as IVF. Accessibility to care is also a consideration.

Further information
Details of the literature study and evidence tables are available in the technical report.

REFERENCES


3.2 Active treatment

**PICO QUESTION: If active treatment is pursued, which type of active treatment for UI?**

### TIMED INTERCOURSE

**Clomiphene citrate and timed intercourse vs. letrozole and timed intercourse**

**Evidence**

No relevant studies were identified comparing clomiphene citrate and timed intercourse vs. letrozole and timed intercourse, following integrity assessment.

**Gonadotropins and timed intercourse vs. clomiphene citrate or letrozole and timed intercourse**

**Evidence**

*No relevant studies were identified comparing timed intercourse with letrozole to OS and IUI in couples with UI.*

### TIMED INTERCOURSE VS. IUI IN A NATURAL CYCLE

**Clomiphene citrate and timed intercourse vs. IUI in a natural cycle**

**Evidence**

In a 3-arm RCT, expectant management was compared with CC and timed intercourse and IUI in a natural cycle. Compared to CC with timed intercourse, treatment with IUI resulted in a higher live birth rate (13% (23/173) vs. 23% (38/165)) (Bhattacharya et al., 2008). However, the RCT was not powered to compare the two active treatment arms to each other.

**Letrozole and timed intercourse vs. IUI in a natural cycle**

**Evidence**

*No relevant studies were identified comparing timed intercourse with letrozole to IUI in a natural cycle in couples with UI.*

**Gonadotropins and timed intercourse vs. IUI in a natural cycle**

**Evidence**

*No relevant studies were identified comparing timed intercourse with gonadotropins to IUI in a natural cycle in couples with UI.*

### TIMED INTERCOURSE VS. OVARIAN STIMULATION AND IUI

**Clomiphene and timed intercourse vs. ovarian stimulation and IUI**

**Evidence**

*Evidence was removed here following the integrity check.*
Letrozole and timed intercourse vs. ovarian stimulation and IUI

Evidence

No relevant studies were identified comparing timed intercourse with letrozole to OS and IUI in couples with UI.

Gonadotropins and timed intercourse vs. ovarian stimulation and IUI

Evidence

A systematic review and meta-analysis, including two RCTs, compared OS with timed intercourse to OS and IUI. It is uncertain whether OS and IUI results in a higher live birth rate than OS with gonadotropins and timed intercourse (OR 1.59, 95% CI 0.88-2.88, 2 RCT, 208 women). It is uncertain whether OS and IUI results in a lower multiple pregnancy rate (OR 1.61, 95% CI 0.44-5.89, 2 RCT, 208 women) than OS with gonadotropins and timed intercourse (Ayeleke et al., 2020).

IUI in a natural cycle vs. ovarian stimulation and IUI

Evidence

A systematic review and meta-analysis, including four RCTs, compared OS with IUI to IUI in a natural cycle. Live birth rate was higher with OS and IUI compared to IUI in a natural cycle (OR 2.07, 95% CI 1.22-3.50, 4 RCT, 396 women). It is uncertain whether OS and IUI result in a higher multiple pregnancy rate (OR 3.00 95% CI 0.11-78.27, 1 RCT, 39 women) (Ayeleke, et al., 2020).

IUI vs. IVF

Evidence

A systematic review and meta-analysis compared IVF with IUI in a natural cycle. Live birth rate was higher with IVF compared to unstimulated IUI (OR 2.47, 95% CI 1.19-5.12, 2 RCT, 156 women). There was no evidence of a difference in multiple pregnancy rate (OR 1.03, 95% CI 0.04-27.29, 1 RCT, 44 women) (Pandian et al., 2015).

Another systematic review and meta-analysis, including 8 RCTs with 1497 couples with UI, compared efficacy and safety of IVF and IUI with OS (Nandi et al., 2022). Live birth rate was significantly higher after IVF compared to IUI with OS (RR 1.54, 95% CI 1.04-2.28, 7 RCT, 1391 women). No significant difference between groups was found for multiple pregnancy rate (RR 0.83, 95% CI 0.50-1.38, 6 RCT, 507 women) or OHSS (RR 1.77, 95% CI 0.49-6.37, 3 RCT, 981 women). In a sensitivity analysis including only studies with women without previous treatment, no significant difference in live birth rate was found in women <38 years (RR 1.01, 95% CI 0.88-1.15, 3 RCT, 925 women). However, in women ≥38 years, live birth rate was significantly higher after IVF treatment (RR 2.15, 95% CI 1.16-4.00, 1 RCT, 154 women) (Goldman et al., 2014, Nandi, et al., 2022).

Overall Recommendation

<table>
<thead>
<tr>
<th>3.2.2</th>
<th>IVF is probably not recommended over IUI with ovarian stimulation in couples with unexplained infertility.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR</td>
<td>either</td>
</tr>
<tr>
<td></td>
<td>It is expected that the decision to use IVF is individualised by patient characteristics such as age, duration of infertility, previous treatment and previous pregnancy.</td>
</tr>
<tr>
<td></td>
<td>PP</td>
</tr>
</tbody>
</table>

ADAPTED Australian Unexplained Infertility Guideline 2023 84
Justification

There is a lack of high-quality RCTs on the topic. Clomiphene, letrozole, gonadotrophins and IUI on their own are not effective compared to expectant management or IUI in a natural cycle. On the other hand, IUI in combination with OS is not inferior to IVF. Furthermore, the additional costs and risks of IVF need to be considered. Therefore, IUI in a stimulated cycle for 3-6 cycles is viewed as the first-line treatment in couples with unexplained infertility. This is taking into account low-dose gonadotropins for OS to avoid a high number of growing follicles, which can increase the risk of multiple pregnancies.

The decision to use IVF is individualised by patient characteristics, such as age, duration of infertility, previous treatments, aspirational family size and previous pregnancy. Consideration that IVF can generate multiple embryos that can be frozen was also noted. Current evidence shows that in treatment-naïve patients, IVF is as effective as IUI with OS. However, as the invasiveness of the procedure and the costs are considerably lower with IUI, it was generally concluded that OS and IUI is recommended as the first-line treatment.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

PICO QUESTION: WHAT IS THE VALUE OF IVF VERSUS ICSI?

Evidence

An RCT, including 60 couples with UI, compared IVF with ICSI. There were no differences in live birth rate between the IVF and ICSI groups (14/30 (46.7%) vs. 15/30 (50%)) (Foong et al., 2006).

A subgroup analysis of a large RCT included 382 couples with UI, randomly assigned to IVF (n=183) and ICSI (n=199), found no significant difference in live birth rate between groups (35.5% (65/183) vs. 36.7% (73/199), RR 1.03 (95% CI 0.79-1.35)) (Dang et al., 2021).

A subgroup analysis of an RCT included 100 couples with UI. There was no difference in pregnancy rates between IVF and ICSI (32% vs. 38%, RR 0.83, 95% CI 0.48-1.45) (Bhattacharya et al., 2001).

Recommendation

| 3.2.3 | ICSI is not recommended over conventional IVF in couples with unexplained infertility. | EBR either | ☒ ☒ ☒ ☐ ☐

Justification

Evidence from RCTs comparing IVF with ICSI in couples with UI showed comparable live birth rates. Furthermore, there is substantial evidence from RCTs showing no difference in live birth rate between IVF and ICSI for non-male factor infertility (Bosch et al., 2020, Dang, et al., 2021). Given this overriding evidence, and the additional resources and costs associated, ICSI is not routinely recommended for UI. In the Australian context there was consideration of the evidence, and by full consensus it was determined that this was a strong recommendation.

Further information

Details of the literature study and evidence tables are available in the Technical Report.

ADAPTED Australian Unexplained Infertility Guideline 2023

85
REFERENCES


Dang VQ, Vuong LN, Luu TM, Pham TD, Ho TM, Ha AN, Truong BT, Phan AK, Nguyen DP, Pham TN *et al.* Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. *Lancet* 2021;397: 1554-1563.


3.3 Mechanical-surgical procedures

**PICO QUESTION: WHAT IS THE VALUE OF MECHANICAL-SURGICAL PROCEDURES?**

**RESECTION OF POLYPS OR FIBROIDS**

Evidence

Spontaneous conception

After applying the integrity check, no evidence was found to address this question.

**Recommendation**

| Hysteroscopy for the detection and possible correction of intrauterine abnormalities not seen at routine imaging requires further research | Research only |

**Justification**

There is insufficient evidence on the effectiveness of hysteroscopic surgery in women with unexplained infertility. Reported randomised trials are at serious risk of bias and other studies lack control groups.

The current evidence was not included after the integrity check and is awaiting classification. Hence there is insufficient evidence to support the correction of these minor intrauterine abnormalities.
Surgery is only advised in a well-controlled research setting (preferably randomised trials) in women with well-defined definitions for abnormality and clinical outcome.

For treatment of uterine fibroids in women with otherwise unexplained infertility there is insufficient evidence to make any recommendation.

In the Australian adaptation process after the integrity check no evidence was included for consideration and only a research recommendation could be made.

Further information
Details of the literature study and evidence tables are available in the Technical Report

**TUBAL FLUSHING**

Evidence
A systematic review and meta-analysis, including 15 RCTs and 3864 women with subfertility, investigated the effect of tubal flushing with oil-soluble contrast media (OSCM) or water-soluble contrast media (WSCM) on reproductive outcomes (Wang et al., 2020).

**Oil soluble contrast media (OSCM) versus no flushing**
OSCM may increase the odds of live birth (OR 3.27, 95% CI 1.57-6.85, 3 RCTs, 204 women) and clinical pregnancy (OR 3.54, 95% CI 2.08-6.02, 4 RCTs, 506 women) (Wang, et al., 2020).

**Water soluble contrast media (WSCM) versus no flushing**
It is uncertain whether flushing with WSCM increases live birth rate (OR 1.13, 95% CI 0.67-1.91, 1 RCT, 334 women). It is uncertain whether flushing with WSCM increases clinical pregnancy rate (OR 1.14, 95% CI 0.71-1.84, 1 RCT, 334 women) (Wang, et al., 2020).

**Oil versus water soluble contrast media**
Live birth rate was reported in 3 RCTs. In two RCTs, a higher live birth rate was reported with OSCM (OR 1.64 95% CI 1.27-2.11, 1119 women; OR 3.45, 95% CI 1.97-6.03, 398 women). In one RCT, no evidence of a difference between groups was found (OR 0.92, 95% CI 0.60-1.40, 533 women). Tubal flushing with OSCM probably increases the odds of clinical pregnancy compared to WSCM (OR 1.42, 95% CI 1.10-1.85, 6 RCTs, 2598 women). Flushing with OSCM probably increased the odds in intravasation (OR 5.00, 95% CI 2.25-11.12, 4 RCTs, 1912 women). No difference in infection or haemorrhage between OSCM and WSCM and no serious adverse events reported (Wang, et al., 2020).

The largest trial comparing oil versus water soluble contrast media involved 1119 (OSCM: n=557 vs. WSCM: n=562) infertile women undergoing HSG with a 5 year follow-up. In the OSCM group, 39.8% of the women needed no other treatment, 34.6% underwent IUI and 25.6% had IVF/ICSI in the 5 years following HSG. In the WSCM group, 35.0% of the women had no other treatment, 34.2% had IUI and 30.8% had IVF/ICSI in the 5 years following HSG (p=0.113). During the 5-year period there was a significantly higher ongoing pregnancy rate (RR 1.07, 95% CI 1.00-1.14) and live birth rate (RR 1.11, 95% CI 1.03-1.20) and a shorter time to ongoing pregnancy (10.0 months (95% CI 8.5-11.5) vs. 13.7 months (95% CI 11.7-15.8)), in favour of OSCM compared with WSCM used at HSG (van Welie et al., 2021).
Recommendation

3.3.1 HSG (i.e., tubal flushing) with an oil-soluble contrast medium should be considered over a water-soluble contrast medium. Risks and benefits of tubal flushing with oil-soluble contrast medium should be discussed with all couples with unexplained infertility.

EBR ⊕⊕  ◯◯

Justification

Current evidence shows that HSG performed with OSCM is preferred over WSCM. This may lead to more clinical pregnancies and live births at no extra cost. Part of the evidence for this question was derived from ovulatory infertile women with diagnosis other than UI. However, the largest trial by Dreyer et al., 2017, included 1119 women with UI (Dreyer et al., 2017).

Risks of tubal flushing with oil-based contrast are low with the most frequently reported complication being intravasation. Since the introduction of oil-based contrast in 1928 serious consequences of embolism have been reported in four cases, emphasising the importance of performing HSG’s under fluorescence guidance in order to abandon the procedure in a timely manner (Roest et al., 2021).

In the Australian context the evidence was reviewed and was considered robust and unaffected by the integrity check and the recommendation was changed to a strong recommendation. Cost was noted as a consideration here also.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

Mild Endometriosis

Evidence

In a Cochrane systematic review evaluating the role of laparoscopic surgery versus diagnostic laparoscopy in women with minimal or mild endometriosis, results from 3 randomised trials were pooled (Bafort et al., 2020). There was an improvement in clinical pregnancy rate with laparoscopy (OR 1.89, 95% CI 1.25-2.86, 3 RCTs, 528 participants). There was insufficient data on the safety of the intervention.

Justification

The GDG recommends against routine laparoscopy. If incidentally minimal to mild endometriosis is found, this is considered outside the scope of this guideline. The reader is referred to the ESHRE guideline on Endometriosis (Becker et al., 2022).

Further information
Details of the literature study and evidence tables are available in the Technical Report.

Endometrial Injury/Scratching

Evidence

Timed intercourse

A recent randomised trial in women with UI included 220 women who were randomised. Endometrial biopsy or placebo procedure took place between D1-12 of the menstrual cycle; second attempt was...
allowed if the first was unsuccessful. Couples had regular unprotected sexual intercourse for 3 cycles. There was no difference in the outcomes of live birth (10/113 (9%) vs. 7/107 (7%); OR 1.39, 95% CI 0.50-4.03), ongoing pregnancy (10/113 (9%) vs. 7/107 (7%); OR 1.39, 95% CI 0.50-4.03) or miscarriage (2/113 (2%) vs. 1/107 (1%); OR 20.01, 95% CI 0.19-43.82) (Wong et al., 2022).

**IUI**

In an RCT with 96 women suffering from infertility of unknown cause undergoing IUI with OS, women received an endometrial scratch in the midluteal phase (days 21–26 of the cycle, n=54) or no endometrial injury (n=42). There was no statistical difference in ongoing pregnancy rate (4/54 (10%) vs. 2/42 (4.76%)) between women undergoing endometrial scratch or not. Multiple pregnancies and miscarriages were not observed (Yildiz et al., 2021).

In a randomised trial, 150 women with UI and an indication for IUI were randomised between scratch on day 6-7 of their treatment cycle or no scratch. Couples received up to 3 cycles of IUI. There was no difference in ongoing pregnancy rate (6/75 (8.0%) vs. 8/75 (10.7%); RR 0.75, 95% CI 0.27-2.06) or multiple pregnancy rate (0/75 vs. 1/75) (Ghuman et al., 2020).

**Recommendation**

| Endometrial scratching should probably not be recommended for unexplained infertility. | EBR against |

**Justification**

In addition to established therapies for UI such as IUI or IVF, endometrial scratching or injury has been proposed to increase the probability of pregnancy. It is hypothesised that local mechanical endometrial injury may enhance the receptivity of the endometrium and facilitate embryo implantation through inflammatory and immunological responses (Dekel et al., 2010, Gnainsky et al., 2015, Gnainsky et al., 2010, Granot et al., 2012).

Timing of injury of the endometrium differed in the studies. In some studies, scratching was performed in the luteal phase of the cycle preceding the treatment cycle (Yildiz, et al., 2021) in others, in the proliferative phase of the treatment cycle (Ghuman, et al., 2020, Wong, et al., 2022). In most studies, the endometrium was injured by taking a biopsy but in one an embryo transfer or biopsy catheter was used and moved up and down to injure the endometrium ( Yildiz, et al., 2021).

Although it is a low-cost procedure, which can be done at the outpatient clinic without anaesthetics, the evidence does not show better pregnancy outcomes if scratching was performed before intercourse or before IUI in couples with UI.

In the Australian context the evidence was reviewed and three studies were removed on the integrity check. Hence, the recommendation was downgraded to conditional against the use of endometrial scratching.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.

**REFERENCES**
3.4 Alternative therapeutic approaches

**PICO QUESTION: WHAT IS THE EFFECTIVENESS OF ALTERNATIVE THERAPEUTIC APPROACHES?**

### Antioxidants

**Evidence**

A systematic review and meta-analysis compared oral antioxidant treatment combined with an infertility treatment with placebo and infertility treatment in couples with unexplained infertility (UI). Similar live birth rates were reported in both groups (OR 1.50, 95% CI 0.60-3.72, 2 RCTs, 133 women). Multiple pregnancy rate was not significantly different (8.9% vs. 11.1%, OR 0.65, 95% CI 0.26-1.62, 1 RCT, 804 women) (Showell et al., 2020). There were two RCTs in this systematic review that were relevant to this question and were primarily considered here.
Recommendation

3.4.1 Adjunct oral antioxidant therapy to females undergoing fertility treatment may not be recommended.

EBR against ◁ ◁ ◁ ◁

3.4.2 Adjunct oral antioxidant therapy to males undergoing fertility treatment may not be recommended.

EBR against ◁ ◁ ◁ ◁

Justification
Current low-quality evidence does not show a benefit of antioxidant treatment in males or females with UI. Generally, antioxidants are not very expensive, however, their benefit was not demonstrated. Both ESHRE and the Australian guideline group made conditional recommendations against use of antioxidants in unexplained infertility.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

ACUPUNCTURE

Evidence
After the integrity check no relevant studies were identified investigating the effect of acupuncture in couples with unexplained infertility, following integrity assessment.

Recommendation

3.4.3 Acupuncture in women undergoing infertility treatment is probably not be recommended.

EBR against ◁ ◁ ◁ ◁

Justification
The evidence on acupuncture in unexplained infertility is very limited and of low quality. In the Australian process some of this evidence was not considered after the integrity check and the certainty fell to very low evidence. Furthermore, in infertility, there is no agreement on the techniques of acupuncture, i.e., acupuncture points to use or timing. Therefore, acupuncture cannot be recommended for patients with unexplained infertility.

Further information
Details of the literature study and evidence tables are available in the Technical Report.

NUTRACEUTICALS (INOSITOL)

Evidence
One RCT including 86 women with UI compared adjuvant treatment with myo-inositol suppositories (n=43) during timed intercourse cycles with placebo (n=43). Pregnancy rates were 18.6% (8/43) in the myo-inositol group compared to 6.97% (3/43) in the control group. No test of statistical significance was performed (Montanino Oliva et al., 2020).
**Recommendation**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inositol supplementation in women may not be recommended.</td>
<td>against</td>
</tr>
</tbody>
</table>

**Justification**

There is a plethora of nutraceuticals and the GDG was unable to find convincing evidence of benefit. The evidence quality was judged to be very low. Nutraceuticals are generally not expensive, however, their benefit was not demonstrated.

**Further information**

Details of the literature study and evidence tables are available in the Technical Report.

**PSYCHOTHERAPY**

**Evidence**

*No relevant studies were identified investigating the effect of psychotherapy in couples with unexplained infertility.*

**Recommendation**

| Psychological support, including psychotherapy, is recommended for patients when needed. | pp |

**Justification**

No studies were identified regarding psychotherapy in patients with UI specifically. However, psychotherapy can help infertility patients to improve health-related quality of life, anxiety and/or depression in broader populations. Further information on psychosocial needs that patients experience across their treatment pathway, and how fertility clinic staff can detect and address these needs can be found in the ESHRE guideline on Routine Psychosocial Care (Gameiro et al., 2015).

**TRADITIONAL CHINESE MEDICINE (TCM)**

**Evidence**

*Most literature was in Chinese language, where only publications in English were considered for this guideline.*

One uncontrolled study was identified, where Onkyeong-tang and herbal medicine for ovulation and implantation were administered to women with UI. After treatment, the women were followed for 3 menstrual cycles of observation. Live birth rate was 7.8% (7/90), ongoing pregnancy per clinical pregnancy was 53.85% (7/13) and 37% (33/90) of women experienced adverse events, but none were serious (Choi et al., 2021).

**DIET, EXERCISE, BEHAVIOURAL THERAPY**

*Behavioural therapy is an umbrella term for types of therapy that treat mental health disorders. This form of therapy looks to identify and help change potentially self-destructive or unhealthy behaviours. It is based on the idea that all behaviours are learned and that behaviours can be changed (McKay and Tryon, 2002).*
Evidence

No relevant studies were identified investigating the effect of diet, exercise or behavioural therapy in couples with UI.

Recommendation

A healthy diet and regular exercise, supported by behavioural therapy, when necessary, are recommended.

Justification

Although the GDG was unable to identify evidence of a specific association between certain diets or exercise regimes and unexplained infertility specifically, reproductive outcomes are known to be impaired in men and women with low and high BMIs. The standard advice and medical investigation and interventions apply equally to patients with UI as to any other causes of infertility. Patients generally value advice about lifestyle and healthy alternatives to maximise fertility in the context of their social and cultural environment. While healthy lifestyle intervention may improve spontaneous conception, active weight loss treatment in assisted reproduction has not yet shown a benefit in getting pregnant.

REFERENCES


4. Quality of Life

PICO QUESTION: IS THERE A DIFFERENCE IN QoL FOR PATIENTS WITH UNEXPLAINED VERSUS EXPLAINED INFERTILITY?

Evidence

In a secondary analysis of two RCTs, the fertility-related quality of life (QoL) was compared between couples with a known infertility cause (PCOS) and couples with unexplained infertility. The fertility-
related quality of life was measured with FertiQoL; a higher score indicates a better QoL. With exception of the relational domain, women with PCOS (n=733) had lower FertiQoL scores than women with UI (n=865), which were largely explained by the differences in BMI, demographics and hirsutism between the groups. Males from a couple with UI (n=849) had lower scores than males partnered with women who had PCOS (n=641) (Santoro et al., 2016).

This result is however not in line with the data by Warchol-Biedermann et al. who surveyed 185 married males on four occasions (before diagnostic disclosure, two to three months after diagnostic disclosure, before the third appointment, and before the fourth appointment) (Warchol-Biedermann, 2021). In this study, it was reported that unintentionally childless males from couples with unexplained infertility undergoing fertility workup and treatment for the first time had significantly higher FertiQoL scores for the emotional, mind-body and relational domains compared to males from a couple suffering from male factor infertility, female factor infertility or mixed factor infertility before diagnostic disclosure and in the follow-up 2 to 3 months after the diagnostic disclosure. The score for the social domain of the FertiQoL was similar over all pathology groups and study visits (Warchol-Biedermann, 2021).

In another cohort study (n = 110), the degree of subjective wellbeing was measured using the von Zerssen symptom checklist resulting in an impairment score; healthy test persons fall close to 14.3. Impairment scores were compared between known infertility (female, male and couple) and unexplained infertility (n=5). No significant difference was found on the level of impairment between the different diagnostic groups of men and women respectively. Women attain the greatest rating of impairment (mean = 17.6) in the symptom checklist when, from a somatic point of view, they solely are responsible for the involuntary childlessness, followed by infertile women with an infertile partner and women with idiopathic infertility; women score the lowest rating if the cause of infertility is only attributed to their partner. Men from a couple with idiopathic sterility score the lowest compared to men in couples with known infertility (Kowalcek et al., 2001).

Recommendation

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>EBR</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1.1 Healthcare professionals should be aware that there is probably no difference in QoL between women with unexplained infertility versus women in couples with known causes of infertility, except when the cause of infertility is PCOS, when QoL is lower.</td>
<td>EBR</td>
<td>☯☯☯☯</td>
</tr>
<tr>
<td>4.1.2 Healthcare professionals should be aware that QoL could be higher in men from a couple with unexplained infertility compared to men from a couple with known causes of infertility except when the cause of infertility is men with a partner with PCOS, then the men from a couple with unexplained infertility have a lower QoL.</td>
<td>EBR</td>
<td>☯☯☯☯</td>
</tr>
<tr>
<td>It should be acknowledged that couples with UI may experience considerable impact on their QoL and they can be offered support and therapeutic counselling.</td>
<td>PP</td>
<td></td>
</tr>
</tbody>
</table>

Justification

Current evidence indicates that there is probably no difference in QoL between women with unexplained and explained infertility, except for PCOS. For males with UI, QoL is probably higher.
compared to explained infertility. It is possible that QoL is impaired in the partner who is perceived to be responsible for infertility (Santoro, et al., 2016).

REFERENCES


Annexes

Annex 1: Guideline development group
Annex 2: Abbreviations
Annex 3: Recommendations for research
Annex 4: Methodology
Annex 5: Stakeholder consultation

See Technical Report for literature study: PICOs, search strategies, flowcharts, list of excluded studies

Evidence tables
Summary of evidence tables
GRADE templates and Evidence to Decision Frameworks
Annex 1: Guideline development group

The ESHRE GDG who developed the original 2023 UI Guideline was composed of.

<table>
<thead>
<tr>
<th>Chair of the GDG</th>
<th>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Woman and Child Health and Public Health, Rome, Italy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniela Romualdi</td>
<td>Koc University, department of Obstetrics and Gynaecology, Istanbul, Turkey</td>
</tr>
<tr>
<td></td>
<td>ART Fertility Clinics, Dubai, United Arab Emirates.</td>
</tr>
<tr>
<td>Baris Ata</td>
<td>University of Aberdeen, School of Medicine, Medical Sciences &amp; Nutrition, Aberdeen, UK.</td>
</tr>
<tr>
<td>Ernesto Bosch</td>
<td>University of New South Wales, Sydney, Australia</td>
</tr>
<tr>
<td>Michael Costello</td>
<td>NHMRC Centre of Research Excellence Women’s Health in Reproductive Life (WHiRL).</td>
</tr>
<tr>
<td>Samuel Dos Santos-Ribeiro</td>
<td>IVI-RMA Lisboa, Lisbon, Portugal.</td>
</tr>
<tr>
<td>Ksenija Gersak</td>
<td>University Medical Centre Ljubljana, department of Obstetrics and Gynaecology, Ljubljana, Slovenia.</td>
</tr>
<tr>
<td>Roy Homburg</td>
<td>Liverpool Womens’ Hospital, Hewitt Fertility Centre, Liverpool, UK.</td>
</tr>
<tr>
<td>Mina Mincheva</td>
<td>Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, UK</td>
</tr>
<tr>
<td>Robert Norman</td>
<td>The Robinson Research Institute The University of Adelaide, Adelaide, Australia</td>
</tr>
<tr>
<td>Terhi Piltonen</td>
<td>NHMRC Centre of Research Excellence Women’s Health in Reproductive Life (WHiRL).</td>
</tr>
<tr>
<td>Sara Somers</td>
<td>Oulu University Hospital, University of Oulu, department of Obstetrics and Gynaecology, Reproductive Endocrinology and IVF unit, PEDEGO Research Unit, Medical Research Centre, Oulu, Finland.</td>
</tr>
<tr>
<td>Sesh K. Sunkara</td>
<td>Ghent University hospital, Ghent, Belgium.</td>
</tr>
<tr>
<td>Harold Verhoeve</td>
<td>The Netherlands.</td>
</tr>
</tbody>
</table>

Patient representative

| Donia Scicluna | Gudja, Malta |

Methodological support

| Nathalie Le Clef | European Society of Human Reproduction and Embryology, Belgium |
The Australian Guideline development group (GDGs) were formed in 2022. These were based on skills (clinical and academic), expertise, geographical spread and were nominated by the CRE and or collaborator organisation. The GDG encompassed a broad range of clinical expertise involved in the care of those with UI, as well as a consumer. The GDG included those listed as authors in the current adapted Guideline.

Guideline development group

<table>
<thead>
<tr>
<th>GDG ROLE</th>
<th>TITLE</th>
<th>NAME</th>
<th>DISCIPLINE</th>
<th>ORGANISATION</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Doctor</td>
<td>Michael Costello</td>
<td>Obstetrician-Gynaecologist; Reproductive</td>
<td>University of NSW</td>
<td>Australia</td>
</tr>
<tr>
<td>Deputy Chair</td>
<td>Professor</td>
<td>Robert Norman</td>
<td>Obstetrician-Gynaecologist; Reproductive Endocrinologist</td>
<td>University of Adelaide</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Doctor</td>
<td>Lisa Bedson</td>
<td>General Practitioner; Fertility Clinician</td>
<td>Repromed</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Doctor</td>
<td>Clare Boothroyd</td>
<td>Obstetrician-Gynaecologist; Reproductive Endocrinologist</td>
<td>Care Fertility</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Professor</td>
<td>Cindy Farquhar</td>
<td>Obstetrician-Gynaecologist</td>
<td>University of Auckland</td>
<td>New Zealand</td>
</tr>
<tr>
<td>Member</td>
<td>Ms</td>
<td>Rebecca Kerner</td>
<td>Psychotherapist and counselor</td>
<td>Independent Practitioner</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Dr</td>
<td>Marlene Kong</td>
<td>General Practitioner</td>
<td>Whitsunday Doctors’ Service</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Ms</td>
<td>Trudy Loos</td>
<td>Fertility nurse</td>
<td>Monash Health</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Ms</td>
<td>Maree Pickens</td>
<td>Consumer advocate</td>
<td>ACCESS Australia’s National Infertility Network</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Professor</td>
<td>Luk Rombauts</td>
<td>Obstetrician-Gynaecologist; Infertility Specialist</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Professor</td>
<td>Helena Teede</td>
<td>Endocrinologist</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
</tbody>
</table>

Steering Committee

<table>
<thead>
<tr>
<th>ROLE</th>
<th>NAME</th>
<th>DISCIPLINE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORGANISATIONAL AFFILIATION / REGION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of Adelaide, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of NSW, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monash University, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centre for Research Excellence in Women’s Health in Reproductive Life, Australia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Australian Fertility Services Reference Group

<table>
<thead>
<tr>
<th>ROLE</th>
<th>NAME</th>
<th>DISCIENCE</th>
<th>ORGANISATIONAL AFFILIATION / REGION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Professor Roger Hart</td>
<td>Obstetrician-Gynaecologist; Reproductive Endocrinologist</td>
<td>The University of Western Australia; City Fertility Clinics Australia</td>
</tr>
<tr>
<td>Member</td>
<td>Professor Georgina Chambers</td>
<td>Epidemiology and statistics</td>
<td>University of New South Wales</td>
</tr>
<tr>
<td>Member</td>
<td>Ms Anna MacLeod</td>
<td>Chief Executive Officer</td>
<td>Victorian Assisted Reproductive Treatment Authority</td>
</tr>
</tbody>
</table>
Evidence integrity committee

Role: The Evidence Integrity Committee is responsible for investigating and managing integrity issues in the identified literature, to ensure recommendations are based on sound evidence. Specifically, the Committee has developed and implemented the RIGID framework (Research Integrity in Guideline Development) to independently review and categorise all relevant studies and to contact authors, before evidence can be used to inform recommendations.

<table>
<thead>
<tr>
<th>TITLE</th>
<th>NAME</th>
<th>ORGANISATION</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor</td>
<td>Ben Mol</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Doctor</td>
<td>Michael Costello</td>
<td>University of NSW</td>
<td>Australia</td>
</tr>
<tr>
<td>Doctor</td>
<td>Madeline Flanagan</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Doctor</td>
<td>Wentao Li</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Doctor</td>
<td>Aya Mousa</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Professor</td>
<td>Robert Norman</td>
<td>University of Adelaide</td>
<td>Australia</td>
</tr>
<tr>
<td>Professor</td>
<td>Helena Teede</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
<tr>
<td>Doctor</td>
<td>Rui Wang</td>
<td>Monash University</td>
<td>Australia</td>
</tr>
</tbody>
</table>

Declarations of interest

All members of the guideline development group were asked to declare possible conflicts of interest by means of the disclosure forms (see ESHRE Manual for Guideline Development).

This ADAPTE process and Australian UI guideline is editorially independent. The primary funders, NHMRC, were not involved in the development of the guideline and have not influenced the scope. They set standards for guideline development and based on independent peer review may approve the guideline process. All members of committees and GDGs publicly disclosed all relevant interests and these were reviewed at each meeting, considered when making recommendations and are publicly available (see Disclosures statement).

Conflicts of interest

<table>
<thead>
<tr>
<th>Name</th>
<th>Conflict of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniela Romualdi</td>
<td>Consulting fees from SICS Editore, UCB Pharma Honoraria from IBSA and Novo Nordisk</td>
</tr>
<tr>
<td>Baris Ata</td>
<td>Speakers fees from Merck, Ferring, IBSA, Organon and Abbott. Remuneration from Oxford University Press as Editor in Chief of Human Reproduction Update Editor and contributing author, Reproductive Medicine for the MRCOG, Cambridge University Press</td>
</tr>
<tr>
<td>Siladitya Bhattacharya</td>
<td>Research grants from Roche diagnostics and IBSA Consulting fees from Merck, Ferring, Gedeon Richter,</td>
</tr>
<tr>
<td>Name</td>
<td>Interests</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Michael Costello</td>
<td>Please see Australian register of interests</td>
</tr>
<tr>
<td>Samuel Dos Santos-Ribeiro</td>
<td>Research grants from MSD, Ferring, Merck, Abbott, Roche, Obseva Consulting fees from Ferring, MSD Speaker’s fees from Ferring, MSD, Besins</td>
</tr>
<tr>
<td>Ksenija Gersak</td>
<td>None declared.</td>
</tr>
<tr>
<td>Roy Homburg</td>
<td>None declared.</td>
</tr>
<tr>
<td>Mina Mincheva</td>
<td>Consulting fees from Mojo Fertility Ltd</td>
</tr>
<tr>
<td>Robert Norman</td>
<td>Please see Australian register of interests. Research grant from Australian National Health and Medical Research Council (NHMRC), Consulting fees from Ferring Australia, Speaker’s fees from Merck India, Past ownership interest by stock or partnership of a healthcare company from FertilitySA</td>
</tr>
<tr>
<td>Terhi Piltonen</td>
<td>Research grant from Roche Speaker’s fees from Gedeon Richter, Roche, Exeltis.</td>
</tr>
<tr>
<td>Sara Somers</td>
<td>None declared.</td>
</tr>
<tr>
<td>Sesh Sunkara</td>
<td>Speaker’s fees from Merck, Ferring, MSD, Pharmasure</td>
</tr>
<tr>
<td>Harold Verhoeve</td>
<td>Consulting fees from Ferring Pharmaceuticals</td>
</tr>
<tr>
<td>Donia Scicluna</td>
<td>None declared.</td>
</tr>
<tr>
<td>Nathalie Le Clef</td>
<td>None declared.</td>
</tr>
</tbody>
</table>

**NHMRC aligned detailed Australian Register of Interest**

Annex 2: Abbreviations and Language

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>Arachidonic acid</td>
</tr>
<tr>
<td>AMH</td>
<td>Anti-Müllerian hormone</td>
</tr>
<tr>
<td>AFC</td>
<td>Antral follicle count</td>
</tr>
<tr>
<td>ART</td>
<td>Assisted reproduction technology</td>
</tr>
<tr>
<td>ASA</td>
<td>Anti-sperm antibodies</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>BBT</td>
<td>Basal body temperature</td>
</tr>
<tr>
<td>CAT</td>
<td>Chlamydia antibody testing</td>
</tr>
<tr>
<td>CC</td>
<td>Clomiphene Citrate</td>
</tr>
<tr>
<td>CCCT</td>
<td>Clomiphene citrate challenge test</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CT</td>
<td>Chlamydia Trachomatis</td>
</tr>
<tr>
<td>DFI</td>
<td>DNA fragmentation index</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>DNA</td>
<td>Desoxynucleic acid</td>
</tr>
<tr>
<td>EIA</td>
<td>Enzyme Immunoassay</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-Linked Immuno Sorbent Assay.</td>
</tr>
<tr>
<td>ET</td>
<td>Embryo transfer</td>
</tr>
<tr>
<td>FRAP</td>
<td>Ferric reducing antioxidant power</td>
</tr>
<tr>
<td>GDG</td>
<td>Guideline development group</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
</tr>
<tr>
<td>HSG</td>
<td>Hysterosalpingography</td>
</tr>
<tr>
<td>HyCoSy</td>
<td>Hystero-contrast-sonography</td>
</tr>
<tr>
<td>HyFoSy</td>
<td>Hystero-foam-sonography</td>
</tr>
<tr>
<td>ICSI</td>
<td>Intracytoplasmic sperm injection</td>
</tr>
<tr>
<td>IgA</td>
<td>Immunoglobulin A</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IF</td>
<td>Immunofluorescence</td>
</tr>
<tr>
<td>IQR</td>
<td>Interquartile range</td>
</tr>
<tr>
<td>IU</td>
<td>International unit/infectious units</td>
</tr>
<tr>
<td>IUI</td>
<td>Intra-uterine insemination</td>
</tr>
<tr>
<td>IVF</td>
<td>In vitro fertilisation</td>
</tr>
<tr>
<td>LH</td>
<td>Luteinizing hormone</td>
</tr>
<tr>
<td>LR</td>
<td>Likelihood ratio</td>
</tr>
<tr>
<td>MAR</td>
<td>Medically assisted reproduction</td>
</tr>
<tr>
<td>MAR test</td>
<td>Mixed antiglobulin reaction test</td>
</tr>
<tr>
<td>MD</td>
<td>Mean difference</td>
</tr>
<tr>
<td>MDA</td>
<td>Malondialdehyde</td>
</tr>
<tr>
<td>MIF</td>
<td>Micro immunofluorescence</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
</tr>
<tr>
<td>NPV</td>
<td>Negative predictive value</td>
</tr>
<tr>
<td>NT</td>
<td>Nitrotyrosine</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>ORT</td>
<td>Ovarian reserve test</td>
</tr>
<tr>
<td>OS</td>
<td>Ovarian stimulation</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>OSCM</td>
<td>Oil-soluble contrast media</td>
</tr>
<tr>
<td>OSI</td>
<td>Oxidative stress index</td>
</tr>
<tr>
<td>PC</td>
<td>Protein carbonyl group</td>
</tr>
<tr>
<td>PID</td>
<td>Pelvic inflammatory disease</td>
</tr>
<tr>
<td>PP</td>
<td>Practice point</td>
</tr>
<tr>
<td>RD</td>
<td>Risk difference</td>
</tr>
<tr>
<td>ROC</td>
<td>Receiver operating characteristics curve</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>PPV</td>
<td>Positive predictive value</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>ROC-AUC</td>
<td>Receiver operating characteristic – area under the curve</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>RR</td>
<td>Relative risk/risk ratio</td>
</tr>
<tr>
<td>SCSA</td>
<td>Sperm chromatin structure assay</td>
</tr>
<tr>
<td>SDF</td>
<td>Sperm DNA fragmentation</td>
</tr>
<tr>
<td>SET</td>
<td>Single embryo transfer</td>
</tr>
<tr>
<td>SH</td>
<td>Thiol group</td>
</tr>
<tr>
<td>SIS</td>
<td>Saline infusion sonography</td>
</tr>
<tr>
<td>SMD</td>
<td>Standardised mean difference</td>
</tr>
<tr>
<td>SOD</td>
<td>Superoxide dismutase</td>
</tr>
<tr>
<td>TAC</td>
<td>Total antioxidant capacity</td>
</tr>
<tr>
<td>TAS</td>
<td>Total antioxidant status</td>
</tr>
<tr>
<td>TBARS</td>
<td>2-thiobarbituric acid-reactive substances</td>
</tr>
<tr>
<td>TOS</td>
<td>Total oxidant status</td>
</tr>
<tr>
<td>TVUS</td>
<td>Transvaginal ultrasound</td>
</tr>
<tr>
<td>UI</td>
<td>Unexplained Infertility</td>
</tr>
<tr>
<td>US</td>
<td>Ultrasound</td>
</tr>
<tr>
<td>WMD</td>
<td>Weighted mean difference</td>
</tr>
<tr>
<td>WSCM</td>
<td>Water-soluble contrast media</td>
</tr>
</tbody>
</table>
Annex 3: Recommendations for research on Unexplained Infertility

From the literature and discussion of the available evidence, several topics were identified for which evidence is inconsistent, insufficient or non-existing. For the benefit of patients with unexplained infertility, the GDG recommends that future research, where possible in well-designed RCTs, should focus on these research gaps.

The top-3 of research recommendations with the highest priority identified by the GDG are:

1. Can a predictive model be developed, tested and validated to compare the outcomes of different management strategies for couples with UI?
2. What is the optimal ART for UI?
3. What is the value of performing current methods to assess sperm DNA integrity to predict clinical outcomes (pregnancy rates, live birth rates and miscarriage rates) in couples with UI?

Furthermore, the GDG would like to draw attention to the importance of research of male infertility. With a steady decline in sperm quality reported in the last 50 years, particularly sperm counts, male infertility has become a global public health issue (Levine et al., 2023, Levine et al., 2017). Over the past decade, there has been increasing evidence showing an association between male reproductive health and general health, with male infertility being proposed as a possible biomarker for current and future health (Burke et al., 2022, Chen et al., 2022, Del Giudice et al., 2021, Ventimiglia et al., 2015). However, up to 70% of male idiopathic and unexplained infertility cases remain with no aetiological factor (Punab et al., 2017, Salonia et al., 2023, Tüttelmann et al., 2018). MAR is routinely used for clinical management of male infertility when no causative factor is identified. Inadequate assessment of the causes of male infertility and the lack of strong evidence-based supported treatment options puts a disproportionate burden on the female partner. Considering that the use of MAR is steadily increasing worldwide (Wyns et al., 2022), a paradigm shift in treatment of male factor infertility becomes essential (Björndahl, 2022, De Jonge and Barratt, 2019, Duffy et al., 2021). Therefore, re-focusing research efforts on addressing gaps in the understanding of male infertility, such as identifying new aetiological causes, clinical diagnostics, and MAR treatment options, will enable the development of a more personalised therapeutic options to manage couple’s infertility and improve reproductive outcomes.

Other research gaps that were identified are:

- What is the role of vaginal microbiota in UI?
- Can a predictive model for fertility based upon ovarian reserve tests be developed, tested and validated
- In women at risk of age-related infertility, does standardized fertility assessment before attempting expectant management improve live birth rates?
- What causes UI?
- What is the relationship between luteal progesterone levels and spontaneous pregnancy?
- What is the impact of sperm DNA damage (evaluated via sperm DNA fragmentation tests and sperm chromatin condensation test) on the clinical management of couples with UI?
- What is the role of lifestyle intervention?
- In women with uterine fibroids, what is the optimal management strategy to preserve fertility?
- In women with otherwise unexplained infertility, does hysteroscopic removal of an endometrial polyp increase live birth rates?
- Can age-related infertility be prevented?
- What is the role of different endometrial biomarkers?
- What is the role of oxidative stress markers in semen in couples with UI?
- In women with a uterine septum and otherwise unexplained infertility does hysteroscopic resection increase live birth rates?
- What is the role of oxidative stress biomarkers in endometrial implantation?
- What is the relationship between regular menstrual cycles and proof of ovulation?
- In women with mild intrauterine adhesions and otherwise unexplained infertility does removal increase live birth rates?

Additional Australian Research Recommendations are noted in the Guideline Recommendation table. The need to understand access, barriers and enablers in the Australian context including geographical and underserved population level barriers was also highlighted, alongside the need to continuously monitor UI treatments for alignment to evidence based practice.

REFERENCES


Chen T, Belladelli F, Del Giudice F, Eisenberg ML. Male fertility as a marker for health. Reproductive biomedicine online 2022;44: 131-144.

De Jonge C, Barratt CLR. The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap. Andrology 2019;7: 762-768.


Annex 4: Methodology

GUIDELINE DEVELOPMENT

The European Society of Human Reproduction and Embryology (ESHRE) guidelines are developed based on the Manual for ESHRE guideline development (N. Vermeulen, N. Le Clef, S. Mcheik, A. D'Angelo, K. Tilleman, Z. Veleva, W.L.D.M. Nelen, Manual for ESHRE guideline development, version 2019), which can be consulted on the ESHRE website (www.eshre.eu/guidelines). The principal aim of this manual is to provide stepwise advice on ESHRE guideline development for members of ESHRE guideline development groups. The manual describes a 12-step procedure for writing clinical management guidelines by the guideline development group, supported by the ESHRE methodological expert:

1. TOPIC SELECTION
2. GDG FORMATION
3. SCOPING
4. KEY QUESTIONS
5. EVIDENCE SEARCH
6. EVIDENCE SYNTHESIS
7. RECOMMENDATIONS
8. DRAFT FOR REVIEW
9. STAKEHOLDER REVIEW
10. EXCO APPROVAL
11. PUBLICATION
12. UPDATING / REVISING

The original ESHRE guideline was developed and funded by ESHRE, which covered expenses associated with the guideline meetings (travel, hotel and catering expenses) associated with the literature searches (library costs, costs associated with the retrieval of papers) and with the implementation of the guideline (printing, publication costs). The National Health and Medical Research Council of Australia covered the expenses of the 2 Australian members of the panel (MC and RJN). Except for reimbursement of their travel expenses, GDG members did not receive any payment for their participation in the guideline development process.

The scope of the guideline and first version of the key questions were drafted by members of the ESHRE Special Interest Group (SIG) Reproductive Endocrinology, SIG Andrology, SIG Safety and Quality in ART and SIG Nurses and Midwives and two representatives of the Monash University NHMRC Centre for Research Excellence in Women’s Reproductive Health. ESHRE strived towards a balance in gender and location within Europe. Several online meetings of the guideline development group were organised to discuss the key questions and redefine them through the PICO process (patients – interventions – comparison – outcome). This resulted in a final list of 21 key questions. Based on the defined key words, literature searches were performed by the methodological expert (Dr. N. Le Clef). Key words were sorted to importance and used for searches in PUBMED/MEDLINE and the Cochrane library. We searched the databases from inception up to 24 October 2022.

Literature searches were performed as an iterative process. In a first step, systematic reviews and meta-analyses were collected. If no results were found, the search was extended to randomized controlled trials, and further to cohort studies and case reports, following the hierarchy of the levels of evidence. References were selected or excluded by the methodological expert and expert GDG member based on title and abstract and knowledge of the existing literature. If necessary, additional
searches were performed in order to get the final list of papers. It is not within ESHRE’s remit to conduct a formal investigation or to draw formal conclusions regarding the misconduct of an individual or group of individuals or to determine whether a published article should be retracted. However, papers that are withdrawn, have a published editorial note of concern or a published expression of concern have been excluded from the guideline. In future revision or update of the guideline, the GDG will actively verify the status of all the referenced studies.

In the Australian ADAPTE process and integrity check and RIGID Framework was implemented as outlined in the technical report.

The quality of the selected papers was assessed by means of the quality assessment checklist, defined in the ESHRE guideline manual. Furthermore, the evidence was collected and summarised in an evidence table according to GIN format (http://www.g-i-n.net/activities/etwg).

The quality assessment and evidence tables were constructed by the expert GDG members. Summary of findings (SoF) tables were prepared following the GRADE approach for intervention studies which reported the critical outcomes. The critical outcomes for this guideline were: live full-term singleton birth, live birth, ongoing pregnancy rate, multiple pregnancies/multiple births.

GDG meetings were organised to discuss the draft recommendations and the supporting evidence and to reach consensus on the final formulation of the recommendations. In a final step, all evidence and recommendations were combined in the evidence-based guideline: “Unexplained Infertility”.

Australian ADAPTE process
Here we followed the guidance from ADAPTE. ¹

Prioritised clinical questions
Prioritisation of guideline clinical questions was informed by expert input from across ESHRE with input from the Australian CRE and GDG.

What the guideline does not address
This guideline does not seek to provide full safety and usage information on pharmacological and surgical interventions. The pharmacological and surgical interventions recommended in the guideline should not be applied without consideration of the individual’s clinical profile and preferences. We recommend that the reader consults relevant regional bodies for prescribing information including indications, drug dosage, method and route of administration, contraindications, supervision and monitoring, product characteristics and adverse effects. All recommendations and practice points need to be considered in the context of healthcare settings and resources. There are very limited studies precluded evidence-based assessments of economic feasibility and impact. The potential impact of cost on recommendations was however considered in the GRADE process.

List of key questions

Definition of unexplained infertility
Question I.1 After how many months of unprotected intercourse should a couple be defined as infertile?
Question I.2 Should frequency of sexual intercourse affect the definition of UI?
Question I.3 Should female or male partner’s age affect the definition of UI?
Question I.4 Should couples with mild infertility factors be included in the definition of UI?
**DIAGNOSIS OF UNEXPLAINED INFERTILITY**

Question II.1 Which is the reliability and convenience of methods to confirm regular ovulation?

Question II.2 What is the reliability of parameters detecting good oocyte/corpus luteum quality?

Question II.3 Should one or more tests of ovarian reserve be included in the diagnostic work-up?

Question II.4 What is the accuracy of commonly used tests of tubal patency?

Question II.5a Which diagnostic procedures should be performed to confirm a normal uterine structure/anatomy, uterine wall/myometrium?

Question II.5b Which additional diagnostic procedures should be performed to confirm an anatomically normal uterine cavity?

Question II.6 Should women undergo a laparoscopy before being diagnosed with UI?

Question II.7 What is the need for female lower genital tract investigations?

Question II.8 Should men undergo additional diagnostic procedures to confirm normal genito-urinary anatomy before being diagnosed with UI?

Question II.9 Is there added value of additional tests in the male with normal WHO semen analysis?

Question II.10 Should there be additional evaluations of possible systemic cause of UI in the couple?

**TREATMENT OF UNEXPLAINED INFERTILITY**

Question III.1 What is the value of expectant management compared to active treatment for patients with UI?

Question III.2a If active treatment is pursued, which type of active treatment for UI?

Question III.2b What is the value of IVF versus ICSI?

Question III.3 What is the value of mechanical-surgical procedures?

Question III.4 What is the effectiveness of alternative therapeutic approaches?

**QUALITY OF LIFE**

Question IV.1 Is there a difference in QoL for patients with unexplained versus explained infertility?

**FORMULATION OF RECOMMENDATIONS**

See the introduction section on interpreting the recommendations.

For each recommendation it is mentioned whether it is strong or conditional and what the quality of the supporting evidence was. In the justification section, more data are provided on the considerations taken into account when formulating the recommendations: balance between desirable and undesirable effects, certainty of the evidence of effects, certainty in how people value the outcome, acceptability and feasibility of the intervention. Impact on health equity and resource impact were only discussed where relevant. For interventions where there was no evidence from studies focussing on unexplained infertility specifically to support the recommendation, the quality of the evidence was automatically graded as very low (+OOO).

**AUSTRALIAN ADAPTE PROCESS:**

Here the certainty of evidence had a direct impact on recommendation strength in the context of the NHMRC processes. Furthermore, after the integrity process, some studies were excluded or area awaiting classification. This resulted in some recommendations being downgraded from strong to conditional and some from conditional to research recommendations. No ESHRE recommendations
changed direction during this process. Some were downgraded to conditional, others were downgraded to research only recommendations.

In the detailed GRADE Evidence to Decision Templates in the Technical Report, specific considerations including regionality, underserved populations and nuances in the Australian Health System were considered for each recommendation. These are noted in the justification where considerations were influential, otherwise these considerations will inform the dissemination and translation program,

OUTCOME PRIORITISATION USING GRADE
The most relevant outcomes were prioritised by ranking their importance by healthcare professionals and consumers to help resolve or clarify disagreements and assist with grading the evidence. The importance of outcomes may vary across cultures and from different perspectives e.g. patients, public, healthcare professionals or policy-makers. Table 4 outlines the considerations when deciding importance of outcomes. GDG members, including consumers also participated in this exercise.

Steps for considering the relative importance of outcomes

<table>
<thead>
<tr>
<th>What</th>
<th>Assessment and prioritisation of outcomes as critical, important but not critical, or low importance. Requires judgement of the balance between the desirable and undesirable health outcomes of an intervention.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Why</td>
<td>To focus attention on those outcomes that are considered most important when conducting evidence review and to resolve or clarify disagreements. To support making a recommendation and to determine the strength of the recommendation.</td>
</tr>
<tr>
<td>How</td>
<td>Scoping the relevant literature. By asking GDG members, including consumers to prioritise outcomes in light of the considerations for ‘what’ and ‘why’.</td>
</tr>
<tr>
<td>Evidence</td>
<td>These judgments are ideally informed by a systematic review of the literature focusing on what the target population considers as critical or important outcomes for decision making. Prior knowledge of the research evidence through systematic reviews; and information about values, preferences or utilities has been explored in the original guideline, that was systematic. Additionally, the collective experience of the GDG members, including consumers, will be used using transparent methods for documenting and considering them.</td>
</tr>
</tbody>
</table>

To facilitate ranking of outcomes according to their importance, the following scale was used.

Rating scale

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>of least importance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of most importance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Outcomes considered critical (rated 7-9) most greatly influenced a recommendation and the overall quality of evidence supporting the recommendation and the strength of the recommendation.

AUSTRALIAN ADAPTE PROCESS
Here we did not reconsider outcomes and included these as per the ESHRE process, however areas such as regionality and nuances for the Australian setting were considered during the GRADE process and when generating the recommendations.
STRATEGY FOR REVIEW OF THE GUIDELINE DRAFT

After finalization of the ESHRE guideline draft, the review process was initiated. The draft guideline was published on the ESHRE website, accompanied by the reviewers’ comments form and a short explanation of the review process. The guideline was open for review between 12 December 2022 and 30 January 2023.

To notify interested clinicians, we sent out an invitation to review the guideline by email to all ESHRE members.

Selected reviewers were invited personally by email. These reviewers included:

- Coordinators and deputies of the ESHRE SIG Reproductive Endocrinology, SIG Andrology, SIG Reproductive Surgery, SIG Safety and Quality in ART and SIG Nurses and Midwives.
- Contact persons of patient organisations across Europe.
- Contact persons of international and national societies focused on IVF/ICSI across Europe.
- Contact persons in CRE WHiRL and those involved in the Australian Guideline

All ESHRE reviewers are listed in annex 5. The Reviewer comments processing report, including further information on the review and a list of all comments per reviewer with the response formulated by the GDG is published on the ESHRE website.

AUSTRALIAN GUIDELINE PUBLIC CONSULTATION PROCESS

The Public consultation process followed the requirements of the Section 14A of the Commonwealth National Health and Medical Research Council Act 19921 and accompanying regulation. This includes consulting directly with all specified stakeholders, across government, health professional and consumer groups and through public consultation via NHMRC. The process and stakeholders are outlined in detail in the Administrative Report with the Guideline at https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation.

GUIDELINE IMPLEMENTATION STRATEGY

ESHRE STRATEGY

The standard dissemination procedure for all ESHRE guidelines comprises publishing and announcement. Each guideline is published on the ESHRE website and in Human Reproduction Open. The announcement procedure includes a news item in “Focus on Reproduction”, a newsflash on the ESHRE website homepage and a short presentation at the ESHRE Annual meeting. All participants in the annual ESHRE meeting will be informed about the development and release of new guidelines; all related national societies and patient organizations are informed about the guideline release. They are asked to encourage local implementation by, for instance, translations or condensed versions, but they are also offered a website link to the original document.

Patient versions of the guideline will be developed by a subgroup of the GDG together with patient representatives. The patient version is a translation of the recommendations in everyday language, with emphasis on questions important to patients. It aims to help patients understand the guideline’s recommendations and facilitates clinical decision-making.

To further enhance implementation of the guideline, the members of the GDG, as experts in the field, will be asked to select recommendations for which they believe implementation will be difficult and make suggestions for tailor-made implementation interventions (e.g. option grids, flow-charts, additional recommendations, addition of graphic/visual material to the guideline).

Further translation tools will be developed by CRE in partnership with ESHRE.

CRE WHiRL DISSEMINATION AND IMPLEMENTATION STRATEGY

This translation strategy will be developed during Guideline Public and NHMRC review and is guided by the implementation plan available at https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation. A comprehensive translation program will disseminate, translate and amplify the impact of the UI guideline. The aims of the translation program are to: educate and build capability of healthcare professionals to deliver high-quality, evidence-based assessment and management of UI
that meets the needs of those affected, augmenting health literacy, optimising diagnosis, improving health outcomes; and promoting best-practice evidence-based care. The principles follow that of our other CRE WHiRL Guideline translation and components are informed by the needs and preferences of those affected, resources are co-created with, and attuned to, the needs of end-users; and dissemination strategies are multi-faceted, and targeted to communication channels of end-users. The program is supported by a comprehensive evaluation framework, measuring impacts and outcomes (see Dissemination and implementation plan).

**SCHEDULE FOR UPDATING THE GUIDELINE**

The current ESHRE guideline will be considered for revision in 2027 (four years after publication). An intermediate search for new evidence will be performed two years after publication, which will inform the GDG of the necessity of an update. The Australian Guideline process will follow on from the ESHRE process with each update.

Every care is taken to ensure that this publication is correct in every detail at the time of publication. Evidence currency here meets NHRMC Guideline requirements, However, in the event of errors or omissions, corrections will be published in the web version of this document, which is the definitive version at all times. This ESHRE version can be found at [www.eshre.eu/guidelines](http://www.eshre.eu/guidelines) and the Australian ADAPTED version at [https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation](https://whirlcre.edu.au/new-knowledge/infertility/guideline-public-consultation).

For more details on the methodology of ESHRE guidelines, visit [www.eshre.eu/guidelines](http://www.eshre.eu/guidelines)

Annex 5: Stakeholder consultation

ESHRE process: As per routine development procedures, the guideline draft was open for review for 6 weeks, between 12 December 2022 and 30 January 2023. All reviewers, their comments and the reply of the guideline development group are summarised in the review report, which is published on the ESHRE website as supporting documentation to the guideline. The list of representatives of professional organisations and individual experts that provided comments to the guideline are summarised below.

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Country</th>
<th>Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>German Society of Andrology (DGA e.V.)</td>
<td>Germany</td>
<td>Sabine Kliesch</td>
</tr>
<tr>
<td>German Society of Urology, working group Andrology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Institute of Reproductive Medicine, Kolkata</td>
<td>India</td>
<td>Pratip Chakraborty</td>
</tr>
<tr>
<td>Centre for Human Reproductive Science, Birmingham Health Partners, The University of Birmingham</td>
<td>UK</td>
<td>Jackson Kirkman-Brown Meurig Gallagher</td>
</tr>
<tr>
<td>Reproductive medicine AmsterdamUMC, The Netherlands and the Netherlands Cochrane Gynaecology&amp;Fertility</td>
<td>The Netherlands</td>
<td>J.A. Wessel, Elena Kostova, Monique Mochtar, Madelon van Wely, Femke Mol, Mariette Goddijn</td>
</tr>
<tr>
<td>European Academy of Andrology</td>
<td>Europe</td>
<td>Dimitrios G. Goulis, Giovanni Corona</td>
</tr>
<tr>
<td>German Society for Reproductive Medicine (DGRM) and URZ</td>
<td>Germany</td>
<td>Ziller V., Goeckenjahn M., Köhn F.-M., Hancke K., Sonntag B.</td>
</tr>
<tr>
<td>Bundesverband Reproduktionsmedizinischer Zentren (BRZ)</td>
<td>Germany</td>
<td>Ulrich A. Knuth, Michael Ludwig</td>
</tr>
<tr>
<td>German Society of Human Reproductive Biology</td>
<td>Germany</td>
<td>Verena Nordhoff</td>
</tr>
<tr>
<td>Unexplained Infertility Guideline CRE WHiRL Adaptation Committee</td>
<td>Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joel Bernstein</td>
<td>Australia</td>
</tr>
<tr>
<td>Gustavo Botti</td>
<td>Argentina</td>
</tr>
<tr>
<td>Maruf Siddiqui</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Jean Calleja-Agius</td>
<td>Malta</td>
</tr>
<tr>
<td>Hunida Elmegrab</td>
<td>Libya</td>
</tr>
<tr>
<td>Bulent Tandogan</td>
<td>Turkey</td>
</tr>
<tr>
<td>Carlos Calhaz-Jorge</td>
<td>Portugal</td>
</tr>
<tr>
<td>Liliana Ramos</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Adam Balen</td>
<td>UK</td>
</tr>
<tr>
<td>George Lainas</td>
<td>Greece</td>
</tr>
<tr>
<td>Mahmoud A Abdel-Aleem</td>
<td>Egypt</td>
</tr>
<tr>
<td>Marco Sbracia</td>
<td>Italy</td>
</tr>
<tr>
<td>Mario Sousa</td>
<td>Portugal</td>
</tr>
<tr>
<td>Maria Elisabetta Coccia</td>
<td>Italy</td>
</tr>
<tr>
<td>Michael Grynberg</td>
<td>France</td>
</tr>
<tr>
<td>Exalto N. Emanuel MH.</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Ben Mol</td>
<td>Australia</td>
</tr>
</tbody>
</table>
References